<!DOCTYPE article
PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.3 20210610//EN" "JATS-archivearticle1-3-mathml3.dtd">
<article xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="review-article" dtd-version="1.3"><?properties open_access?><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Reprod Biol Endocrinol</journal-id><journal-id journal-id-type="iso-abbrev">Reprod Biol Endocrinol</journal-id><journal-title-group><journal-title>Reproductive Biology and Endocrinology : RB&#x00026;E</journal-title></journal-title-group><issn pub-type="epub">1477-7827</issn><publisher><publisher-name>BioMed Central</publisher-name><publisher-loc>London</publisher-loc></publisher></journal-meta>
<article-meta><article-id pub-id-type="pmid">40001128</article-id><article-id pub-id-type="pmc">PMC11863420</article-id>
<article-id pub-id-type="publisher-id">1359</article-id><article-id pub-id-type="doi">10.1186/s12958-025-01359-2</article-id><article-categories><subj-group subj-group-type="heading"><subject>Review</subject></subj-group></article-categories><title-group><article-title>Pharmacogenomic of LH and its receptor: are we ready for clinical practice?</article-title></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">http://orcid.org/0000-0002-5676-0055</contrib-id><name><surname>Conforti</surname><given-names>Alessandro</given-names></name><address><email>alessandro.conforti@unina.it</email></address><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Di Girolamo</surname><given-names>Raffaella</given-names></name><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Guida</surname><given-names>Maurizio</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Alviggi</surname><given-names>Carlo</given-names></name><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Casarini</surname><given-names>Livio</given-names></name><xref ref-type="aff" rid="Aff3">3</xref><xref ref-type="aff" rid="Aff4">4</xref></contrib><aff id="Aff1"><label>1</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/05290cv24</institution-id><institution-id institution-id-type="GRID">grid.4691.a</institution-id><institution-id institution-id-type="ISNI">0000 0001 0790 385X</institution-id><institution>Department of Neuroscience, Reproductive Science and Odontostomatology, </institution><institution>University of Naples Federico II, </institution></institution-wrap>Via Sergio Pansini, 5, Napoli, 80131 Italy </aff><aff id="Aff2"><label>2</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/05290cv24</institution-id><institution-id institution-id-type="GRID">grid.4691.a</institution-id><institution-id institution-id-type="ISNI">0000 0001 0790 385X</institution-id><institution>Department of Public Health, </institution><institution>University of Naples Federico II, </institution></institution-wrap>Naples, Italy </aff><aff id="Aff3"><label>3</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/02d4c4y02</institution-id><institution-id institution-id-type="GRID">grid.7548.e</institution-id><institution-id institution-id-type="ISNI">0000 0001 2169 7570</institution-id><institution>Unit of Endocrinology, Department of Biomedical, Metabolic and Neural Sciences, </institution><institution>University of Modena and Reggio Emilia, </institution></institution-wrap>Modena, Italy </aff><aff id="Aff4"><label>4</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/02d4c4y02</institution-id><institution-id institution-id-type="GRID">grid.7548.e</institution-id><institution-id institution-id-type="ISNI">0000 0001 2169 7570</institution-id><institution>Center for Genomic Research, </institution><institution>University of Modena and Reggio Emilia, </institution></institution-wrap>Modena, Italy </aff></contrib-group><pub-date pub-type="epub"><day>25</day><month>2</month><year>2025</year></pub-date><pub-date pub-type="pmc-release"><day>25</day><month>2</month><year>2025</year></pub-date><pub-date pub-type="collection"><year>2025</year></pub-date><volume>23</volume><issue>Suppl 1</issue><issue-sponsor>The publication of this supplement was supported by Merck KGaA, Darmstadt, Germany. Merck KGaA had no involvement in the preparation, review, or approval of the content. The articles have undergone the journal's standard peer review process for supplements. The Supplement Editors declare that they have no competing interests.</issue-sponsor><elocation-id>29</elocation-id><history><date date-type="received"><day>28</day><month>6</month><year>2023</year></date><date date-type="accepted"><day>5</day><month>2</month><year>2025</year></date></history><permissions><copyright-statement>&#x000a9; The Author(s) 2025</copyright-statement><copyright-year>2025</copyright-year><license><ali:license_ref specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p><bold>Open Access</bold> This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link>.</license-p></license></permissions><abstract id="Abs1"><p id="Par1">Luteinizing hormone (LH) is fundamental to support development and reproduction. It acts through a receptor expressed in the gonads, modulating mitogenic, anti-apoptotic, and steroidogenic signals. LH is also marketed as a drug for controlled ovarian stimulation (COS), where it is administered to women to support the action of follicle-stimulating hormone and can lead to specific responses, depending on the individual genetic background. These concepts underline the relevance of a pharmacogenetic approach to COS, in the attempt to optimize clinical outcomes and avoid adverse events. However, knowledge is currently limited by the paucity of clinical studies. This review aims to provide a comprehensive overview of LH and its receptor activity, starting from the description of their molecular pathways from in vitro studies. Data on LH action from in vivo studies were described, as well as the impact of LH and LH/choriogonadotropin (hCG) receptor genetic variants on folliculogenesis and its association with infertility or polycystic ovarian syndrome. Finally, evidence from clinical studies evaluating genetic polymorphisms in the context of assisted reproductive technology treatments and its implications for a pharmacogenomic approach were discussed.</p><sec><title>Supplementary Information</title><p>The online version contains supplementary material available at 10.1186/s12958-025-01359-2.</p></sec></abstract><kwd-group xml:lang="en"><title>Keywords</title><kwd>LH</kwd><kwd>LHCGR</kwd><kwd>Genetic variants</kwd><kwd>Pharmacogenomic</kwd><kwd>IVF</kwd><kwd>Ovarian stimulation</kwd></kwd-group><conference xlink:href="https://medeaacademy.com/event/lh2022/"><conf-name>3rd World Conference on Luteinizing Hormone in ART: Applying technologies, learning from nature</conf-name><conf-loc>Naples, Italy</conf-loc><conf-date>27-28 May 2022</conf-date></conference><custom-meta-group><custom-meta><meta-name>issue-copyright-statement</meta-name><meta-value>&#x000a9; BioMed Central Ltd., part of Springer Nature 2025</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="Sec1"><title>Introduction</title><p id="Par28">Luteinizing hormone (LH) is a gonadotropin fundamental to development and reproduction. It is a dimeric glycoprotein released in a pulsatile fashion by the pituitary gland and acts through the LH/choriogonadotropin (hCG) receptor (LHCGR), which is expressed in the gonads [<xref ref-type="bibr" rid="CR1">1</xref>]. LH has a &#x003b2; subunit (LH&#x003b2;), specific for receptor binding, and an &#x003b1; subunit shared with other structurally similar glycoproteins: follicle-stimulating hormone (FSH), thyroid-stimulating hormone (TSH), and hCG [<xref ref-type="bibr" rid="CR2">2</xref>]. The &#x003b2;-subunit is coded by the <italic>LHB</italic> gene located in the genomic locus 19q13.33, while the &#x003b1;-subunit is coded by the <italic>CGA</italic> gene, located at 6q14.3, and is assembled with LH&#x003b2; within pituitary gonadotropic cells. The final product is a&#x02009;~&#x02009;33 kDa molecule that, in women of fertile age, exerts a key role in supporting the production of ovarian sex steroids and modulating mitogenic and anti-apoptotic signals. These functions sustain follicular growth, oocyte maturation, and ovulation, as well as the luteinization of granulosa cells.</p><p id="Par29">LHCGR is coded by the homonym gene, located in the genomic position 2p16.3, which spans about 80 kbases with 11 exons and 10 introns, and consists in a common receptor for both LH and hCG [<xref ref-type="bibr" rid="CR3">3</xref>]. These two ligands have different physiological functions: hCG is the pregnancy hormone, produced by trophoblast cells to induce progesterone production; hCG&#x003b2; molecules are coded by cluster genes (<italic>CGB</italic>s), located in proximity of <italic>LHB</italic> and likely evolved from a common ancestral sequence [<xref ref-type="bibr" rid="CR4">4</xref>]. However, hCG&#x003b2; has an additional carboxyl-terminal peptide of about 30 amino acids carrying six glycosylation sites, and an extended half-life [<xref ref-type="bibr" rid="CR5">5</xref>].</p><p id="Par30">Although LH and hCG display these physiological, structural, and biochemical differences, they are marketed as recombinant or extractive and highly purified drugs to support FSH in controlled ovarian stimulation (COS), in the context of assisted reproduction [<xref ref-type="bibr" rid="CR6">6</xref>]. The action of these molecules is modulated by hormone and receptor polymorphic variants that influence individual response to COS, as well as predisposition to diseases and adverse events [<xref ref-type="bibr" rid="CR7">7</xref>]. The pharmacogenomic approach could represent an opportunity to improve the efficiency of COS [<xref ref-type="bibr" rid="CR8">8</xref>]. Apart from FSH, it is widely acknowledged that LH is crucial for folliculogenesis [<xref ref-type="bibr" rid="CR9">9</xref>, <xref ref-type="bibr" rid="CR10">10</xref>]. Several studies have demonstrated that a specific subset of women undergoing IVF treatment &#x02013; namely, those with low prognosis according to POSEIDON criteria &#x02013; may benefit from LH during COS [<xref ref-type="bibr" rid="CR11">11</xref>&#x02013;<xref ref-type="bibr" rid="CR13">13</xref>]. Moreover, there are specific genetic variants of LH and its receptor that could benefit from FSH or LH dose adjustment during assisted reproductive therapy (ART) [<xref ref-type="bibr" rid="CR14">14</xref>&#x02013;<xref ref-type="bibr" rid="CR16">16</xref>]. These concepts form the basis of the pharmacogenetic approach to assisted reproduction; this review provides a summary of the molecular pathways and pharmacogenetics of LH in clinical practice. Moreover, results from in vivo and in vitro studies about LH signaling, LH&#x003b2; and LHCGR variants, as well as their clinical impact, were discussed.</p></sec><sec id="Sec2"><title>Materials and methods</title><p id="Par31">We performed a literature search in PubMed, Scopus, Embase, and the ISI Web of Science database. The search terms were: &#x02018;LHCGR&#x02019;, &#x02018;LH&#x02019;, &#x02018;polymorphisms&#x02019;, &#x02018;genetic variants&#x02019;, &#x02018;ART&#x02019;, &#x02018;IVF&#x02019;, &#x02018;polycystic ovarian syndrome&#x02019;, and &#x02018;PCOS&#x02019; from the inception to January 2024. The most relevant studies that analyzed the impact of LH or LHCGR polymorphism on IVF outcomes are summarized in Supplemental Table 1. No language or time restriction was adopted.</p></sec><sec id="Sec3"><title>Results</title><sec id="Sec4"><title>Molecular pathways involved in LH signaling results from in vitro studies</title><p id="Par32">LHCGR is a 7-transmembrane, class A, G protein-coupled receptor (GPCR) [<xref ref-type="bibr" rid="CR1">1</xref>]; its active and inactive conformations have been recently resolved by cryogenic electron microscopy [<xref ref-type="bibr" rid="CR17">17</xref>]. Hormone binding to the receptor extracellular domain induces a &#x02018;push/pull&#x02019; movement involving the hinge region and impacting the spatial arrangement of the transmembrane stretches [<xref ref-type="bibr" rid="CR17">17</xref>], resulting in the activation of multiple intracellular signaling cascades [<xref ref-type="bibr" rid="CR3">3</xref>]. It is generally accepted that LHCGR mediates both cAMP and intracellular Ca<sup>2+</sup> increase, as well as sex steroid hormone production. These molecules were detectable using the first, pioneering assays available, such as radioimmunoassay, and have long been considered the main players involved in LH/hCG signaling [<xref ref-type="bibr" rid="CR18">18</xref>, <xref ref-type="bibr" rid="CR19">19</xref>].</p><p id="Par33">cAMP and Ca<sup>2+</sup> increase rapidly and belong to two separate signaling pathways mediated by different G proteins: G<sub>&#x003b1;</sub>s and G<sub>&#x003b1;</sub>q, respectively [<xref ref-type="bibr" rid="CR20">20</xref>]. cAMP is a second messenger inducing the activation of PKA and the phosphorylation of CREB, before being metabolized to AMP [<xref ref-type="bibr" rid="CR21">21</xref>]. In granulosa cells, relatively high intracellular cAMP concentrations have been linked to pro-apoptotic effects [<xref ref-type="bibr" rid="CR22">22</xref>&#x02013;<xref ref-type="bibr" rid="CR24">24</xref>] and, at the same time, to the compartmentalization of progesterone synthesis and androgen conversion to estrogens [<xref ref-type="bibr" rid="CR25">25</xref>].</p><p id="Par34">Androgens, mainly androstenedione, are produced by theca cells upon binding of phosphorylated CREB (pCREB) to <italic>CRE</italic> DNA target sequences. This is a PKA-dependent event that induces the transcription of steroidogenic enzyme-coding genes such as steroidogenic acute regulatory protein (<italic>STARD1</italic>), cytochrome P450 family 17 subfamily A member 1 (<italic>CYP17A1</italic>), and aromatase (<italic>CYP19A1</italic>) [<xref ref-type="bibr" rid="CR26">26</xref>]. PKA activation is also followed by phosphorylation of the extracellular-regulated kinase 1/2 (ERK1/2), accompanying the inhibition of progesterone production and stimulation of androgens synthesis [<xref ref-type="bibr" rid="CR27">27</xref>], and upregulating mitogenic processes in gonadal steroidogenic cells [<xref ref-type="bibr" rid="CR28">28</xref>, <xref ref-type="bibr" rid="CR29">29</xref>]. Moreover, ERK1/2 phosphorylation is linked to the downregulation of receptor mRNA transcripts [<xref ref-type="bibr" rid="CR28">28</xref>] and activation of GPCR kinases responsible for receptor phosphorylation and internalization into intracellular vesicles [<xref ref-type="bibr" rid="CR29">29</xref>]. In particular, the compartmentalization of LHCGR is mediated by &#x003b2;-arrestins, which are proteins responsible for a second wave of ERK1/2 phosphorylation [<xref ref-type="bibr" rid="CR30">30</xref>], occurring possibly as an opposing effect to cAMP-dependent pro-apoptotic signals [<xref ref-type="bibr" rid="CR31">31</xref>] (Fig. <xref rid="Fig1" ref-type="fig">1</xref>).</p><p id="Par35">
<fig id="Fig1"><label>Fig. 1</label><caption><p>Main LHCGR-mediated signaling pathways. Upon hormone binding, LHCGR activates multiple signaling pathways via G protein and B-arrestin recruitment. These signaling cascades converge mainly into steroidogenic and pro-apoptotic stimuli, counterbalanced by mitogenic and anti-apoptotic signals</p></caption><graphic xlink:href="12958_2025_1359_Fig1_HTML" id="MO1"/></fig>
</p><p id="Par36">In vitro experiments in transfected cells, expressing the murine receptor, demonstrated that gonadotropins are responsible for G<sub>&#x003b1;</sub>q protein and phospholipase C (PLC) activation, inositol trisphosphate (IP<sub>3</sub>) binding to calcium channels of endoplasmic reticulum, and mobilization of intracellular Ca<sup>2+</sup> [<xref ref-type="bibr" rid="CR20">20</xref>]. Calcium ions modulate the activity of protein calmodulin kinases, a key event to control cell proliferation [<xref ref-type="bibr" rid="CR32">32</xref>] and transport of cholesterol into the mitochondrion, as a rate-limiting step for steroidogenesis [<xref ref-type="bibr" rid="CR33">33</xref>, <xref ref-type="bibr" rid="CR34">34</xref>]. Interestingly, the half-maximal (EC<sub>50</sub>) hCG concentration activating the cAMP/PKA pathway is ~&#x02009;20 times lower than that required to trigger PLC/Ca<sup>2+</sup> pathway activation, suggesting that LHCGR has dual signaling potential [<xref ref-type="bibr" rid="CR35">35</xref>].</p><p id="Par37">Recent scientific advancements have demonstrated the existence of multiple intracellular signaling cascades, providing a more detailed picture of LH- and hCG-mediated signals. For instance, the &#x003b2;&#x003b3; dimer of G protein may indirectly lead to protein kinase B (AKT) activation, which upregulates survival signals [<xref ref-type="bibr" rid="CR36">36</xref>], inhibits aromatase [<xref ref-type="bibr" rid="CR37">37</xref>] and supports <italic>STARD1</italic> expression [<xref ref-type="bibr" rid="CR38">38</xref>]. The preferential activation of specific signaling patterns depends on several factors. First, LHCGR signaling may be allosterically modulated by other 7-transmembrane partners, which can physically interact with the receptor to form heteromeric assemblies in the cell surface [<xref ref-type="bibr" rid="CR22">22</xref>, <xref ref-type="bibr" rid="CR39">39</xref>&#x02013;<xref ref-type="bibr" rid="CR41">41</xref>]. Second, prevalent &#x003b2;-arrestin/ERK1/2 and AKT activation was found at low receptor density [<xref ref-type="bibr" rid="CR42">42</xref>, <xref ref-type="bibr" rid="CR43">43</xref>], while marked cAMP activation would be due to increased G<sub>&#x003b1;</sub>s coupling occurring at relatively high receptor expression levels [<xref ref-type="bibr" rid="CR22">22</xref>, <xref ref-type="bibr" rid="CR23">23</xref>]. These aspects shed light on the physiological impact of extremely variable gonadotropin receptor levels throughout the human menstrual cycle [<xref ref-type="bibr" rid="CR44">44</xref>]. Agonist binding induces receptor aggregation [<xref ref-type="bibr" rid="CR45">45</xref>] and sequestration from the cell surface [<xref ref-type="bibr" rid="CR46">46</xref>], preceding its internalization in endosomal vesicles [<xref ref-type="bibr" rid="CR47">47</xref>]. In particular, LHCGR internalization is mediated by GPCR kinases and other modulators, such as &#x003b2;-arrestins, that may form super-complexes of signaling modules sustaining prolonged cAMP [<xref ref-type="bibr" rid="CR48">48</xref>, <xref ref-type="bibr" rid="CR49">49</xref>] and direct ERK1/2 activation [<xref ref-type="bibr" rid="CR23">23</xref>].</p><p id="Par38">Taken together, LHCGR mediates a complex, spatial-temporal network of multiple signaling pathways triggered by LH and hCG. The two hormones act as different ligands linked to specific signaling patterns [<xref ref-type="bibr" rid="CR3">3</xref>], increasing the complexity of the picture. LH binding to LHCGR leads to preferential activation of proliferative and anti-apoptotic signals delivered through ERK1/2 and AKT, essential to ovarian follicle growth and maturation, while hCG is a potent progestational based on its physiological role [<xref ref-type="bibr" rid="CR50">50</xref>&#x02013;<xref ref-type="bibr" rid="CR54">54</xref>]. These data illustrate the different activity exerted by LH and hCG in vitro, which was confirmed also in a clinical setting [<xref ref-type="bibr" rid="CR55">55</xref>], and suggest the existence of natural, specific regulatory mechanisms adapting gonadotropin signals to physiological requirements (steroidogenesis, cell death, or survival).</p></sec><sec id="Sec5"><title>Knowledge about LH action from in vivo studies</title><p id="Par39">Recent decades have seen the generation of mutant hormone/receptor mice, allowing LH functions to be elucidated in vivo. Results from these studies must be interpreted with caution, since animal models for gonadotropin functioning, especially multi-ovulatory species, cannot be fully representative of human physiology.</p><p id="Par40">One of the first genetically modified mice overexpressed <italic>CGB</italic> and <italic>CGA</italic> [<xref ref-type="bibr" rid="CR56">56</xref>]. These animals were developed expecting to resemble the phenotype of humans with activating LHCGR mutations (i.e., males affected by testotoxicosis, tumorigenesis, or precocious puberty) and overall asymptomatic females. Instead, transgenic male mice had normal phenotypes, whereas females displayed luteinized ovarian follicles with hemorrhagic cysts and luteomas, precocious puberty, obesity, and other non-reproductive features, such as pituitary adenomas, mammary tumors, and pseudopregnancy [<xref ref-type="bibr" rid="CR56">56</xref>, <xref ref-type="bibr" rid="CR57">57</xref>]. An overall similar phenotype was obtained in female mice overexpressing a chimeric LH&#x003b2; fused with the carboxyl-terminal peptide of hCG. This molecule has additional glycosylations, extending its half-life, and can lead to polycystic ovaries, relatively high levels of sex steroids, infertility, and ovarian tumors [<xref ref-type="bibr" rid="CR58">58</xref>].</p><p id="Par41">Knockout mice were developed, starting with the deletion of the <italic>CGA</italic> gene. These animals had obvious hypogonadism and hypothyroidism [<xref ref-type="bibr" rid="CR59">59</xref>], due to the lack of full LH molecules, as well as FSH and TSH, which share the same &#x003b1; subunit. <italic>LHB</italic> knockout mice were also developed, reflecting this condition in humans. Male mice were affected by hypogonadism and displayed very low androgen levels and hypoplastic Leydig cells despite overall normal FSH levels, while females showed anovulation and collapse of antral follicles, and were infertile [<xref ref-type="bibr" rid="CR60">60</xref>].</p><p id="Par42">LH receptor knockout mouse models (LuRKO) have phenotypes similar to the LH&#x003b2; knockout, although they are not fully representative of the condition in humans, where full inactivation of LHCGR leads to type-1 Leydig cell hypoplasia and hermaphroditism. In mice at the fetal stage, the production of testosterone can occur through a gonadotropin-independent pathway [<xref ref-type="bibr" rid="CR61">61</xref>], stimulating fetal Leydig cells even in the absence of LH or its receptor, given the support of other paracrine factors [<xref ref-type="bibr" rid="CR62">62</xref>]. Therefore, LuRKO mice display impaired sexual maturation but have similar phenotypes of the wild-type at birth. Interestingly, the effects of the absence of LH receptors may be partially rescued in older mice (&#x02265;&#x02009;12 months), where LH-independent testosterone production could support qualitatively, but not quantitatively, similar spermatogenesis to wild-type mice [<xref ref-type="bibr" rid="CR63">63</xref>]. In LuRKO mice, similar effects were obtained by FSH receptor (FSHR) activating mutations, where spermatogenesis is rescued even in the presence of the anti-androgen flutamide [<xref ref-type="bibr" rid="CR64">64</xref>].</p><p id="Par43">These findings suggest the existence of Sertoli cell&#x02013;dependent paracrine factors capable of supporting partially Leydig cell functions, reflective of partially overlapping spermatogenic pathways. Moreover, these data suggest that the hormonal regulation of spermatogenesis has shifted from the dominance of gonadotropins to sex steroids during evolution. However, these data were not fully replicated in female LuRKO mice, where the expression of constitutively active FSHR led to the progression of antral follicles to the preovulatory stage and enhanced estrogenic activity but failed to rescue the healthy phenotype from hypogonadism and anovulation [<xref ref-type="bibr" rid="CR65">65</xref>]. Taken together, studies from in vivo models have confirmed the relevance of the LH/LHCGR system for reproduction, although potential translation of results to humans must take careful account of sex- and species-specific effects.</p></sec><sec id="Sec6"><title>The impact of LH and LHCGR genetic variants on signal transduction during folliculogenesis</title><p id="Par44">Few single-nucleotide polymorphisms (SNPs) within the <italic>LHB</italic>/<italic>CGB</italic> gene cluster have been described. In general, though little is known about <italic>CGB</italic> SNPs and their possible association with miscarriage [<xref ref-type="bibr" rid="CR66">66</xref>], <italic>LHB</italic> SNPs are linked to human phenotypic variations that might mildly contribute to the pathogenesis of reproductive diseases, such as polycystic ovary syndrome (PCOS) [<xref ref-type="bibr" rid="CR67">67</xref>]. The main molecular mechanism by which <italic>LHB</italic> and <italic>LHCGR</italic> SNPs impact ovarian functions would rely on the modulation of androgen production and, in turn, on the subsequent perturbation of the hypothalamic-pituitary-gonadal axis. However, it is plausible that mitogenic signals mediated directly by gonadotropins, fundamental to support gametogenesis, could also be perturbed. The endocrine adaptation to androgen levels is controlled by feedback mechanisms that lead to changes of serum LH and FSH, as well as levels of gonadal and adrenal steroids. Together, these events impact on gametogenesis and metabolism, as functions that, in large part, are directly or indirectly dependent on gonadotropins and steroids. However, clinical data are limited, and functional characterizations are mostly missing, suggesting that these SNPs do not substantially impact fertility [<xref ref-type="bibr" rid="CR67">67</xref>].</p><p id="Par45">One of the best-characterized <italic>LHB</italic> polymorphic variants was found in the Finnish population: V-LH, which consists in the double amino acid tryptophan&#x02013;arginine and isoleucine&#x02013;threonine change at positions 28 and 35 of the protein chain [<xref ref-type="bibr" rid="CR68">68</xref>, <xref ref-type="bibr" rid="CR69">69</xref>]. It has an additional glycosylation site [<xref ref-type="bibr" rid="CR70">70</xref>], lower half-life, and receptor binding, as well as decreased potency in activating progesterone and cAMP, than the classical LH form [<xref ref-type="bibr" rid="CR71">71</xref>, <xref ref-type="bibr" rid="CR72">72</xref>]. The V-LH variant was associated with infertility in homozygous Japanese women [<xref ref-type="bibr" rid="CR73">73</xref>], as well as with the worst outcome of intracytoplasmic sperm injection procedures, reflecting enhanced pro-apoptotic signals detected in vitro, such as caspase 3 cleavage and DNA fragmentation index [<xref ref-type="bibr" rid="CR74">74</xref>]. However, these data were never extensively replicated by independent studies in different ethnic groups, suggesting that the impact of V-LH on the phenotype is overall weak. This hormone variant is less frequent in obese PCOS women than in non-obese PCOS and healthy women, indicating that it might be protective against certain metabolic features related to the disease [<xref ref-type="bibr" rid="CR75">75</xref>], although a further investigation failed to confirm this association [<xref ref-type="bibr" rid="CR76">76</xref>]. Interestingly, the relatively low hormone bioactivity is compensated by higher V-LH expression than LH, due to SNPs falling within the promoter region in linkage disequilibrium with those at positions 25 and 35, increasing its activity in vivo [<xref ref-type="bibr" rid="CR77">77</xref>, <xref ref-type="bibr" rid="CR78">78</xref>]. Together, these data suggest that the V-LH consists of a polymorphic variant associated with overall mild phenotypes.</p><p id="Par46">In women, some other <italic>LHB</italic> SNPs were associated with infertility [<xref ref-type="bibr" rid="CR79">79</xref>] or central precocious puberty [<xref ref-type="bibr" rid="CR80">80</xref>]. In particular, a SNP characterized by the synonymous amino acid T&#x02013;C change within the exon 3 at gene sequence position 294, was found to be more frequent in South Indian women with PCOS compared with healthy controls [<xref ref-type="bibr" rid="CR81">81</xref>]. Although the role of this SNP in PCOS pathogenesis is unknown, it was hypothesized that it could impact the function of a <italic>LHB</italic> palindromic gene <italic>RUVBL2</italic>, coding a protein involved in the regulation of DNA transcription [<xref ref-type="bibr" rid="CR82">82</xref>]. Another <italic>LHB</italic> SNP of potential clinical interest is provided by the asparagine&#x02013;serine change at position 312 (p.Asn312Ser) of the protein chain, which is close to a glycosylation site and could impact sensitivity to the hormone and live birth rate [<xref ref-type="bibr" rid="CR15">15</xref>, <xref ref-type="bibr" rid="CR83">83</xref>, <xref ref-type="bibr" rid="CR84">84</xref>]. Although <italic>LHB</italic> polymorphic variants could be promising targets for future pharmacogenomic research, these results require confirmation by independent clinical studies in other populations and functional in vitro support.</p><p id="Par47">Most SNPs modulating LH/hCG signaling are carried by LHCGR [<xref ref-type="bibr" rid="CR3">3</xref>]. The receptor is a hot-spot for certain reproductive diseases, such as PCOS [<xref ref-type="bibr" rid="CR85">85</xref>&#x02013;<xref ref-type="bibr" rid="CR87">87</xref>], reflecting the relevance of a fine-tuned regulation of LH signaling to support folliculogenesis. Although the mechanism of PCOS pathogenesis is still largely unclear, marked LHCGR-dependent signals are likely important. They could lead to excessive androgen production which, in turn, impacts the endocrine control of the hypothalamus-pituitary-gonadal axis, interfering with ovarian follicular maturation and metabolism [<xref ref-type="bibr" rid="CR88">88</xref>]. In fact, several <italic>LHCGR</italic> SNPs were associated with PCOS in different populations [<xref ref-type="bibr" rid="CR89">89</xref>&#x02013;<xref ref-type="bibr" rid="CR96">96</xref>]. For instance, the exon 10 SNP characterized by the alanine&#x02013;serine change at position 312 was associated with serum LH levels in PCOS patients [<xref ref-type="bibr" rid="CR97">97</xref>]. Interestingly, the same SNP was linked to spermatogenic damage and infertility in males [<xref ref-type="bibr" rid="CR98">98</xref>], suggesting that the variant falls within a key region for receptor functioning. Beyond PCOS, the possible link between <italic>LHCGR</italic> SNPs and clinical outcome of assisted reproduction, such as oocyte/embryo quality, was also discussed [<xref ref-type="bibr" rid="CR99">99</xref>]. Although these findings are encouraging, the LHCGR-dependent molecular mechanism at the basis of PCOS pathogenesis remains poorly understood and the role of the receptor as a potential target for pharmacological approach to the disease is under-researched [<xref ref-type="bibr" rid="CR99">99</xref>]. The clinical effect of LH&#x003b2; and LHCGR genetic variants, as well as of possible pharmacogenomic approaches, will be discussed in the next sections.</p></sec><sec id="Sec7"><title>The clinical effect of <italic>LHB</italic> genetic variants</title><p id="Par48">In COS, it has been suggested that elevated requirement of FSH may result from weak LHCGR activity. Therefore, these patients might benefit from exogenous LH administration rather than increased FSH dose. This effect could be linked to V-LH which, in the context of COS, cannot achieve adequate levels to compensate for its reduced bioactivity. In a retrospective analysis [<xref ref-type="bibr" rid="CR100">100</xref>], where patients were divided into three groups according to the FSH dose required, the frequency of V-LH was higher in women with ovarian resistance to FSH administration in association with a lower number of oocytes retrieved. The LH versus V-LH genotypes were stratified in another multicentric study, demonstrating that elevated cumulative doses of FSH were associated with the V-LH genetic variant [<xref ref-type="bibr" rid="CR16">16</xref>]. The mean number of oocytes retrieved, fertilization rate, and pregnancy rate did not differ between the two groups, indicating that the highest doses of FSH may counterbalance the negative impact of low V-LH bioactivity in inducing oocyte competence and impacting on IVF outcome. However, a significant reduction in the mean of embryo number transferred has been reported. The investigators posited an interplay between FSH- and LH-mediated signals to determine successful oocyte maturation and meiosis [<xref ref-type="bibr" rid="CR16">16</xref>]. Recently, V-LH was associated with a lower pregnancy rate in gonadotropin-releasing hormone (GnRH) antagonists, but not in long GnRH agonist cycles; these differences were attributed to variations in clinical protocols [<xref ref-type="bibr" rid="CR101">101</xref>]. Endogenous LH levels were lower with the antagonist cycle, compared with the agonist cycle [<xref ref-type="bibr" rid="CR102">102</xref>&#x02013;<xref ref-type="bibr" rid="CR104">104</xref>]. Therefore, V-LH carriers are associated with reduced pregnancy rates only when they undergo profound LH suppression induced by antagonist protocols.</p><p id="Par49">Another clinically interesting LH&#x003b2; variant consists in the single missense exon 3 variation, consisting in the amino acid serine&#x02013;glycine changes at position 102 (Gly1502Ser, rs1056917). This variant may change LH bioactivity, since a single study reported the association between the SNP and reduced LH level, and history of infertility [<xref ref-type="bibr" rid="CR105">105</xref>]. However, another study prospectively enrolling 220 women undergoing long protocol for COS and IVF found no significant association between this SNP and ovarian response [<xref ref-type="bibr" rid="CR106">106</xref>], suggesting that overall effects of this genetic variation are likely mild.</p></sec><sec id="Sec8"><title>The clinical effect of LHCGR genetic variants</title><sec id="Sec9"><title>LHCGR exon 10 polymorphisms</title><p id="Par50">One of the most studied polymorphisms is the exon 10 p.Asn312Ser. It is relatively common: in European Caucasians, the allele frequency is 41% asparagine (Asn) and 49% serine (Ser), compared with 68% Asn and 32% Ser in the Sub-Saharan African population (<ext-link ext-link-type="uri" xlink:href="https://www.ncbi.nlm.nih.gov/snp/rs2293275">https://www.ncbi.nlm.nih.gov/snp/rs2293275</ext-link>). It was demonstrated that Asn-homozygous women required a lower amount of gonadotropin per day, during COS, than Ser-homozygous [<xref ref-type="bibr" rid="CR84">84</xref>], while the latter have a fourfold higher chance of pregnancy than Asn-homozygous. In the same population, authors later reported significantly higher live birth and cumulative live birth rates in Ser-variant versus Asn-variant carriers [<xref ref-type="bibr" rid="CR83">83</xref>]. This was explained by the increased number of good-quality embryos found in the Ser carrier group [<xref ref-type="bibr" rid="CR83">83</xref>], according to the guidelines by Gardner and Schoolcraft [<xref ref-type="bibr" rid="CR107">107</xref>, <xref ref-type="bibr" rid="CR108">108</xref>]. Consistently with Lindgren findings, in a prospective study involving 210 women, higher clinical pregnancy rate was observed in Ser-homozygous carriers than heterozygous women after fresh embryo transfer [<xref ref-type="bibr" rid="CR109">109</xref>]. However, we obtained different results in a multicenter retrospective study involving 94 normogonadotropic women from three European IVF centers, where no significant association was found in terms of ovarian response (number of oocytes retrieved, MII oocytes) and pregnancy rate among different LHCGR haplotypes [<xref ref-type="bibr" rid="CR110">110</xref>]. Our findings were corroborated by a recent analysis involving 1183 women, ages 18&#x02013;40 years and undergoing their first assisted reproductive technology cycle, where the association between the LHCGR Asn312Ser variant and pregnancy rate was not detected [<xref ref-type="bibr" rid="CR111">111</xref>]. Discrepancies between those studies could be linked to differences in their study designs, IVF protocols adopted, and ethnicity of participants.</p><p id="Par51">Another exon 10 LHCGR polymorphism consists of the Asn&#x02013;Ser change at position 291 (rs12470652). This variant was associated with increased receptor sensitivity [<xref ref-type="bibr" rid="CR112">112</xref>] and has a prevalence of 5% in Europe (<ext-link ext-link-type="uri" xlink:href="https://www.ncbi.nlm.nih.gov/snp/rs12470652">https://www.ncbi.nlm.nih.gov/snp/rs12470652</ext-link>). The clinical relevance of this polymorphism was assessed; no association was found with PCOS risk [<xref ref-type="bibr" rid="CR113">113</xref>, <xref ref-type="bibr" rid="CR114">114</xref>], nor response to testicular cancer treatment [<xref ref-type="bibr" rid="CR115">115</xref>]. In our multicenter prospective studies, we observed that this variant was associated with greater response to COS, evaluated as oocytes, and mature oocytes retrieved [<xref ref-type="bibr" rid="CR110">110</xref>, <xref ref-type="bibr" rid="CR116">116</xref>]. In combination with other FSHR polymorphisms, this variant is associated with the ratio between cumulative FSH dose and total number of oocytes retrieved (odds ratio [OR] 5.44, 95% CI 3.18&#x02013;7.71; <italic>p</italic>&#x02009;&#x0003c;&#x02009;0.001), supporting the concept of varying sensitivity to the ligand depending on LHCGR Asn291Ser phenotype [<xref ref-type="bibr" rid="CR110">110</xref>, <xref ref-type="bibr" rid="CR116">116</xref>]. These results were confirmed by recent research demonstrating that the Ser variant was significantly associated with PCOS risk, which is typically characterized by an increased sensitivity to exogenous gonadotropin during COS. Unfortunately, the evidence reported so far is limited due to the overall low prevalence of the Ser variant and a paucity of data on homozygotic carriers [<xref ref-type="bibr" rid="CR113">113</xref>, <xref ref-type="bibr" rid="CR114">114</xref>, <xref ref-type="bibr" rid="CR116">116</xref>].</p></sec><sec id="Sec10"><title>LHCGR A&#x02013;G intronic nucleotide variation</title><p id="Par52">Another LHCGR polymorphism consists in the A&#x02013;G intronic nucleotide variation (rs13405728), which was strongly associated with PCOS and first described in a genome-wide association study in Chinese women [<xref ref-type="bibr" rid="CR85">85</xref>]. The G allele occurs in 8% of the global population, with the highest prevalence in Africa (27&#x02013;31%); <ext-link ext-link-type="uri" xlink:href="https://www.ncbi.nlm.nih.gov/snp/rs13405728#frequency_tab">https://www.ncbi.nlm.nih.gov/snp/rs13405728#frequency_tab</ext-link>). A meta-analysis revealed that the OR for developing PCOS was significantly lower in G than in A carriers (OR 0.735, 95% CI 0.699&#x02013;0.773; <italic>p</italic>&#x02009;&#x0003c;&#x02009;0.001). Consistent with these results, a recent case&#x02013;control study involving 400 PCOS women compared with 480 healthy controls confirmed the reduced risk among G carriers of developing PCOS syndrome [<xref ref-type="bibr" rid="CR117">117</xref>]. The mechanism by which this polymorphism could promote PCOS is still not understood. A recent study suggested that <italic>LHCGR</italic> rs13405728 could modulate the <italic>STON1</italic> and <italic>FSHR</italic> transduction, thereby influencing metabolic processes and androgen receptor expression [<xref ref-type="bibr" rid="CR118">118</xref>].</p></sec><sec id="Sec11"><title>LHCGR missense polymorphisms</title><p id="Par53">Finally, LHCGR missense polymorphism Asn312Ser (rs2293275) has been found to be associated with PCOS [<xref ref-type="bibr" rid="CR93">93</xref>, <xref ref-type="bibr" rid="CR113">113</xref>, <xref ref-type="bibr" rid="CR119">119</xref>, <xref ref-type="bibr" rid="CR120">120</xref>]. In a meta-analysis collecting six association studies, Caucasian homozygous Ser carriers have an increased risk of developing ovarian hyperstimulation syndrome (OHSS) than Asn-homozygous and heterozygous (OR 4.11, CI 95% 1.03&#x02013;16.38) [<xref ref-type="bibr" rid="CR119">119</xref>]. Recently, a study involving 421 PCOS and 322 regularly menstruating women found the highest prevalence of the Ser variant among individuals with the disease [<xref ref-type="bibr" rid="CR91">91</xref>].</p></sec></sec><sec id="Sec12"><title>Pharmacogenomic approach in women with clinical variants affecting the LH system</title><p id="Par54">The pharmacogenomic approach consists of the prescription of medication based on the individual genetic profile. Specific genetic variants could influence the pharmacokinetics or pharmacodynamics of a drug. For instance, some individuals have increased or reduced receptor sensitivity to an exogenous medication or display a different drug half-life. In patients at risk of adverse events, the pharmacogenomic approach could help to minimize safety issues [<xref ref-type="bibr" rid="CR121">121</xref>]. In the context of assisted reproduction, we have at least two possible adverse events linked to exogenous gonadotropin administration. One is OHSS, potentially a life-threatening event, in which an exaggerated ovarian response to gonadotropins occurs, leading to the development of multiple follicles, ascites, and thrombotic events [<xref ref-type="bibr" rid="CR122">122</xref>, <xref ref-type="bibr" rid="CR123">123</xref>]. Moreover, women could have poor ovarian response to gonadotropins, leading to poor outcomes with assisted reproduction techniques and dropout from IVF treatment [<xref ref-type="bibr" rid="CR124">124</xref>].</p><p id="Par55">So far, very few studies have been conducted using a pharmacogenomic approach in the context of IVF. Regarding SNPs modulating LH/LHCGR signals, a prospective analysis of 193 women with a history of unsuccessful IVF cycles was performed [<xref ref-type="bibr" rid="CR14">14</xref>]. Seventy-eight women were supplemented with 75 UI of LH from day 6 (control group), while 115 were supplemented with LH, according to LHCGR Asn312Ser phenotype, from day 1 (study group). Homozygous Asn carriers received no LH; 37.5 UI of LH was prescribed to heterozygous, and 75 UI to Ser-homozygous, carriers. Women receiving genotype-based LH personalized treatment had a higher clinical pregnancy rate than the control group (56/115 vs. 26/78; <italic>p</italic>&#x02009;=&#x02009;0.049). However, limitations of this study must be acknowledged, such as its retrospective design and the duration of LH treatment, which was significantly higher in the study group than in controls. In another retrospective analysis, 533 women underwent a long protocol with FSH and LH coadministration, according to previously established criteria [<xref ref-type="bibr" rid="CR125">125</xref>]. Authors found that Ser-homozygous women required more LH during COS, although they had a higher rate of pregnancies than women with other haplotypes [<xref ref-type="bibr" rid="CR15">15</xref>].</p></sec></sec><sec id="Sec13"><title>Knowledge gaps and future research</title><p id="Par56">Pharmacogenomics aims to improve the efficacy of therapeutic approaches, based on the susceptibility of genetic profiles. However, what is still debated is whether to promote the widespread use of this genetic information in clinical practice, since only a limited set of genetic variations have significant impact.</p><p id="Par57">In specific subsets of ART patients, the reproductive outcome may benefit from LH supplementation. These patients consist in women with hypo-response to exogenous FSH alone [<xref ref-type="bibr" rid="CR126">126</xref>&#x02013;<xref ref-type="bibr" rid="CR129">129</xref>], and women of advanced reproductive age (&#x02265;&#x02009;35 years) [<xref ref-type="bibr" rid="CR130">130</xref>]. The genetic aspects beyond LH deficiency have been poorly understood. As previously reported, serine carriers of the LHCGR variant (rs2293275) may require higher amounts of LH, as a FSH supplement during COS, than other LHCGR genotypes [<xref ref-type="bibr" rid="CR15">15</xref>]. Moreover carriers of LHB variant might need increased FSH dosage during COS [<xref ref-type="bibr" rid="CR100">100</xref>]. The impact of LHCGR variant on pregnancy and cumulative pregnancy was observed by just one research group [<xref ref-type="bibr" rid="CR83">83</xref>, <xref ref-type="bibr" rid="CR84">84</xref>] but unfortunately not corroborated by other studies [<xref ref-type="bibr" rid="CR110">110</xref>, <xref ref-type="bibr" rid="CR111">111</xref>]. These mixed findings could be explained by inter-study differences in design and protocols. Another issue concerning pregnancy rate resides in the difficulty to reach the adequate sample size in IVF studies [<xref ref-type="bibr" rid="CR131">131</xref>]. Finally, in our opinion the interaction among polymorphisms is still under-investigated. In other words, instead of focusing on single genetic association, future studies should focus more on simultaneous analysis of the genetic variants involved in COS [<xref ref-type="bibr" rid="CR110">110</xref>, <xref ref-type="bibr" rid="CR132">132</xref>, <xref ref-type="bibr" rid="CR133">133</xref>].</p><p id="Par58">So far, the lack of studies on gonadotropin polymorphisms could be explained by high costs of genetic tests, in comparison to hormonal assays, which are easier to perform, less expensive, and routinely used in clinical practice to guide COS during ART.</p><p id="Par59">Dose-finding procedures, appropriate protocols, duration of stimulation, and number of cycles all warrant further investigation to improve our knowledge of ovarian response. Hence, the identification of genetic determinants for reduced ovarian response might lead to tailored medical approaches, reduce the overall costs of IVF treatments, and improve COS efficiency.</p><p id="Par60">Predictive medicine also takes advantage of indexes to assess specific conditions. In ART, parameters such as the Follicle to Oocyte Index (FOI) and Follicular Output Rate (FORT) have been applied to practically define the ovarian response to COS [<xref ref-type="bibr" rid="CR134">134</xref>]. However, no studies have been performed to evaluate the association between specific gonadotropin polymorphisms and ovarian sensitivity indexes. This knowledge might play a key role in increasing the chance of recruiting more oocytes and optimizing the chance of a live birth [<xref ref-type="bibr" rid="CR135">135</xref>]. Informative results on whether such genetic polymorphisms could be associated with reduced response to COS may be obtained from poor responder women, who belong to groups 3 and 4 of the POSEIDON classification. Nonetheless, there is a need for large multicenter studies of real-world data, across different ages and ethnic groups, to further evaluate benefits of genetic testing in ART.</p></sec><sec id="Sec14"><title>Conclusion</title><p id="Par61">The pharmacogenomic approach based on <italic>LHB</italic> and/or <italic>LHCGR</italic> genotypes remains under-researched. The most promising SNP that might be used to personalize COS is the LHCGR Asn312Ser, but the evidence so far is poor and limited to very few studies. Although a possible cumulative effect between LH and LHCGR SNPs has been reported in several studies, these findings have yet to be supported by any randomized clinical trials. Without such investigations, it is not yet possible to suggest a pharmacogenomic approach in clinical practice.</p></sec><sec id="Sec15" sec-type="supplementary-material"><title>Supplementary Information</title><p>
<supplementary-material content-type="local-data" id="MOESM1"><media xlink:href="12958_2025_1359_MOESM1_ESM.docx"><caption><p>Supplementary Material 1.</p></caption></media></supplementary-material></p></sec></body><back><glossary><title>Abbreviations</title><def-list><def-item><term>AKT</term><def><p id="Par2">Protein kinase B</p></def></def-item><def-item><term>AMP</term><def><p id="Par3">Adenosine monophosphate</p></def></def-item><def-item><term>ART</term><def><p id="Par4">Assisted reproductive therapy</p></def></def-item><def-item><term>Ca<sup>2+</sup></term><def><p id="Par5">Calcium ion</p></def></def-item><def-item><term>cAMP</term><def><p id="Par6">Cyclic adenosine monophosphate</p></def></def-item><def-item><term>CGA</term><def><p id="Par7">Human &#x003b1; subunit-coding gene</p></def></def-item><def-item><term>CGB</term><def><p id="Par8">Human &#x003b2; subunit-coding gene</p></def></def-item><def-item><term>COS</term><def><p id="Par9">Controlled ovarian stimulation</p></def></def-item><def-item><term>CREB</term><def><p id="Par10">cAMP response element&#x02013;binding protein</p></def></def-item><def-item><term>ERK1/2</term><def><p id="Par11">Extracellular-regulated kinase 1/2</p></def></def-item><def-item><term>FSH[R]</term><def><p id="Par12">Follicle-stimulating hormone [receptor</p></def></def-item><def-item><term>GnRH</term><def><p id="Par13">Gonadotropin-releasing hormone</p></def></def-item><def-item><term>GPCR</term><def><p id="Par14">G protein-coupled receptor</p></def></def-item><def-item><term>hCG</term><def><p id="Par15">Human chorionic gonadotropin</p></def></def-item><def-item><term>IP<sub>3</sub></term><def><p id="Par16">Inositol trisphosphate</p></def></def-item><def-item><term>IVF</term><def><p id="Par17">in vitro fertilization</p></def></def-item><def-item><term>LH</term><def><p id="Par18">Luteinizing hormone</p></def></def-item><def-item><term>LHCGR</term><def><p id="Par19">Luteinizing hormone/choriogonadotropin receptor</p></def></def-item><def-item><term>LuRKO</term><def><p id="Par20">LH receptor knockout</p></def></def-item><def-item><term>OHSS</term><def><p id="Par21">Ovarian hyperstimulation syndrome</p></def></def-item><def-item><term>OR</term><def><p id="Par22">Odds ratio</p></def></def-item><def-item><term>PCOS</term><def><p id="Par23">Polycystic ovary syndrome</p></def></def-item><def-item><term>PKA</term><def><p id="Par24">Protein kinase A</p></def></def-item><def-item><term>PLC</term><def><p id="Par25">Phospholipase C</p></def></def-item><def-item><term>SNP</term><def><p id="Par26">Single-nucleotide polymorphism</p></def></def-item><def-item><term>TSH</term><def><p id="Par27">Thyroid-stimulating hormone</p></def></def-item></def-list></glossary><fn-group><fn><p><bold>Publisher&#x02019;s Note</bold></p><p>Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.</p></fn></fn-group><ack><title>Acknowledgements</title><p>This work was supported by Le Studium Loire Valley Institute for Advanced Studies, Orl&#x000e9;ans, and Tours, France, through the ARD CVL Biopharmaceuticals program funded by the Centre-Val de Loire region.</p><sec id="FPar1"><title>About this supplement</title><p id="Par62">This article has been published as part of Reproductive Biology and Endocrinology, Volume 23 Supplement 01, 2025:Luteinizing Hormone throughout the fertility journey. The full contents of the supplement are available at <ext-link ext-link-type="uri" xlink:href="https://rbej.biomedcentral.com/articles/supplements/volume-23-supplement-1">https://rbej.biomedcentral.com/articles/supplements/volume-23-supplement-1</ext-link>.</p></sec></ack><notes notes-type="author-contribution"><title>Authors&#x02019; contributions</title><p>All authors (AC, RDG, MG, CA, and LC) were involved in the drafting, review, and final approval of the manuscript for publication.</p></notes><notes notes-type="funding-information"><title>Funding</title><p>The authors received no specific funding for this work.</p></notes><notes notes-type="data-availability"><title>Data availability</title><p>Not applicable.</p></notes><notes><title>Declarations</title><notes id="FPar2"><title>Ethics approval and consent to participate</title><p id="Par63">Not applicable.</p></notes><notes id="FPar3"><title>Consent for publication</title><p id="Par64">Not applicable.</p></notes><notes id="FPar4" notes-type="COI-statement"><title>Competing interests</title><p id="Par65">The authors declare that they have no competing interests.</p></notes></notes><ref-list id="Bib1"><title>References</title><ref id="CR1"><label>1.</label><citation-alternatives><element-citation id="ec-CR1" publication-type="journal"><person-group person-group-type="author"><name><surname>Ascoli</surname><given-names>M</given-names></name><name><surname>Fanelli</surname><given-names>F</given-names></name><name><surname>Segaloff</surname><given-names>DL</given-names></name></person-group><article-title>The lutropin/choriogonadotropin receptor, a 2002 perspective</article-title><source>Endocr Rev</source><year>2002</year><volume>23</volume><fpage>141</fpage><lpage>174</lpage><pub-id pub-id-type="doi">10.1210/edrv.23.2.0462</pub-id><pub-id pub-id-type="pmid">11943741</pub-id>
</element-citation><mixed-citation id="mc-CR1" publication-type="journal">Ascoli M, Fanelli F, Segaloff DL. The lutropin/choriogonadotropin receptor, a 2002 perspective. Endocr Rev. 2002;23:141&#x02013;74.<pub-id pub-id-type="pmid">11943741</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR2"><label>2.</label><citation-alternatives><element-citation id="ec-CR2" publication-type="journal"><person-group person-group-type="author"><name><surname>Pierce</surname><given-names>JG</given-names></name><name><surname>Faith</surname><given-names>MR</given-names></name><name><surname>Giudice</surname><given-names>LC</given-names></name><name><surname>Reeve</surname><given-names>JR</given-names></name></person-group><article-title>Structure and structure&#x02013;function relationships in glycoprotein hormones</article-title><source>Ciba Found Symp</source><year>1976</year><volume>41</volume><fpage>225</fpage><lpage>50</lpage><pub-id pub-id-type="pmid">780075</pub-id>
</element-citation><mixed-citation id="mc-CR2" publication-type="journal">Pierce JG, Faith MR, Giudice LC, Reeve JR. Structure and structure&#x02013;function relationships in glycoprotein hormones. Ciba Found Symp. 1976;41:225&#x02013;50.<pub-id pub-id-type="pmid">780075</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR3"><label>3.</label><citation-alternatives><element-citation id="ec-CR3" publication-type="journal"><person-group person-group-type="author"><name><surname>Casarini</surname><given-names>L</given-names></name><name><surname>Santi</surname><given-names>D</given-names></name><name><surname>Brigante</surname><given-names>G</given-names></name><name><surname>Simoni</surname><given-names>M</given-names></name></person-group><article-title>Two hormones for one receptor: evolution, biochemistry, actions, and pathophysiology of LH and hCG</article-title><source>Endocr Rev</source><year>2018</year><volume>39</volume><fpage>549</fpage><lpage>592</lpage><pub-id pub-id-type="doi">10.1210/er.2018-00065</pub-id><pub-id pub-id-type="pmid">29905829</pub-id>
</element-citation><mixed-citation id="mc-CR3" publication-type="journal">Casarini L, Santi D, Brigante G, Simoni M. Two hormones for one receptor: evolution, biochemistry, actions, and pathophysiology of LH and hCG. Endocr Rev. 2018;39:549&#x02013;92.<pub-id pub-id-type="pmid">29905829</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR4"><label>4.</label><citation-alternatives><element-citation id="ec-CR4" publication-type="journal"><person-group person-group-type="author"><name><surname>Hallast</surname><given-names>P</given-names></name><name><surname>Nagirnaja</surname><given-names>L</given-names></name><name><surname>Margus</surname><given-names>T</given-names></name><name><surname>Laan</surname><given-names>M</given-names></name></person-group><article-title>Segmental duplications and gene conversion: human luteinizing hormone/chorionic gonadotropin beta gene cluster</article-title><source>Genome Res</source><year>2005</year><volume>15</volume><fpage>1535</fpage><lpage>1546</lpage><pub-id pub-id-type="doi">10.1101/gr.4270505</pub-id><pub-id pub-id-type="pmid">16251463</pub-id>
</element-citation><mixed-citation id="mc-CR4" publication-type="journal">Hallast P, Nagirnaja L, Margus T, Laan M. Segmental duplications and gene conversion: human luteinizing hormone/chorionic gonadotropin beta gene cluster. Genome Res. 2005;15:1535&#x02013;46.<pub-id pub-id-type="pmid">16251463</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR5"><label>5.</label><citation-alternatives><element-citation id="ec-CR5" publication-type="journal"><person-group person-group-type="author"><name><surname>Fiddes</surname><given-names>JC</given-names></name><name><surname>Goodman</surname><given-names>HM</given-names></name></person-group><article-title>The cDNA for the beta-subunit of human chorionic gonadotropin suggests evolution of a gene by readthrough into the 3&#x02019;-untranslated region</article-title><source>Nature</source><year>1980</year><volume>286</volume><fpage>684</fpage><lpage>687</lpage><pub-id pub-id-type="doi">10.1038/286684a0</pub-id><pub-id pub-id-type="pmid">6774259</pub-id>
</element-citation><mixed-citation id="mc-CR5" publication-type="journal">Fiddes JC, Goodman HM. The cDNA for the beta-subunit of human chorionic gonadotropin suggests evolution of a gene by readthrough into the 3&#x02019;-untranslated region. Nature. 1980;286:684&#x02013;7.<pub-id pub-id-type="pmid">6774259</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR6"><label>6.</label><citation-alternatives><element-citation id="ec-CR6" publication-type="journal"><person-group person-group-type="author"><name><surname>De Leo</surname><given-names>V</given-names></name><name><surname>Musacchio</surname><given-names>MC</given-names></name><name><surname>Di Sabatino</surname><given-names>A</given-names></name><name><surname>Tosti</surname><given-names>C</given-names></name><name><surname>Morgante</surname><given-names>G</given-names></name><name><surname>Petraglia</surname><given-names>F</given-names></name></person-group><article-title>Present and future of recombinant gonadotropins in reproductive medicine</article-title><source>Curr Pharm Biotechnol</source><year>2012</year><volume>13</volume><fpage>379</fpage><lpage>391</lpage><pub-id pub-id-type="doi">10.2174/138920112799361918</pub-id><pub-id pub-id-type="pmid">21657999</pub-id>
</element-citation><mixed-citation id="mc-CR6" publication-type="journal">De Leo V, Musacchio MC, Di Sabatino A, Tosti C, Morgante G, Petraglia F. Present and future of recombinant gonadotropins in reproductive medicine. Curr Pharm Biotechnol. 2012;13:379&#x02013;91.<pub-id pub-id-type="pmid">21657999</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR7"><label>7.</label><citation-alternatives><element-citation id="ec-CR7" publication-type="journal"><person-group person-group-type="author"><name><surname>Rivero-M&#x000fc;ller</surname><given-names>A</given-names></name><name><surname>Huhtaniemi</surname><given-names>I</given-names></name></person-group><article-title>Genetic variants of gonadotrophins and their receptors: impact on the diagnosis and management of the infertile patient</article-title><source>Best Pract Res Clin Endocrinol Metab</source><year>2022</year><volume>36</volume><fpage>101596</fpage><pub-id pub-id-type="doi">10.1016/j.beem.2021.101596</pub-id><pub-id pub-id-type="pmid">34802912</pub-id>
</element-citation><mixed-citation id="mc-CR7" publication-type="journal">Rivero-M&#x000fc;ller A, Huhtaniemi I. Genetic variants of gonadotrophins and their receptors: impact on the diagnosis and management of the infertile patient. Best Pract Res Clin Endocrinol Metab. 2022;36:101596.<pub-id pub-id-type="pmid">34802912</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR8"><label>8.</label><citation-alternatives><element-citation id="ec-CR8" publication-type="journal"><person-group person-group-type="author"><name><surname>Conforti</surname><given-names>A</given-names></name><name><surname>Vaiarelli</surname><given-names>A</given-names></name><name><surname>Cimadomo</surname><given-names>D</given-names></name><name><surname>Bagnulo</surname><given-names>F</given-names></name><name><surname>Peluso</surname><given-names>S</given-names></name><name><surname>Carbone</surname><given-names>L</given-names></name><etal/></person-group><article-title>Pharmacogenetics of FSH action in the female</article-title><source>Front Endocrinol (Lausanne)</source><year>2019</year><volume>10</volume><fpage>398</fpage><pub-id pub-id-type="doi">10.3389/fendo.2019.00398</pub-id><pub-id pub-id-type="pmid">31293516</pub-id>
</element-citation><mixed-citation id="mc-CR8" publication-type="journal">Conforti A, Vaiarelli A, Cimadomo D, Bagnulo F, Peluso S, Carbone L, et al. Pharmacogenetics of FSH action in the female. Front Endocrinol (Lausanne). 2019;10:398.<pub-id pub-id-type="pmid">31293516</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR9"><label>9.</label><citation-alternatives><element-citation id="ec-CR9" publication-type="journal"><person-group person-group-type="author"><name><surname>L&#x000e9;vy</surname><given-names>DP</given-names></name><name><surname>Navarro</surname><given-names>JM</given-names></name><name><surname>Schattman</surname><given-names>GL</given-names></name><name><surname>Davis</surname><given-names>OK</given-names></name><name><surname>Rosenwaks</surname><given-names>Z</given-names></name></person-group><article-title>The role of LH in ovarian stimulation: exogenous LH: let&#x02019;s design the future</article-title><source>Hum Reprod</source><year>2000</year><volume>15</volume><fpage>2258</fpage><lpage>65</lpage><pub-id pub-id-type="doi">10.1093/humrep/15.11.2258</pub-id><pub-id pub-id-type="pmid">11056116</pub-id>
</element-citation><mixed-citation id="mc-CR9" publication-type="journal">L&#x000e9;vy DP, Navarro JM, Schattman GL, Davis OK, Rosenwaks Z. The role of LH in ovarian stimulation: exogenous LH: let&#x02019;s design the future. Hum Reprod. 2000;15:2258&#x02013;65.<pub-id pub-id-type="pmid">11056116</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR10"><label>10.</label><citation-alternatives><element-citation id="ec-CR10" publication-type="journal"><person-group person-group-type="author"><name><surname>Alviggi</surname><given-names>C</given-names></name><name><surname>Clarizia</surname><given-names>R</given-names></name><name><surname>Mollo</surname><given-names>A</given-names></name><name><surname>Ranieri</surname><given-names>A</given-names></name><name><surname>De Placido</surname><given-names>G</given-names></name></person-group><article-title>Who needs LH in ovarian stimulation?</article-title><source>Reprod Biomed Online</source><year>2011</year><volume>22</volume><fpage>s33</fpage><lpage>41</lpage><pub-id pub-id-type="doi">10.1016/S1472-6483(11)60007-2</pub-id><pub-id pub-id-type="pmid">21575848</pub-id>
</element-citation><mixed-citation id="mc-CR10" publication-type="journal">Alviggi C, Clarizia R, Mollo A, Ranieri A, De Placido G. Who needs LH in ovarian stimulation? Reprod Biomed Online. 2011;22:s33-41.<pub-id pub-id-type="pmid">21575848</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR11"><label>11.</label><citation-alternatives><element-citation id="ec-CR11" publication-type="journal"><person-group person-group-type="author"><name><surname>Humaidan</surname><given-names>P</given-names></name><name><surname>Alviggi</surname><given-names>C</given-names></name><name><surname>Fischer</surname><given-names>R</given-names></name><name><surname>Esteves</surname><given-names>SC</given-names></name></person-group><article-title>The novel POSEIDON stratification of low prognosis patients in assisted reproductive technology and its proposed marker of successful outcome</article-title><source>F1000Res</source><year>2016</year><volume>5</volume><fpage>2911</fpage><pub-id pub-id-type="doi">10.12688/f1000research.10382.1</pub-id><pub-id pub-id-type="pmid">28232864</pub-id>
</element-citation><mixed-citation id="mc-CR11" publication-type="journal">Humaidan P, Alviggi C, Fischer R, Esteves SC. The novel POSEIDON stratification of low prognosis patients in assisted reproductive technology and its proposed marker of successful outcome. F1000Res. 2016;5:2911.<pub-id pub-id-type="pmid">28232864</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR12"><label>12.</label><citation-alternatives><element-citation id="ec-CR12" publication-type="journal"><person-group person-group-type="author"><name><surname>Sunkara</surname><given-names>SK</given-names></name><name><surname>Ramaraju</surname><given-names>GA</given-names></name><name><surname>Kamath</surname><given-names>MS</given-names></name></person-group><article-title>Management strategies for POSEIDON group 2</article-title><source>Front Endocrinol (Lausanne)</source><year>2020</year><volume>11</volume><fpage>105</fpage><pub-id pub-id-type="doi">10.3389/fendo.2020.00105</pub-id><pub-id pub-id-type="pmid">32174892</pub-id>
</element-citation><mixed-citation id="mc-CR12" publication-type="journal">Sunkara SK, Ramaraju GA, Kamath MS. Management strategies for POSEIDON group 2. Front Endocrinol (Lausanne). 2020;11:105.<pub-id pub-id-type="pmid">32174892</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR13"><label>13.</label><citation-alternatives><element-citation id="ec-CR13" publication-type="journal"><person-group person-group-type="author"><name><surname>Haahr</surname><given-names>T</given-names></name><name><surname>Dosouto</surname><given-names>C</given-names></name><name><surname>Alviggi</surname><given-names>C</given-names></name><name><surname>Esteves</surname><given-names>SC</given-names></name><name><surname>Humaidan</surname><given-names>P</given-names></name></person-group><article-title>Management strategies for POSEIDON groups 3 and 4</article-title><source>Front Endocrinol (Lausanne)</source><year>2019</year><volume>10</volume><fpage>614</fpage><pub-id pub-id-type="doi">10.3389/fendo.2019.00614</pub-id><pub-id pub-id-type="pmid">31572298</pub-id>
</element-citation><mixed-citation id="mc-CR13" publication-type="journal">Haahr T, Dosouto C, Alviggi C, Esteves SC, Humaidan P. Management strategies for POSEIDON groups 3 and 4. Front Endocrinol (Lausanne). 2019;10:614.<pub-id pub-id-type="pmid">31572298</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR14"><label>14.</label><citation-alternatives><element-citation id="ec-CR14" publication-type="journal"><person-group person-group-type="author"><name><surname>Ramaraju</surname><given-names>GA</given-names></name><name><surname>Cheemakurthi</surname><given-names>R</given-names></name><name><surname>Kalagara</surname><given-names>M</given-names></name><name><surname>Prathigudupu</surname><given-names>K</given-names></name><name><surname>Balabomma</surname><given-names>KL</given-names></name><name><surname>Mahapatro</surname><given-names>P</given-names></name><etal/></person-group><article-title>Effect of LHCGR gene polymorphism (rs2293275) on LH supplementation protocol outcomes in second IVF cycles: a retrospective study</article-title><source>Front Endocrinol (Lausanne)</source><year>2021</year><volume>12</volume><fpage>628169</fpage><pub-id pub-id-type="doi">10.3389/fendo.2021.628169</pub-id><pub-id pub-id-type="pmid">34046009</pub-id>
</element-citation><mixed-citation id="mc-CR14" publication-type="journal">Ramaraju GA, Cheemakurthi R, Kalagara M, Prathigudupu K, Balabomma KL, Mahapatro P, et al. Effect of LHCGR gene polymorphism (rs2293275) on LH supplementation protocol outcomes in second IVF cycles: a retrospective study. Front Endocrinol (Lausanne). 2021;12:628169.<pub-id pub-id-type="pmid">34046009</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR15"><label>15.</label><citation-alternatives><element-citation id="ec-CR15" publication-type="journal"><person-group person-group-type="author"><name><surname>Ramaraju</surname><given-names>GA</given-names></name><name><surname>Cheemakurthi</surname><given-names>R</given-names></name><name><surname>Prathigudupu</surname><given-names>K</given-names></name><name><surname>Balabomma</surname><given-names>KL</given-names></name><name><surname>Kalagara</surname><given-names>M</given-names></name><name><surname>Thota</surname><given-names>S</given-names></name><etal/></person-group><article-title>Role of Lh polymorphisms and r-hLh supplementation in GnRh agonist treated ART cycles: a cross sectional study</article-title><source>Eur J Obstet Gynecol Reprod Biol</source><year>2018</year><volume>222</volume><fpage>119</fpage><lpage>125</lpage><pub-id pub-id-type="doi">10.1016/j.ejogrb.2018.01.025</pub-id><pub-id pub-id-type="pmid">29408742</pub-id>
</element-citation><mixed-citation id="mc-CR15" publication-type="journal">Ramaraju GA, Cheemakurthi R, Prathigudupu K, Balabomma KL, Kalagara M, Thota S, et al. Role of Lh polymorphisms and r-hLh supplementation in GnRh agonist treated ART cycles: a cross sectional study. Eur J Obstet Gynecol Reprod Biol. 2018;222:119&#x02013;25.<pub-id pub-id-type="pmid">29408742</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR16"><label>16.</label><citation-alternatives><element-citation id="ec-CR16" publication-type="journal"><person-group person-group-type="author"><name><surname>Alviggi</surname><given-names>C</given-names></name><name><surname>Pettersson</surname><given-names>K</given-names></name><name><surname>Longobardi</surname><given-names>S</given-names></name><name><surname>Andersen</surname><given-names>CY</given-names></name><name><surname>Conforti</surname><given-names>A</given-names></name><name><surname>De Rosa</surname><given-names>P</given-names></name><etal/></person-group><article-title>A common polymorphic allele of the LH beta-subunit gene is associated with higher exogenous FSH consumption during controlled ovarian stimulation for assisted reproductive technology</article-title><source>Reprod Biol Endocrinol</source><year>2013</year><volume>11</volume><fpage>51</fpage><lpage>51</lpage><pub-id pub-id-type="doi">10.1186/1477-7827-11-51</pub-id><pub-id pub-id-type="pmid">23725475</pub-id>
</element-citation><mixed-citation id="mc-CR16" publication-type="journal">Alviggi C, Pettersson K, Longobardi S, Andersen CY, Conforti A, De Rosa P, et al. A common polymorphic allele of the LH beta-subunit gene is associated with higher exogenous FSH consumption during controlled ovarian stimulation for assisted reproductive technology. Reprod Biol Endocrinol. 2013;11:51&#x02013;51.<pub-id pub-id-type="pmid">23725475</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR17"><label>17.</label><citation-alternatives><element-citation id="ec-CR17" publication-type="journal"><person-group person-group-type="author"><name><surname>Duan</surname><given-names>J</given-names></name><name><surname>Xu</surname><given-names>P</given-names></name><name><surname>Cheng</surname><given-names>X</given-names></name><name><surname>Mao</surname><given-names>C</given-names></name><name><surname>Croll</surname><given-names>T</given-names></name><name><surname>He</surname><given-names>X</given-names></name><etal/></person-group><article-title>Structures of full-length glycoprotein hormone receptor signalling complexes</article-title><source>Nature</source><year>2021</year><volume>598</volume><fpage>688</fpage><lpage>692</lpage><pub-id pub-id-type="doi">10.1038/s41586-021-03924-2</pub-id><pub-id pub-id-type="pmid">34552239</pub-id>
</element-citation><mixed-citation id="mc-CR17" publication-type="journal">Duan J, Xu P, Cheng X, Mao C, Croll T, He X, et al. Structures of full-length glycoprotein hormone receptor signalling complexes. Nature. 2021;598:688&#x02013;92.<pub-id pub-id-type="pmid">34552239</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR18"><label>18.</label><citation-alternatives><element-citation id="ec-CR18" publication-type="journal"><person-group person-group-type="author"><name><surname>Jagiello</surname><given-names>G</given-names></name><name><surname>Ducayen</surname><given-names>M</given-names></name><name><surname>Miller</surname><given-names>W</given-names></name><name><surname>Graffeo</surname><given-names>J</given-names></name><name><surname>Fang</surname><given-names>JS</given-names></name></person-group><article-title>Stimulation and inhibition with LH and other hormones of female mammalian meiosis in vitro</article-title><source>J Reprod Fertil</source><year>1975</year><volume>43</volume><fpage>9</fpage><lpage>22</lpage><pub-id pub-id-type="doi">10.1530/jrf.0.0430009</pub-id><pub-id pub-id-type="pmid">165291</pub-id>
</element-citation><mixed-citation id="mc-CR18" publication-type="journal">Jagiello G, Ducayen M, Miller W, Graffeo J, Fang JS. Stimulation and inhibition with LH and other hormones of female mammalian meiosis in vitro. J Reprod Fertil. 1975;43:9&#x02013;22.<pub-id pub-id-type="pmid">165291</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR19"><label>19.</label><citation-alternatives><element-citation id="ec-CR19" publication-type="journal"><person-group person-group-type="author"><name><surname>Papadopoulos</surname><given-names>V</given-names></name><name><surname>Carreau</surname><given-names>S</given-names></name><name><surname>Drosdowsky</surname><given-names>MA</given-names></name></person-group><article-title>Effect of phorbol ester and phospholipase C on LH-stimulated steroidogenesis in purified rat leydig cells</article-title><source>FEBS Lett</source><year>1985</year><volume>188</volume><fpage>312</fpage><lpage>316</lpage><pub-id pub-id-type="doi">10.1016/0014-5793(85)80393-8</pub-id><pub-id pub-id-type="pmid">2993025</pub-id>
</element-citation><mixed-citation id="mc-CR19" publication-type="journal">Papadopoulos V, Carreau S, Drosdowsky MA. Effect of phorbol ester and phospholipase C on LH-stimulated steroidogenesis in purified rat leydig cells. FEBS Lett. 1985;188:312&#x02013;6.<pub-id pub-id-type="pmid">2993025</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR20"><label>20.</label><citation-alternatives><element-citation id="ec-CR20" publication-type="journal"><person-group person-group-type="author"><name><surname>Gudermann</surname><given-names>T</given-names></name><name><surname>Nichols</surname><given-names>C</given-names></name><name><surname>Levy</surname><given-names>FO</given-names></name><name><surname>Birnbaumer</surname><given-names>M</given-names></name><name><surname>Birnbaumer</surname><given-names>L</given-names></name></person-group><article-title>Ca2 + mobilization by the LH receptor expressed in Xenopus oocytes independent of 3&#x02019;,5&#x02019;-cyclic adenosine monophosphate formation: evidence for parallel activation of two signaling pathways</article-title><source>Mol Endocrinol</source><year>1992</year><volume>6</volume><fpage>272</fpage><lpage>8</lpage><pub-id pub-id-type="pmid">1314958</pub-id>
</element-citation><mixed-citation id="mc-CR20" publication-type="journal">Gudermann T, Nichols C, Levy FO, Birnbaumer M, Birnbaumer L. Ca2 + mobilization by the LH receptor expressed in Xenopus oocytes independent of 3&#x02019;,5&#x02019;-cyclic adenosine monophosphate formation: evidence for parallel activation of two signaling pathways. Mol Endocrinol. 1992;6:272&#x02013;8.<pub-id pub-id-type="pmid">1314958</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR21"><label>21.</label><citation-alternatives><element-citation id="ec-CR21" publication-type="journal"><person-group person-group-type="author"><name><surname>Montminy</surname><given-names>MR</given-names></name><name><surname>Bilezikjian</surname><given-names>LM</given-names></name></person-group><article-title>Binding of a nuclear protein to the cyclic-AMP response element of the somatostatin gene</article-title><source>Nature</source><year>1987</year><volume>328</volume><fpage>175</fpage><lpage>178</lpage><pub-id pub-id-type="doi">10.1038/328175a0</pub-id><pub-id pub-id-type="pmid">2885756</pub-id>
</element-citation><mixed-citation id="mc-CR21" publication-type="journal">Montminy MR, Bilezikjian LM. Binding of a nuclear protein to the cyclic-AMP response element of the somatostatin gene. Nature. 1987;328:175&#x02013;8.<pub-id pub-id-type="pmid">2885756</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR22"><label>22.</label><citation-alternatives><element-citation id="ec-CR22" publication-type="journal"><person-group person-group-type="author"><name><surname>Casarini</surname><given-names>L</given-names></name><name><surname>Lazzaretti</surname><given-names>C</given-names></name><name><surname>Paradiso</surname><given-names>E</given-names></name><name><surname>Limoncella</surname><given-names>S</given-names></name><name><surname>Riccetti</surname><given-names>L</given-names></name><name><surname>Sperduti</surname><given-names>S</given-names></name><etal/></person-group><article-title>Membrane estrogen receptor (GPER) and follicle-stimulating hormone receptor (FSHR) heteromeric complexes promote human ovarian follicle survival</article-title><source>iScience</source><year>2020</year><volume>23</volume><fpage>101812</fpage><pub-id pub-id-type="doi">10.1016/j.isci.2020.101812</pub-id><pub-id pub-id-type="pmid">33299978</pub-id>
</element-citation><mixed-citation id="mc-CR22" publication-type="journal">Casarini L, Lazzaretti C, Paradiso E, Limoncella S, Riccetti L, Sperduti S, et al. Membrane estrogen receptor (GPER) and follicle-stimulating hormone receptor (FSHR) heteromeric complexes promote human ovarian follicle survival. iScience. 2020;23: 101812.<pub-id pub-id-type="pmid">33299978</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR23"><label>23.</label><citation-alternatives><element-citation id="ec-CR23" publication-type="journal"><person-group person-group-type="author"><name><surname>Casarini</surname><given-names>L</given-names></name><name><surname>Reiter</surname><given-names>E</given-names></name><name><surname>Simoni</surname><given-names>M</given-names></name></person-group><article-title>&#x003b2;-arrestins regulate gonadotropin receptor-mediated cell proliferation and apoptosis by controlling different FSHR or LHCGR intracellular signaling in the hGL5 cell line</article-title><source>Mol Cell Endocrinol</source><year>2016</year><volume>437</volume><fpage>11</fpage><lpage>21</lpage><pub-id pub-id-type="doi">10.1016/j.mce.2016.08.005</pub-id><pub-id pub-id-type="pmid">27502035</pub-id>
</element-citation><mixed-citation id="mc-CR23" publication-type="journal">Casarini L, Reiter E, Simoni M. &#x003b2;-arrestins regulate gonadotropin receptor-mediated cell proliferation and apoptosis by controlling different FSHR or LHCGR intracellular signaling in the hGL5 cell line. Mol Cell Endocrinol. 2016;437:11&#x02013;21.<pub-id pub-id-type="pmid">27502035</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR24"><label>24.</label><citation-alternatives><element-citation id="ec-CR24" publication-type="journal"><person-group person-group-type="author"><name><surname>Zwain</surname><given-names>IH</given-names></name><name><surname>Amato</surname><given-names>P</given-names></name></person-group><article-title>cAMP-induced apoptosis in granulosa cells is associated with up-regulation of P53 and bax and down-regulation of clusterin</article-title><source>Endocr Res</source><year>2001</year><volume>27</volume><fpage>233</fpage><lpage>249</lpage><pub-id pub-id-type="doi">10.1081/ERC-100107184</pub-id><pub-id pub-id-type="pmid">11428715</pub-id>
</element-citation><mixed-citation id="mc-CR24" publication-type="journal">Zwain IH, Amato P. cAMP-induced apoptosis in granulosa cells is associated with up-regulation of P53 and bax and down-regulation of clusterin. Endocr Res. 2001;27:233&#x02013;49.<pub-id pub-id-type="pmid">11428715</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR25"><label>25.</label><citation-alternatives><element-citation id="ec-CR25" publication-type="journal"><person-group person-group-type="author"><name><surname>Regan</surname><given-names>SLP</given-names></name><name><surname>Knight</surname><given-names>PG</given-names></name><name><surname>Yovich</surname><given-names>JL</given-names></name><name><surname>Leung</surname><given-names>Y</given-names></name><name><surname>Arfuso</surname><given-names>F</given-names></name><name><surname>Dharmarajan</surname><given-names>A</given-names></name></person-group><article-title>Granulosa cell apoptosis in the ovarian follicle &#x02013; a changing view</article-title><source>Front Endocrinol (Lausanne)</source><year>2018</year><volume>9</volume><fpage>61</fpage><pub-id pub-id-type="doi">10.3389/fendo.2018.00061</pub-id><pub-id pub-id-type="pmid">29551992</pub-id>
</element-citation><mixed-citation id="mc-CR25" publication-type="journal">Regan SLP, Knight PG, Yovich JL, Leung Y, Arfuso F, Dharmarajan A. Granulosa cell apoptosis in the ovarian follicle &#x02013; a changing view. Front Endocrinol (Lausanne). 2018;9:61.<pub-id pub-id-type="pmid">29551992</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR26"><label>26.</label><citation-alternatives><element-citation id="ec-CR26" publication-type="journal"><person-group person-group-type="author"><name><surname>Miller</surname><given-names>WL</given-names></name><name><surname>Auchus</surname><given-names>RJ</given-names></name></person-group><article-title>The molecular biology, biochemistry, and physiology of human steroidogenesis and its disorders</article-title><source>Endocr Rev</source><year>2011</year><volume>32</volume><fpage>81</fpage><lpage>151</lpage><pub-id pub-id-type="doi">10.1210/er.2010-0013</pub-id><pub-id pub-id-type="pmid">21051590</pub-id>
</element-citation><mixed-citation id="mc-CR26" publication-type="journal">Miller WL, Auchus RJ. The molecular biology, biochemistry, and physiology of human steroidogenesis and its disorders. Endocr Rev. 2011;32:81&#x02013;151.<pub-id pub-id-type="pmid">21051590</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR27"><label>27.</label><citation-alternatives><element-citation id="ec-CR27" publication-type="journal"><person-group person-group-type="author"><name><surname>Tajima</surname><given-names>K</given-names></name><name><surname>Yoshii</surname><given-names>K</given-names></name><name><surname>Fukuda</surname><given-names>S</given-names></name><name><surname>Orisaka</surname><given-names>M</given-names></name><name><surname>Miyamoto</surname><given-names>K</given-names></name><name><surname>Amsterdam</surname><given-names>A</given-names></name><etal/></person-group><article-title>Luteinizing hormone-induced extracellular-signal regulated kinase activation differently modulates progesterone and androstenedione production in bovine theca cells</article-title><source>Endocrinology</source><year>2005</year><volume>146</volume><fpage>2903</fpage><lpage>2910</lpage><pub-id pub-id-type="doi">10.1210/en.2005-0093</pub-id><pub-id pub-id-type="pmid">15817663</pub-id>
</element-citation><mixed-citation id="mc-CR27" publication-type="journal">Tajima K, Yoshii K, Fukuda S, Orisaka M, Miyamoto K, Amsterdam A, et al. Luteinizing hormone-induced extracellular-signal regulated kinase activation differently modulates progesterone and androstenedione production in bovine theca cells. Endocrinology. 2005;146:2903&#x02013;10.<pub-id pub-id-type="pmid">15817663</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR28"><label>28.</label><citation-alternatives><element-citation id="ec-CR28" publication-type="journal"><person-group person-group-type="author"><name><surname>Menon</surname><given-names>B</given-names></name><name><surname>Franzo-Romain</surname><given-names>M</given-names></name><name><surname>Damanpour</surname><given-names>S</given-names></name><name><surname>Menon</surname><given-names>KMJ</given-names></name></person-group><article-title>Luteinizing hormone receptor mRNA down-regulation is mediated through ERK-dependent induction of RNA binding protein</article-title><source>Mol Endocrinol</source><year>2011</year><volume>25</volume><fpage>282</fpage><lpage>290</lpage><pub-id pub-id-type="doi">10.1210/me.2010-0366</pub-id><pub-id pub-id-type="pmid">21147848</pub-id>
</element-citation><mixed-citation id="mc-CR28" publication-type="journal">Menon B, Franzo-Romain M, Damanpour S, Menon KMJ. Luteinizing hormone receptor mRNA down-regulation is mediated through ERK-dependent induction of RNA binding protein. Mol Endocrinol. 2011;25:282&#x02013;90.<pub-id pub-id-type="pmid">21147848</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR29"><label>29.</label><citation-alternatives><element-citation id="ec-CR29" publication-type="journal"><person-group person-group-type="author"><name><surname>Ren</surname><given-names>X-R</given-names></name><name><surname>Reiter</surname><given-names>E</given-names></name><name><surname>Ahn</surname><given-names>S</given-names></name><name><surname>Kim</surname><given-names>J</given-names></name><name><surname>Chen</surname><given-names>W</given-names></name><name><surname>Lefkowitz</surname><given-names>RJ</given-names></name></person-group><article-title>Different G protein-coupled receptor kinases govern G protein and beta-arrestin-mediated signaling of V2 vasopressin receptor</article-title><source>Proc Natl Acad Sci U S A</source><year>2005</year><volume>102</volume><fpage>1448</fpage><lpage>1453</lpage><pub-id pub-id-type="doi">10.1073/pnas.0409534102</pub-id><pub-id pub-id-type="pmid">15671180</pub-id>
</element-citation><mixed-citation id="mc-CR29" publication-type="journal">Ren X-R, Reiter E, Ahn S, Kim J, Chen W, Lefkowitz RJ. Different G protein-coupled receptor kinases govern G protein and beta-arrestin-mediated signaling of V2 vasopressin receptor. Proc Natl Acad Sci U S A. 2005;102:1448&#x02013;53.<pub-id pub-id-type="pmid">15671180</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR30"><label>30.</label><citation-alternatives><element-citation id="ec-CR30" publication-type="journal"><person-group person-group-type="author"><name><surname>Martinat</surname><given-names>N</given-names></name><name><surname>Cr&#x000e9;pieux</surname><given-names>P</given-names></name><name><surname>Reiter</surname><given-names>E</given-names></name><name><surname>Guillou</surname><given-names>F</given-names></name></person-group><article-title>Extracellular signal-regulated kinases (ERK) 1, 2 are required for luteinizing hormone (LH)-induced steroidogenesis in primary Leydig cells and control steroidogenic acute regulatory (StAR) expression</article-title><source>Reprod Nutr Dev</source><year>2005</year><volume>45</volume><fpage>101</fpage><lpage>108</lpage><pub-id pub-id-type="doi">10.1051/rnd:2005007</pub-id><pub-id pub-id-type="pmid">15868656</pub-id>
</element-citation><mixed-citation id="mc-CR30" publication-type="journal">Martinat N, Cr&#x000e9;pieux P, Reiter E, Guillou F. Extracellular signal-regulated kinases (ERK) 1, 2 are required for luteinizing hormone (LH)-induced steroidogenesis in primary Leydig cells and control steroidogenic acute regulatory (StAR) expression. Reprod Nutr Dev. 2005;45:101&#x02013;8.<pub-id pub-id-type="pmid">15868656</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR31"><label>31.</label><citation-alternatives><element-citation id="ec-CR31" publication-type="journal"><person-group person-group-type="author"><name><surname>Tohgo</surname><given-names>A</given-names></name><name><surname>Choy</surname><given-names>EW</given-names></name><name><surname>Gesty-Palmer</surname><given-names>D</given-names></name><name><surname>Pierce</surname><given-names>KL</given-names></name><name><surname>Laporte</surname><given-names>S</given-names></name><name><surname>Oakley</surname><given-names>RH</given-names></name><etal/></person-group><article-title>The stability of the G protein-coupled receptor-beta-arrestin interaction determines the mechanism and functional consequence of ERK activation</article-title><source>J Biol Chem</source><year>2003</year><volume>278</volume><fpage>6258</fpage><lpage>6267</lpage><pub-id pub-id-type="doi">10.1074/jbc.M212231200</pub-id><pub-id pub-id-type="pmid">12473660</pub-id>
</element-citation><mixed-citation id="mc-CR31" publication-type="journal">Tohgo A, Choy EW, Gesty-Palmer D, Pierce KL, Laporte S, Oakley RH, et al. The stability of the G protein-coupled receptor-beta-arrestin interaction determines the mechanism and functional consequence of ERK activation. J Biol Chem. 2003;278:6258&#x02013;67.<pub-id pub-id-type="pmid">12473660</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR32"><label>32.</label><citation-alternatives><element-citation id="ec-CR32" publication-type="journal"><person-group person-group-type="author"><name><surname>Mertens-Walker</surname><given-names>I</given-names></name><name><surname>Bolitho</surname><given-names>C</given-names></name><name><surname>Baxter</surname><given-names>RC</given-names></name><name><surname>Marsh</surname><given-names>DJ</given-names></name></person-group><article-title>Gonadotropin-induced ovarian cancer cell migration and proliferation require extracellular signal-regulated kinase 1/2 activation regulated by calcium and protein kinase C{delta}</article-title><source>Endocr Relat Cancer</source><year>2010</year><volume>17</volume><fpage>335</fpage><lpage>349</lpage><pub-id pub-id-type="doi">10.1677/ERC-09-0152</pub-id><pub-id pub-id-type="pmid">20215102</pub-id>
</element-citation><mixed-citation id="mc-CR32" publication-type="journal">Mertens-Walker I, Bolitho C, Baxter RC, Marsh DJ. Gonadotropin-induced ovarian cancer cell migration and proliferation require extracellular signal-regulated kinase 1/2 activation regulated by calcium and protein kinase C{delta}. Endocr Relat Cancer. 2010;17:335&#x02013;49.<pub-id pub-id-type="pmid">20215102</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR33"><label>33.</label><citation-alternatives><element-citation id="ec-CR33" publication-type="journal"><person-group person-group-type="author"><name><surname>Manna</surname><given-names>PR</given-names></name><name><surname>Pakarinen</surname><given-names>P</given-names></name><name><surname>El-Hefnawy</surname><given-names>T</given-names></name><name><surname>Huhtaniemi</surname><given-names>IT</given-names></name></person-group><article-title>Functional assessment of the calcium messenger system in cultured mouse Leydig tumor cells: regulation of human chorionic gonadotropin-induced expression of the steroidogenic acute regulatory protein</article-title><source>Endocrinology</source><year>1999</year><volume>140</volume><fpage>1739</fpage><lpage>1751</lpage><pub-id pub-id-type="doi">10.1210/endo.140.4.6650</pub-id><pub-id pub-id-type="pmid">10098511</pub-id>
</element-citation><mixed-citation id="mc-CR33" publication-type="journal">Manna PR, Pakarinen P, El-Hefnawy T, Huhtaniemi IT. Functional assessment of the calcium messenger system in cultured mouse Leydig tumor cells: regulation of human chorionic gonadotropin-induced expression of the steroidogenic acute regulatory protein. Endocrinology. 1999;140:1739&#x02013;51.<pub-id pub-id-type="pmid">10098511</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR34"><label>34.</label><citation-alternatives><element-citation id="ec-CR34" publication-type="journal"><person-group person-group-type="author"><name><surname>Pezzi</surname><given-names>V</given-names></name><name><surname>Clark</surname><given-names>BJ</given-names></name><name><surname>Ando</surname><given-names>S</given-names></name><name><surname>Stocco</surname><given-names>DM</given-names></name><name><surname>Rainey</surname><given-names>WE</given-names></name></person-group><article-title>Role of calmodulin-dependent protein kinase II in the acute stimulation of aldosterone production</article-title><source>J Steroid Biochem Mol Biol</source><year>1996</year><volume>58</volume><fpage>417</fpage><lpage>424</lpage><pub-id pub-id-type="doi">10.1016/0960-0760(96)00052-0</pub-id><pub-id pub-id-type="pmid">8903426</pub-id>
</element-citation><mixed-citation id="mc-CR34" publication-type="journal">Pezzi V, Clark BJ, Ando S, Stocco DM, Rainey WE. Role of calmodulin-dependent protein kinase II in the acute stimulation of aldosterone production. J Steroid Biochem Mol Biol. 1996;58:417&#x02013;24.<pub-id pub-id-type="pmid">8903426</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR35"><label>35.</label><citation-alternatives><element-citation id="ec-CR35" publication-type="journal"><person-group person-group-type="author"><name><surname>Zhu</surname><given-names>X</given-names></name><name><surname>Gilbert</surname><given-names>S</given-names></name><name><surname>Birnbaumer</surname><given-names>M</given-names></name><name><surname>Birnbaumer</surname><given-names>L</given-names></name></person-group><article-title>Dual signaling potential is common among Gs-coupled receptors and dependent on receptor density</article-title><source>Mol Pharmacol</source><year>1994</year><volume>46</volume><fpage>460</fpage><lpage>469</lpage><pub-id pub-id-type="doi">10.1016/S0026-895X(25)09722-6</pub-id><pub-id pub-id-type="pmid">7935326</pub-id>
</element-citation><mixed-citation id="mc-CR35" publication-type="journal">Zhu X, Gilbert S, Birnbaumer M, Birnbaumer L. Dual signaling potential is common among Gs-coupled receptors and dependent on receptor density. Mol Pharmacol. 1994;46:460&#x02013;9.<pub-id pub-id-type="pmid">7935326</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR36"><label>36.</label><citation-alternatives><element-citation id="ec-CR36" publication-type="journal"><person-group person-group-type="author"><name><surname>Tai</surname><given-names>P</given-names></name><name><surname>Shiraishi</surname><given-names>K</given-names></name><name><surname>Ascoli</surname><given-names>M</given-names></name></person-group><article-title>Activation of the lutropin/choriogonadotropin receptor inhibits apoptosis of immature Leydig cells in primary culture</article-title><source>Endocrinology</source><year>2009</year><volume>150</volume><fpage>3766</fpage><lpage>3773</lpage><pub-id pub-id-type="doi">10.1210/en.2009-0207</pub-id><pub-id pub-id-type="pmid">19406941</pub-id>
</element-citation><mixed-citation id="mc-CR36" publication-type="journal">Tai P, Shiraishi K, Ascoli M. Activation of the lutropin/choriogonadotropin receptor inhibits apoptosis of immature Leydig cells in primary culture. Endocrinology. 2009;150:3766&#x02013;73.<pub-id pub-id-type="pmid">19406941</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR37"><label>37.</label><citation-alternatives><element-citation id="ec-CR37" publication-type="journal"><person-group person-group-type="author"><name><surname>Andric</surname><given-names>N</given-names></name><name><surname>Thomas</surname><given-names>M</given-names></name><name><surname>Ascoli</surname><given-names>M</given-names></name></person-group><article-title>Transactivation of the epidermal growth factor receptor is involved in the lutropin receptor-mediated down-regulation of ovarian aromatase expression in vivo</article-title><source>Mol Endocrinol</source><year>2010</year><volume>24</volume><fpage>552</fpage><lpage>560</lpage><pub-id pub-id-type="doi">10.1210/me.2009-0450</pub-id><pub-id pub-id-type="pmid">20093417</pub-id>
</element-citation><mixed-citation id="mc-CR37" publication-type="journal">Andric N, Thomas M, Ascoli M. Transactivation of the epidermal growth factor receptor is involved in the lutropin receptor-mediated down-regulation of ovarian aromatase expression in vivo. Mol Endocrinol. 2010;24:552&#x02013;60.<pub-id pub-id-type="pmid">20093417</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR38"><label>38.</label><citation-alternatives><element-citation id="ec-CR38" publication-type="journal"><person-group person-group-type="author"><name><surname>Light</surname><given-names>A</given-names></name><name><surname>Hammes</surname><given-names>SR</given-names></name></person-group><article-title>Membrane receptor cross talk in steroidogenesis: recent insights and clinical implications</article-title><source>Steroids</source><year>2013</year><volume>78</volume><fpage>633</fpage><lpage>638</lpage><pub-id pub-id-type="doi">10.1016/j.steroids.2012.12.016</pub-id><pub-id pub-id-type="pmid">23380369</pub-id>
</element-citation><mixed-citation id="mc-CR38" publication-type="journal">Light A, Hammes SR. Membrane receptor cross talk in steroidogenesis: recent insights and clinical implications. Steroids. 2013;78:633&#x02013;8.<pub-id pub-id-type="pmid">23380369</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR39"><label>39.</label><citation-alternatives><element-citation id="ec-CR39" publication-type="journal"><person-group person-group-type="author"><name><surname>Casarini</surname><given-names>L</given-names></name><name><surname>Santi</surname><given-names>D</given-names></name><name><surname>Simoni</surname><given-names>M</given-names></name><name><surname>Pot&#x000ec;</surname><given-names>F</given-names></name></person-group><article-title>Spare luteinizing hormone receptors: facts and fiction</article-title><source>Trends Endocrinol Metab</source><year>2018</year><volume>29</volume><fpage>208</fpage><lpage>217</lpage><pub-id pub-id-type="doi">10.1016/j.tem.2018.01.007</pub-id><pub-id pub-id-type="pmid">29429918</pub-id>
</element-citation><mixed-citation id="mc-CR39" publication-type="journal">Casarini L, Santi D, Simoni M, Pot&#x000ec; F. Spare luteinizing hormone receptors: facts and fiction. Trends Endocrinol Metab. 2018;29:208&#x02013;17.<pub-id pub-id-type="pmid">29429918</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR40"><label>40.</label><citation-alternatives><element-citation id="ec-CR40" publication-type="journal"><person-group person-group-type="author"><name><surname>Ji</surname><given-names>I</given-names></name><name><surname>Lee</surname><given-names>C</given-names></name><name><surname>Jeoung</surname><given-names>M</given-names></name><name><surname>Koo</surname><given-names>Y</given-names></name><name><surname>Sievert</surname><given-names>GA</given-names></name><name><surname>Ji</surname><given-names>TH</given-names></name></person-group><article-title>Trans-activation of mutant follicle-stimulating hormone receptors selectively generates only one of two hormone signals</article-title><source>Mol Endocrinol</source><year>2004</year><volume>18</volume><fpage>968</fpage><lpage>978</lpage><pub-id pub-id-type="doi">10.1210/me.2003-0443</pub-id><pub-id pub-id-type="pmid">14726491</pub-id>
</element-citation><mixed-citation id="mc-CR40" publication-type="journal">Ji I, Lee C, Jeoung M, Koo Y, Sievert GA, Ji TH. Trans-activation of mutant follicle-stimulating hormone receptors selectively generates only one of two hormone signals. Mol Endocrinol. 2004;18:968&#x02013;78.<pub-id pub-id-type="pmid">14726491</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR41"><label>41.</label><citation-alternatives><element-citation id="ec-CR41" publication-type="journal"><person-group person-group-type="author"><name><surname>Feng</surname><given-names>X</given-names></name><name><surname>Zhang</surname><given-names>M</given-names></name><name><surname>Guan</surname><given-names>R</given-names></name><name><surname>Segaloff</surname><given-names>DL</given-names></name></person-group><article-title>Heterodimerization between the lutropin and follitropin receptors is associated with an attenuation of hormone-dependent signaling</article-title><source>Endocrinology</source><year>2013</year><volume>154</volume><fpage>3925</fpage><lpage>3930</lpage><pub-id pub-id-type="doi">10.1210/en.2013-1407</pub-id><pub-id pub-id-type="pmid">23825122</pub-id>
</element-citation><mixed-citation id="mc-CR41" publication-type="journal">Feng X, Zhang M, Guan R, Segaloff DL. Heterodimerization between the lutropin and follitropin receptors is associated with an attenuation of hormone-dependent signaling. Endocrinology. 2013;154:3925&#x02013;30.<pub-id pub-id-type="pmid">23825122</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR42"><label>42.</label><citation-alternatives><element-citation id="ec-CR42" publication-type="journal"><person-group person-group-type="author"><name><surname>Tranchant</surname><given-names>T</given-names></name><name><surname>Durand</surname><given-names>G</given-names></name><name><surname>Gauthier</surname><given-names>C</given-names></name><name><surname>Cr&#x000e9;pieux</surname><given-names>P</given-names></name><name><surname>Ulloa-Aguirre</surname><given-names>A</given-names></name><name><surname>Roy&#x000e8;re</surname><given-names>D</given-names></name><etal/></person-group><article-title>Preferential &#x003b2;-arrestin signalling at low receptor density revealed by functional characterization of the human FSH receptor A189 V mutation</article-title><source>Mol Cell Endocrinol</source><year>2011</year><volume>331</volume><fpage>109</fpage><lpage>118</lpage><pub-id pub-id-type="doi">10.1016/j.mce.2010.08.016</pub-id><pub-id pub-id-type="pmid">20801186</pub-id>
</element-citation><mixed-citation id="mc-CR42" publication-type="journal">Tranchant T, Durand G, Gauthier C, Cr&#x000e9;pieux P, Ulloa-Aguirre A, Roy&#x000e8;re D, et al. Preferential &#x003b2;-arrestin signalling at low receptor density revealed by functional characterization of the human FSH receptor A189 V mutation. Mol Cell Endocrinol. 2011;331:109&#x02013;18.<pub-id pub-id-type="pmid">20801186</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR43"><label>43.</label><citation-alternatives><element-citation id="ec-CR43" publication-type="journal"><person-group person-group-type="author"><name><surname>Donadeu</surname><given-names>FX</given-names></name><name><surname>Ascoli</surname><given-names>M</given-names></name></person-group><article-title>The differential effects of the gonadotropin receptors on aromatase expression in primary cultures of immature rat granulosa cells are highly dependent on the density of receptors expressed and the activation of the inositol phosphate cascade</article-title><source>Endocrinology</source><year>2005</year><volume>146</volume><fpage>3907</fpage><lpage>3916</lpage><pub-id pub-id-type="doi">10.1210/en.2005-0403</pub-id><pub-id pub-id-type="pmid">15919743</pub-id>
</element-citation><mixed-citation id="mc-CR43" publication-type="journal">Donadeu FX, Ascoli M. The differential effects of the gonadotropin receptors on aromatase expression in primary cultures of immature rat granulosa cells are highly dependent on the density of receptors expressed and the activation of the inositol phosphate cascade. Endocrinology. 2005;146:3907&#x02013;16.<pub-id pub-id-type="pmid">15919743</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR44"><label>44.</label><citation-alternatives><element-citation id="ec-CR44" publication-type="journal"><person-group person-group-type="author"><name><surname>Jeppesen</surname><given-names>JV</given-names></name><name><surname>Kristensen</surname><given-names>SG</given-names></name><name><surname>Nielsen</surname><given-names>ME</given-names></name><name><surname>Humaidan</surname><given-names>P</given-names></name><name><surname>Dal Canto</surname><given-names>M</given-names></name><name><surname>Fadini</surname><given-names>R</given-names></name><etal/></person-group><article-title>LH-receptor gene expression in human granulosa and cumulus cells from antral and preovulatory follicles</article-title><source>J Clin Endocrinol Metab</source><year>2012</year><volume>97</volume><fpage>E1524</fpage><lpage>1531</lpage><pub-id pub-id-type="doi">10.1210/jc.2012-1427</pub-id><pub-id pub-id-type="pmid">22659248</pub-id>
</element-citation><mixed-citation id="mc-CR44" publication-type="journal">Jeppesen JV, Kristensen SG, Nielsen ME, Humaidan P, Dal Canto M, Fadini R, et al. LH-receptor gene expression in human granulosa and cumulus cells from antral and preovulatory follicles. J Clin Endocrinol Metab. 2012;97:E1524-1531.<pub-id pub-id-type="pmid">22659248</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR45"><label>45.</label><citation-alternatives><element-citation id="ec-CR45" publication-type="journal"><person-group person-group-type="author"><name><surname>Hunzicker-Dunn</surname><given-names>M</given-names></name><name><surname>Barisas</surname><given-names>G</given-names></name><name><surname>Song</surname><given-names>J</given-names></name><name><surname>Roess</surname><given-names>DA</given-names></name></person-group><article-title>Membrane organization of luteinizing hormone receptors differs between actively signaling and desensitized receptors</article-title><source>J Biol Chem</source><year>2003</year><volume>278</volume><fpage>42744</fpage><lpage>42749</lpage><pub-id pub-id-type="doi">10.1074/jbc.M306133200</pub-id><pub-id pub-id-type="pmid">12930832</pub-id>
</element-citation><mixed-citation id="mc-CR45" publication-type="journal">Hunzicker-Dunn M, Barisas G, Song J, Roess DA. Membrane organization of luteinizing hormone receptors differs between actively signaling and desensitized receptors. J Biol Chem. 2003;278:42744&#x02013;9.<pub-id pub-id-type="pmid">12930832</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR46"><label>46.</label><citation-alternatives><element-citation id="ec-CR46" publication-type="journal"><person-group person-group-type="author"><name><surname>Hirakawa</surname><given-names>T</given-names></name><name><surname>Galet</surname><given-names>C</given-names></name><name><surname>Kishi</surname><given-names>M</given-names></name><name><surname>Ascoli</surname><given-names>M</given-names></name></person-group><article-title>GIPC binds to the human lutropin receptor (hLHR) through an unusual PDZ domain binding motif, and it regulates the sorting of the internalized human choriogonadotropin and the density of cell surface hLHR</article-title><source>J Biol Chem</source><year>2003</year><volume>278</volume><fpage>49348</fpage><lpage>49357</lpage><pub-id pub-id-type="doi">10.1074/jbc.M306557200</pub-id><pub-id pub-id-type="pmid">14507927</pub-id>
</element-citation><mixed-citation id="mc-CR46" publication-type="journal">Hirakawa T, Galet C, Kishi M, Ascoli M. GIPC binds to the human lutropin receptor (hLHR) through an unusual PDZ domain binding motif, and it regulates the sorting of the internalized human choriogonadotropin and the density of cell surface hLHR. J Biol Chem. 2003;278:49348&#x02013;57.<pub-id pub-id-type="pmid">14507927</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR47"><label>47.</label><citation-alternatives><element-citation id="ec-CR47" publication-type="journal"><person-group person-group-type="author"><name><surname>Hanyaloglu</surname><given-names>AC</given-names></name></person-group><article-title>Advances in membrane trafficking and endosomal signaling of G protein-coupled receptors</article-title><source>Int Rev Cell Mol Biol</source><year>2018</year><volume>339</volume><fpage>93</fpage><lpage>131</lpage><pub-id pub-id-type="doi">10.1016/bs.ircmb.2018.03.001</pub-id><pub-id pub-id-type="pmid">29776606</pub-id>
</element-citation><mixed-citation id="mc-CR47" publication-type="journal">Hanyaloglu AC. Advances in membrane trafficking and endosomal signaling of G protein-coupled receptors. Int Rev Cell Mol Biol. 2018;339:93&#x02013;131.<pub-id pub-id-type="pmid">29776606</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR48"><label>48.</label><citation-alternatives><element-citation id="ec-CR48" publication-type="journal"><person-group person-group-type="author"><name><surname>Thomsen</surname><given-names>ARB</given-names></name><name><surname>Plouffe</surname><given-names>B</given-names></name><name><surname>Cahill</surname><given-names>TJ</given-names></name><name><surname>Shukla</surname><given-names>AK</given-names></name><name><surname>Tarrasch</surname><given-names>JT</given-names></name><name><surname>Dosey</surname><given-names>AM</given-names></name><etal/></person-group><article-title>GPCR-G protein-&#x003b2;-arrestin super-complex mediates sustained G protein signaling</article-title><source>Cell</source><year>2016</year><volume>166</volume><fpage>907</fpage><lpage>919</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2016.07.004</pub-id><pub-id pub-id-type="pmid">27499021</pub-id>
</element-citation><mixed-citation id="mc-CR48" publication-type="journal">Thomsen ARB, Plouffe B, Cahill TJ, Shukla AK, Tarrasch JT, Dosey AM, et al. GPCR-G protein-&#x003b2;-arrestin super-complex mediates sustained G protein signaling. Cell. 2016;166:907&#x02013;19.<pub-id pub-id-type="pmid">27499021</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR49"><label>49.</label><citation-alternatives><element-citation id="ec-CR49" publication-type="journal"><person-group person-group-type="author"><name><surname>Sposini</surname><given-names>S</given-names></name><name><surname>Jean-Alphonse</surname><given-names>FG</given-names></name><name><surname>Ayoub</surname><given-names>MA</given-names></name><name><surname>Oqua</surname><given-names>A</given-names></name><name><surname>West</surname><given-names>C</given-names></name><name><surname>Lavery</surname><given-names>S</given-names></name><etal/></person-group><article-title>Integration of GPCR signaling and sorting from very early endosomes via opposing APPL1 mechanisms</article-title><source>Cell Rep</source><year>2017</year><volume>21</volume><fpage>2855</fpage><lpage>2867</lpage><pub-id pub-id-type="doi">10.1016/j.celrep.2017.11.023</pub-id><pub-id pub-id-type="pmid">29212031</pub-id>
</element-citation><mixed-citation id="mc-CR49" publication-type="journal">Sposini S, Jean-Alphonse FG, Ayoub MA, Oqua A, West C, Lavery S, et al. Integration of GPCR signaling and sorting from very early endosomes via opposing APPL1 mechanisms. Cell Rep. 2017;21:2855&#x02013;67.<pub-id pub-id-type="pmid">29212031</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR50"><label>50.</label><citation-alternatives><element-citation id="ec-CR50" publication-type="journal"><person-group person-group-type="author"><name><surname>Casarini</surname><given-names>L</given-names></name><name><surname>Lispi</surname><given-names>M</given-names></name><name><surname>Longobardi</surname><given-names>S</given-names></name><name><surname>Milosa</surname><given-names>F</given-names></name><name><surname>La Marca</surname><given-names>A</given-names></name><name><surname>Tagliasacchi</surname><given-names>D</given-names></name><etal/></person-group><article-title>LH and hCG action on the same receptor results in quantitatively and qualitatively different intracellular signalling</article-title><source>PLoS One</source><year>2012</year><volume>7</volume><fpage>e46682</fpage><pub-id pub-id-type="doi">10.1371/journal.pone.0046682</pub-id><pub-id pub-id-type="pmid">23071612</pub-id>
</element-citation><mixed-citation id="mc-CR50" publication-type="journal">Casarini L, Lispi M, Longobardi S, Milosa F, La Marca A, Tagliasacchi D, et al. LH and hCG action on the same receptor results in quantitatively and qualitatively different intracellular signalling. PLoS One. 2012;7:e46682.<pub-id pub-id-type="pmid">23071612</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR51"><label>51.</label><citation-alternatives><element-citation id="ec-CR51" publication-type="journal"><person-group person-group-type="author"><name><surname>Casarini</surname><given-names>L</given-names></name><name><surname>Riccetti</surname><given-names>L</given-names></name><name><surname>De Pascali</surname><given-names>F</given-names></name><name><surname>Nicoli</surname><given-names>A</given-names></name><name><surname>Tagliavini</surname><given-names>S</given-names></name><name><surname>Trenti</surname><given-names>T</given-names></name><etal/></person-group><article-title>Follicle-stimulating hormone potentiates the steroidogenic activity of chorionic gonadotropin and the anti-apoptotic activity of luteinizing hormone in human granulosa-lutein cells in vitro</article-title><source>Mol Cell Endocrinol</source><year>2016</year><volume>422</volume><fpage>103</fpage><lpage>114</lpage><pub-id pub-id-type="doi">10.1016/j.mce.2015.12.008</pub-id><pub-id pub-id-type="pmid">26690776</pub-id>
</element-citation><mixed-citation id="mc-CR51" publication-type="journal">Casarini L, Riccetti L, De Pascali F, Nicoli A, Tagliavini S, Trenti T, et al. Follicle-stimulating hormone potentiates the steroidogenic activity of chorionic gonadotropin and the anti-apoptotic activity of luteinizing hormone in human granulosa-lutein cells in vitro. Mol Cell Endocrinol. 2016;422:103&#x02013;14.<pub-id pub-id-type="pmid">26690776</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR52"><label>52.</label><citation-alternatives><element-citation id="ec-CR52" publication-type="journal"><person-group person-group-type="author"><name><surname>Riccetti</surname><given-names>L</given-names></name><name><surname>De Pascali</surname><given-names>F</given-names></name><name><surname>Gilioli</surname><given-names>L</given-names></name><name><surname>Pot&#x000ec;</surname><given-names>F</given-names></name><name><surname>Giva</surname><given-names>LB</given-names></name><name><surname>Marino</surname><given-names>M</given-names></name><etal/></person-group><article-title>Human LH and hCG stimulate differently the early signalling pathways but result in equal testosterone synthesis in mouse leydig cells in vitro</article-title><source>Reprod Biol Endocrinol</source><year>2017</year><volume>15</volume><fpage>2</fpage><pub-id pub-id-type="doi">10.1186/s12958-016-0224-3</pub-id><pub-id pub-id-type="pmid">28056997</pub-id>
</element-citation><mixed-citation id="mc-CR52" publication-type="journal">Riccetti L, De Pascali F, Gilioli L, Pot&#x000ec; F, Giva LB, Marino M, et al. Human LH and hCG stimulate differently the early signalling pathways but result in equal testosterone synthesis in mouse leydig cells in vitro. Reprod Biol Endocrinol. 2017;15:2.<pub-id pub-id-type="pmid">28056997</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR53"><label>53.</label><citation-alternatives><element-citation id="ec-CR53" publication-type="journal"><person-group person-group-type="author"><name><surname>Riccetti</surname><given-names>L</given-names></name><name><surname>Yvinec</surname><given-names>R</given-names></name><name><surname>Klett</surname><given-names>D</given-names></name><name><surname>Gallay</surname><given-names>N</given-names></name><name><surname>Combarnous</surname><given-names>Y</given-names></name><name><surname>Reiter</surname><given-names>E</given-names></name><etal/></person-group><article-title>Human luteinizing hormone and chorionic gonadotropin display biased agonism at the LH and LH/CG receptors</article-title><source>Sci Rep</source><year>2017</year><volume>7</volume><fpage>940</fpage><pub-id pub-id-type="doi">10.1038/s41598-017-01078-8</pub-id><pub-id pub-id-type="pmid">28424471</pub-id>
</element-citation><mixed-citation id="mc-CR53" publication-type="journal">Riccetti L, Yvinec R, Klett D, Gallay N, Combarnous Y, Reiter E, et al. Human luteinizing hormone and chorionic gonadotropin display biased agonism at the LH and LH/CG receptors. Sci Rep. 2017;7:940.<pub-id pub-id-type="pmid">28424471</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR54"><label>54.</label><citation-alternatives><element-citation id="ec-CR54" publication-type="journal"><person-group person-group-type="author"><name><surname>Casarini</surname><given-names>L</given-names></name><name><surname>Riccetti</surname><given-names>L</given-names></name><name><surname>De Pascali</surname><given-names>F</given-names></name><name><surname>Gilioli</surname><given-names>L</given-names></name><name><surname>Marino</surname><given-names>M</given-names></name><name><surname>Vecchi</surname><given-names>E</given-names></name><etal/></person-group><article-title>Estrogen modulates specific life and death signals induced by LH and hCG in human primary granulosa cells in vitro</article-title><source>Int J Mol Sci</source><year>2017</year><volume>18</volume><fpage>926</fpage><pub-id pub-id-type="doi">10.3390/ijms18050926</pub-id><pub-id pub-id-type="pmid">28452938</pub-id>
</element-citation><mixed-citation id="mc-CR54" publication-type="journal">Casarini L, Riccetti L, De Pascali F, Gilioli L, Marino M, Vecchi E, et al. Estrogen modulates specific life and death signals induced by LH and hCG in human primary granulosa cells in vitro. Int J Mol Sci. 2017;18:926.<pub-id pub-id-type="pmid">28452938</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR55"><label>55.</label><citation-alternatives><element-citation id="ec-CR55" publication-type="journal"><person-group person-group-type="author"><name><surname>Santi</surname><given-names>D</given-names></name><name><surname>Casarini</surname><given-names>L</given-names></name><name><surname>Alviggi</surname><given-names>C</given-names></name><name><surname>Simoni</surname><given-names>M</given-names></name></person-group><article-title>Efficacy of follicle-stimulating hormone (FSH) alone, FSH + luteinizing hormone, human menopausal gonadotropin or FSH + human chorionic gonadotropin on assisted reproductive technology outcomes in the personalized medicine era: a meta-analysis</article-title><source>Front Endocrinol</source><year>2017</year><volume>8</volume><fpage>114</fpage><pub-id pub-id-type="doi">10.3389/fendo.2017.00114</pub-id></element-citation><mixed-citation id="mc-CR55" publication-type="journal">Santi D, Casarini L, Alviggi C, Simoni M. Efficacy of follicle-stimulating hormone (FSH) alone, FSH + luteinizing hormone, human menopausal gonadotropin or FSH + human chorionic gonadotropin on assisted reproductive technology outcomes in the personalized medicine era: a meta-analysis. Front Endocrinol. 2017;8:114.</mixed-citation></citation-alternatives></ref><ref id="CR56"><label>56.</label><citation-alternatives><element-citation id="ec-CR56" publication-type="journal"><person-group person-group-type="author"><name><surname>Rulli</surname><given-names>SB</given-names></name><name><surname>Kuorelahti</surname><given-names>A</given-names></name><name><surname>Karaer</surname><given-names>O</given-names></name><name><surname>Pelliniemi</surname><given-names>LJ</given-names></name><name><surname>Poutanen</surname><given-names>M</given-names></name><name><surname>Huhtaniemi</surname><given-names>I</given-names></name></person-group><article-title>Reproductive disturbances, pituitary lactotrope adenomas, and mammary gland tumors in transgenic female mice producing high levels of human chorionic gonadotropin</article-title><source>Endocrinology</source><year>2002</year><volume>143</volume><fpage>4084</fpage><lpage>4095</lpage><pub-id pub-id-type="doi">10.1210/en.2002-220490</pub-id><pub-id pub-id-type="pmid">12239120</pub-id>
</element-citation><mixed-citation id="mc-CR56" publication-type="journal">Rulli SB, Kuorelahti A, Karaer O, Pelliniemi LJ, Poutanen M, Huhtaniemi I. Reproductive disturbances, pituitary lactotrope adenomas, and mammary gland tumors in transgenic female mice producing high levels of human chorionic gonadotropin. Endocrinology. 2002;143:4084&#x02013;95.<pub-id pub-id-type="pmid">12239120</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR57"><label>57.</label><citation-alternatives><element-citation id="ec-CR57" publication-type="journal"><person-group person-group-type="author"><name><surname>Peltoketo</surname><given-names>H</given-names></name><name><surname>Rivero-M&#x000fc;ller</surname><given-names>A</given-names></name><name><surname>Ahtiainen</surname><given-names>P</given-names></name><name><surname>Poutanen</surname><given-names>M</given-names></name><name><surname>Huhtaniemi</surname><given-names>I</given-names></name></person-group><article-title>Consequences of genetic manipulations of gonadotrophins and gonadotrophin receptors in mice</article-title><source>Ann Endocrinol (Paris)</source><year>2010</year><volume>71</volume><fpage>170</fpage><lpage>176</lpage><pub-id pub-id-type="doi">10.1016/j.ando.2010.02.022</pub-id><pub-id pub-id-type="pmid">20362970</pub-id>
</element-citation><mixed-citation id="mc-CR57" publication-type="journal">Peltoketo H, Rivero-M&#x000fc;ller A, Ahtiainen P, Poutanen M, Huhtaniemi I. Consequences of genetic manipulations of gonadotrophins and gonadotrophin receptors in mice. Ann Endocrinol (Paris). 2010;71:170&#x02013;6.<pub-id pub-id-type="pmid">20362970</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR58"><label>58.</label><citation-alternatives><element-citation id="ec-CR58" publication-type="journal"><person-group person-group-type="author"><name><surname>Risma</surname><given-names>KA</given-names></name><name><surname>Clay</surname><given-names>CM</given-names></name><name><surname>Nett</surname><given-names>TM</given-names></name><name><surname>Wagner</surname><given-names>T</given-names></name><name><surname>Yun</surname><given-names>J</given-names></name><name><surname>Nilson</surname><given-names>JH</given-names></name></person-group><article-title>Targeted overexpression of luteinizing hormone in transgenic mice leads to infertility, polycystic ovaries, and ovarian tumors</article-title><source>Proc Natl Acad Sci U S A</source><year>1995</year><volume>92</volume><fpage>1322</fpage><lpage>1326</lpage><pub-id pub-id-type="doi">10.1073/pnas.92.5.1322</pub-id><pub-id pub-id-type="pmid">7877975</pub-id>
</element-citation><mixed-citation id="mc-CR58" publication-type="journal">Risma KA, Clay CM, Nett TM, Wagner T, Yun J, Nilson JH. Targeted overexpression of luteinizing hormone in transgenic mice leads to infertility, polycystic ovaries, and ovarian tumors. Proc Natl Acad Sci U S A. 1995;92:1322&#x02013;6.<pub-id pub-id-type="pmid">7877975</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR59"><label>59.</label><citation-alternatives><element-citation id="ec-CR59" publication-type="journal"><person-group person-group-type="author"><name><surname>Kendall</surname><given-names>SK</given-names></name><name><surname>Samuelson</surname><given-names>LC</given-names></name><name><surname>Saunders</surname><given-names>TL</given-names></name><name><surname>Wood</surname><given-names>RI</given-names></name><name><surname>Camper</surname><given-names>SA</given-names></name></person-group><article-title>Targeted disruption of the pituitary glycoprotein hormone alpha-subunit produces hypogonadal and hypothyroid mice</article-title><source>Genes Dev</source><year>1995</year><volume>9</volume><fpage>2007</fpage><lpage>2019</lpage><pub-id pub-id-type="doi">10.1101/gad.9.16.2007</pub-id><pub-id pub-id-type="pmid">7544315</pub-id>
</element-citation><mixed-citation id="mc-CR59" publication-type="journal">Kendall SK, Samuelson LC, Saunders TL, Wood RI, Camper SA. Targeted disruption of the pituitary glycoprotein hormone alpha-subunit produces hypogonadal and hypothyroid mice. Genes Dev. 1995;9:2007&#x02013;19.<pub-id pub-id-type="pmid">7544315</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR60"><label>60.</label><citation-alternatives><element-citation id="ec-CR60" publication-type="journal"><person-group person-group-type="author"><name><surname>Ma</surname><given-names>X</given-names></name><name><surname>Dong</surname><given-names>Y</given-names></name><name><surname>Matzuk</surname><given-names>MM</given-names></name><name><surname>Kumar</surname><given-names>TR</given-names></name></person-group><article-title>Targeted disruption of luteinizing hormone beta-subunit leads to hypogonadism, defects in gonadal steroidogenesis, and infertility</article-title><source>Proc Natl Acad Sci U S A</source><year>2004</year><volume>101</volume><fpage>17294</fpage><lpage>17299</lpage><pub-id pub-id-type="doi">10.1073/pnas.0404743101</pub-id><pub-id pub-id-type="pmid">15569941</pub-id>
</element-citation><mixed-citation id="mc-CR60" publication-type="journal">Ma X, Dong Y, Matzuk MM, Kumar TR. Targeted disruption of luteinizing hormone beta-subunit leads to hypogonadism, defects in gonadal steroidogenesis, and infertility. Proc Natl Acad Sci U S A. 2004;101:17294&#x02013;9.<pub-id pub-id-type="pmid">15569941</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR61"><label>61.</label><citation-alternatives><element-citation id="ec-CR61" publication-type="journal"><person-group person-group-type="author"><name><surname>O&#x02019;Shaughnessy</surname><given-names>PJ</given-names></name><name><surname>Fleming</surname><given-names>LM</given-names></name><name><surname>Jackson</surname><given-names>G</given-names></name><name><surname>Hochgeschwender</surname><given-names>U</given-names></name><name><surname>Reed</surname><given-names>P</given-names></name><name><surname>Baker</surname><given-names>PJ</given-names></name></person-group><article-title>Adrenocorticotropic hormone directly stimulates testosterone production by the fetal and neonatal mouse testis</article-title><source>Endocrinology</source><year>2003</year><volume>144</volume><fpage>3279</fpage><lpage>3284</lpage><pub-id pub-id-type="doi">10.1210/en.2003-0277</pub-id><pub-id pub-id-type="pmid">12865302</pub-id>
</element-citation><mixed-citation id="mc-CR61" publication-type="journal">O&#x02019;Shaughnessy PJ, Fleming LM, Jackson G, Hochgeschwender U, Reed P, Baker PJ. Adrenocorticotropic hormone directly stimulates testosterone production by the fetal and neonatal mouse testis. Endocrinology. 2003;144:3279&#x02013;84.<pub-id pub-id-type="pmid">12865302</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR62"><label>62.</label><citation-alternatives><element-citation id="ec-CR62" publication-type="journal"><person-group person-group-type="author"><name><surname>El-Gehani</surname><given-names>F</given-names></name><name><surname>Zhang</surname><given-names>FP</given-names></name><name><surname>Pakarinen</surname><given-names>P</given-names></name><name><surname>Rannikko</surname><given-names>A</given-names></name><name><surname>Huhtaniemi</surname><given-names>I</given-names></name></person-group><article-title>Gonadotropin-independent regulation of steroidogenesis in the fetal rat testis</article-title><source>Biol Reprod</source><year>1998</year><volume>58</volume><fpage>116</fpage><lpage>23</lpage><pub-id pub-id-type="doi">10.1095/biolreprod58.1.116</pub-id><pub-id pub-id-type="pmid">9472931</pub-id>
</element-citation><mixed-citation id="mc-CR62" publication-type="journal">El-Gehani F, Zhang FP, Pakarinen P, Rannikko A, Huhtaniemi I. Gonadotropin-independent regulation of steroidogenesis in the fetal rat testis. Biol Reprod. 1998;58:116&#x02013;23.<pub-id pub-id-type="pmid">9472931</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR63"><label>63.</label><citation-alternatives><element-citation id="ec-CR63" publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>F-P</given-names></name><name><surname>Pakarainen</surname><given-names>T</given-names></name><name><surname>Poutanen</surname><given-names>M</given-names></name><name><surname>Toppari</surname><given-names>J</given-names></name><name><surname>Huhtaniemi</surname><given-names>I</given-names></name></person-group><article-title>The low gonadotropin-independent constitutive production of testicular testosterone is sufficient to maintain spermatogenesis</article-title><source>Proc Natl Acad Sci U S A</source><year>2003</year><volume>100</volume><fpage>13692</fpage><lpage>7</lpage><pub-id pub-id-type="doi">10.1073/pnas.2232815100</pub-id><pub-id pub-id-type="pmid">14585929</pub-id>
</element-citation><mixed-citation id="mc-CR63" publication-type="journal">Zhang F-P, Pakarainen T, Poutanen M, Toppari J, Huhtaniemi I. The low gonadotropin-independent constitutive production of testicular testosterone is sufficient to maintain spermatogenesis. Proc Natl Acad Sci U S A. 2003;100:13692&#x02013;7.<pub-id pub-id-type="pmid">14585929</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR64"><label>64.</label><citation-alternatives><element-citation id="ec-CR64" publication-type="journal"><person-group person-group-type="author"><name><surname>Oduwole</surname><given-names>OO</given-names></name><name><surname>Peltoketo</surname><given-names>H</given-names></name><name><surname>Poliandri</surname><given-names>A</given-names></name><name><surname>Vengadabady</surname><given-names>L</given-names></name><name><surname>Chrusciel</surname><given-names>M</given-names></name><name><surname>Doroszko</surname><given-names>M</given-names></name><etal/></person-group><article-title>Constitutively active follicle-stimulating hormone receptor enables androgen-independent spermatogenesis</article-title><source>J Clin Invest</source><year>2018</year><volume>128</volume><fpage>1787</fpage><lpage>92</lpage><pub-id pub-id-type="doi">10.1172/JCI96794</pub-id><pub-id pub-id-type="pmid">29584617</pub-id>
</element-citation><mixed-citation id="mc-CR64" publication-type="journal">Oduwole OO, Peltoketo H, Poliandri A, Vengadabady L, Chrusciel M, Doroszko M, et al. Constitutively active follicle-stimulating hormone receptor enables androgen-independent spermatogenesis. J Clin Invest. 2018;128:1787&#x02013;92.<pub-id pub-id-type="pmid">29584617</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR65"><label>65.</label><citation-alternatives><element-citation id="ec-CR65" publication-type="journal"><person-group person-group-type="author"><name><surname>Jonas</surname><given-names>KC</given-names></name><name><surname>Rivero M&#x000fc;ller</surname><given-names>A</given-names></name><name><surname>Oduwole</surname><given-names>O</given-names></name><name><surname>Peltoketo</surname><given-names>H</given-names></name><name><surname>Huhtaniemi</surname><given-names>I</given-names></name></person-group><article-title>The luteinizing hormone receptor knockout mouse as a tool to probe the in vivo actions of gonadotropic hormones/receptors in females</article-title><source>Endocrinology</source><year>2021</year><volume>162</volume><fpage>bqab035</fpage><pub-id pub-id-type="doi">10.1210/endocr/bqab035</pub-id><pub-id pub-id-type="pmid">33605422</pub-id>
</element-citation><mixed-citation id="mc-CR65" publication-type="journal">Jonas KC, Rivero M&#x000fc;ller A, Oduwole O, Peltoketo H, Huhtaniemi I. The luteinizing hormone receptor knockout mouse as a tool to probe the in vivo actions of gonadotropic hormones/receptors in females. Endocrinology. 2021;162:bqab035.<pub-id pub-id-type="pmid">33605422</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR66"><label>66.</label><citation-alternatives><element-citation id="ec-CR66" publication-type="journal"><person-group person-group-type="author"><name><surname>Rull</surname><given-names>K</given-names></name><name><surname>Laan</surname><given-names>M</given-names></name></person-group><article-title>Expression of beta-subunit of HCG genes during normal and failed pregnancy</article-title><source>Hum Reprod</source><year>2005</year><volume>20</volume><fpage>3360</fpage><lpage>3368</lpage><pub-id pub-id-type="doi">10.1093/humrep/dei261</pub-id><pub-id pub-id-type="pmid">16123088</pub-id>
</element-citation><mixed-citation id="mc-CR66" publication-type="journal">Rull K, Laan M. Expression of beta-subunit of HCG genes during normal and failed pregnancy. Hum Reprod. 2005;20:3360&#x02013;8.<pub-id pub-id-type="pmid">16123088</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR67"><label>67.</label><citation-alternatives><element-citation id="ec-CR67" publication-type="journal"><person-group person-group-type="author"><name><surname>Conforti</surname><given-names>A</given-names></name><name><surname>T&#x000fc;ttelmann</surname><given-names>F</given-names></name><name><surname>Alviggi</surname><given-names>C</given-names></name><name><surname>Behre</surname><given-names>HM</given-names></name><name><surname>Fischer</surname><given-names>R</given-names></name><name><surname>Hu</surname><given-names>L</given-names></name><etal/></person-group><article-title>Effect of genetic variants of gonadotropins and their receptors on ovarian stimulation outcomes: a Delphi consensus</article-title><source>Front Endocrinol (Lausanne)</source><year>2021</year><volume>12</volume><fpage>797365</fpage><pub-id pub-id-type="doi">10.3389/fendo.2021.797365</pub-id><pub-id pub-id-type="pmid">35178027</pub-id>
</element-citation><mixed-citation id="mc-CR67" publication-type="journal">Conforti A, T&#x000fc;ttelmann F, Alviggi C, Behre HM, Fischer R, Hu L, et al. Effect of genetic variants of gonadotropins and their receptors on ovarian stimulation outcomes: a Delphi consensus. Front Endocrinol (Lausanne). 2021;12:797365.<pub-id pub-id-type="pmid">35178027</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR68"><label>68.</label><citation-alternatives><element-citation id="ec-CR68" publication-type="journal"><person-group person-group-type="author"><name><surname>Pettersson</surname><given-names>K</given-names></name><name><surname>Ding</surname><given-names>YQ</given-names></name><name><surname>Huhtaniemi</surname><given-names>I</given-names></name></person-group><article-title>An immunologically anomalous luteinizing hormone variant in a healthy woman</article-title><source>J Clin Endocrinol Metab</source><year>1992</year><volume>74</volume><fpage>164</fpage><lpage>171</lpage><pub-id pub-id-type="pmid">1727817</pub-id>
</element-citation><mixed-citation id="mc-CR68" publication-type="journal">Pettersson K, Ding YQ, Huhtaniemi I. An immunologically anomalous luteinizing hormone variant in a healthy woman. J Clin Endocrinol Metab. 1992;74:164&#x02013;71.<pub-id pub-id-type="pmid">1727817</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR69"><label>69.</label><citation-alternatives><element-citation id="ec-CR69" publication-type="journal"><person-group person-group-type="author"><name><surname>Nilsson</surname><given-names>C</given-names></name><name><surname>Jiang</surname><given-names>M</given-names></name><name><surname>Pettersson</surname><given-names>K</given-names></name><name><surname>Iiti&#x000e4;</surname><given-names>A</given-names></name><name><surname>M&#x000e4;kel&#x000e4;</surname><given-names>M</given-names></name><name><surname>Simonsen</surname><given-names>H</given-names></name><etal/></person-group><article-title>Determination of a common genetic variant of luteinizing hormone using DNA hybridization and immunoassays</article-title><source>Clin Endocrinol (Oxf)</source><year>1998</year><volume>49</volume><fpage>369</fpage><lpage>376</lpage><pub-id pub-id-type="doi">10.1046/j.1365-2265.1998.00532.x</pub-id><pub-id pub-id-type="pmid">9861329</pub-id>
</element-citation><mixed-citation id="mc-CR69" publication-type="journal">Nilsson C, Jiang M, Pettersson K, Iiti&#x000e4; A, M&#x000e4;kel&#x000e4; M, Simonsen H, et al. Determination of a common genetic variant of luteinizing hormone using DNA hybridization and immunoassays. Clin Endocrinol (Oxf). 1998;49:369&#x02013;76.<pub-id pub-id-type="pmid">9861329</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR70"><label>70.</label><citation-alternatives><element-citation id="ec-CR70" publication-type="journal"><person-group person-group-type="author"><name><surname>Suganuma</surname><given-names>N</given-names></name><name><surname>Furui</surname><given-names>K</given-names></name><name><surname>Kikkawa</surname><given-names>F</given-names></name><name><surname>Tomoda</surname><given-names>Y</given-names></name><name><surname>Furuhashi</surname><given-names>M</given-names></name></person-group><article-title>Effects of the mutations (Trp8 --&#x0003e; arg and Ile15 --&#x0003e; thr) in human luteinizing hormone (LH) beta-subunit on LH bioactivity in vitro and in vivo</article-title><source>Endocrinology</source><year>1996</year><volume>137</volume><fpage>831</fpage><lpage>838</lpage><pub-id pub-id-type="doi">10.1210/endo.137.3.8603592</pub-id><pub-id pub-id-type="pmid">8603592</pub-id>
</element-citation><mixed-citation id="mc-CR70" publication-type="journal">Suganuma N, Furui K, Kikkawa F, Tomoda Y, Furuhashi M. Effects of the mutations (Trp8 --&#x0003e; arg and Ile15 --&#x0003e; thr) in human luteinizing hormone (LH) beta-subunit on LH bioactivity in vitro and in vivo. Endocrinology. 1996;137:831&#x02013;8.<pub-id pub-id-type="pmid">8603592</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR71"><label>71.</label><citation-alternatives><element-citation id="ec-CR71" publication-type="journal"><person-group person-group-type="author"><name><surname>Jiang</surname><given-names>M</given-names></name><name><surname>Lamminen</surname><given-names>T</given-names></name><name><surname>Pakarinen</surname><given-names>P</given-names></name><name><surname>Hellman</surname><given-names>J</given-names></name><name><surname>Manna</surname><given-names>P</given-names></name><name><surname>Herrera</surname><given-names>RJ</given-names></name><etal/></person-group><article-title>A novel Ala(-3)thr mutation in the signal peptide of human luteinizing hormone beta-subunit: potentiation of the inositol phosphate signalling pathway and attenuation of the adenylate cyclase pathway by recombinant variant hormone</article-title><source>Mol Hum Reprod</source><year>2002</year><volume>8</volume><fpage>201</fpage><lpage>212</lpage><pub-id pub-id-type="doi">10.1093/molehr/8.3.201</pub-id><pub-id pub-id-type="pmid">11870227</pub-id>
</element-citation><mixed-citation id="mc-CR71" publication-type="journal">Jiang M, Lamminen T, Pakarinen P, Hellman J, Manna P, Herrera RJ, et al. A novel Ala(-3)thr mutation in the signal peptide of human luteinizing hormone beta-subunit: potentiation of the inositol phosphate signalling pathway and attenuation of the adenylate cyclase pathway by recombinant variant hormone. Mol Hum Reprod. 2002;8:201&#x02013;12.<pub-id pub-id-type="pmid">11870227</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR72"><label>72.</label><citation-alternatives><element-citation id="ec-CR72" publication-type="journal"><person-group person-group-type="author"><name><surname>Liao</surname><given-names>WX</given-names></name><name><surname>Goh</surname><given-names>HH</given-names></name><name><surname>Roy</surname><given-names>AC</given-names></name></person-group><article-title>Functional characterization of a natural variant of luteinizing hormone</article-title><source>Hum Genet</source><year>2002</year><volume>111</volume><fpage>219</fpage><lpage>224</lpage><pub-id pub-id-type="doi">10.1007/s00439-002-0781-8</pub-id><pub-id pub-id-type="pmid">12189497</pub-id>
</element-citation><mixed-citation id="mc-CR72" publication-type="journal">Liao WX, Goh HH, Roy AC. Functional characterization of a natural variant of luteinizing hormone. Hum Genet. 2002;111:219&#x02013;24.<pub-id pub-id-type="pmid">12189497</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR73"><label>73.</label><citation-alternatives><element-citation id="ec-CR73" publication-type="journal"><person-group person-group-type="author"><name><surname>Liu</surname><given-names>S</given-names></name><name><surname>Ogata</surname><given-names>T</given-names></name><name><surname>Maruyama</surname><given-names>T</given-names></name><name><surname>Yoshimura</surname><given-names>Y</given-names></name><name><surname>Ishizuka</surname><given-names>B</given-names></name></person-group><article-title>Association of common LH variant with hyperfunctional promoter in a Japanese infertile woman</article-title><source>Endocr J</source><year>2005</year><volume>52</volume><fpage>781</fpage><lpage>784</lpage><pub-id pub-id-type="doi">10.1507/endocrj.52.781</pub-id><pub-id pub-id-type="pmid">16410673</pub-id>
</element-citation><mixed-citation id="mc-CR73" publication-type="journal">Liu S, Ogata T, Maruyama T, Yoshimura Y, Ishizuka B. Association of common LH variant with hyperfunctional promoter in a Japanese infertile woman. Endocr J. 2005;52:781&#x02013;4.<pub-id pub-id-type="pmid">16410673</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR74"><label>74.</label><citation-alternatives><element-citation id="ec-CR74" publication-type="journal"><person-group person-group-type="author"><name><surname>Bosco</surname><given-names>L</given-names></name><name><surname>Ruvolo</surname><given-names>G</given-names></name><name><surname>Luparello</surname><given-names>C</given-names></name><name><surname>Ferrari</surname><given-names>S</given-names></name><name><surname>Valerio</surname><given-names>D</given-names></name><name><surname>Santi</surname><given-names>D</given-names></name><etal/></person-group><article-title>Gene expression and apoptosis levels in cumulus cells of patients with polymorphisms of FSHR and LHB undergoing in vitro fertilization program</article-title><source>Cell Physiol Biochem</source><year>2017</year><volume>43</volume><fpage>2391</fpage><lpage>2404</lpage><pub-id pub-id-type="doi">10.1159/000484392</pub-id><pub-id pub-id-type="pmid">29073627</pub-id>
</element-citation><mixed-citation id="mc-CR74" publication-type="journal">Bosco L, Ruvolo G, Luparello C, Ferrari S, Valerio D, Santi D, et al. Gene expression and apoptosis levels in cumulus cells of patients with polymorphisms of FSHR and LHB undergoing in vitro fertilization program. Cell Physiol Biochem. 2017;43:2391&#x02013;404.<pub-id pub-id-type="pmid">29073627</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR75"><label>75.</label><citation-alternatives><element-citation id="ec-CR75" publication-type="journal"><person-group person-group-type="author"><name><surname>Tapanainen</surname><given-names>JS</given-names></name><name><surname>Koivunen</surname><given-names>R</given-names></name><name><surname>Fauser</surname><given-names>BC</given-names></name><name><surname>Taylor</surname><given-names>AE</given-names></name><name><surname>Clayton</surname><given-names>RN</given-names></name><name><surname>Rajkowa</surname><given-names>M</given-names></name><etal/></person-group><article-title>A new contributing factor to polycystic ovary syndrome: the genetic variant of luteinizing hormone</article-title><source>J Clin Endocrinol Metab</source><year>1999</year><volume>84</volume><fpage>1711</fpage><lpage>1715</lpage><pub-id pub-id-type="pmid">10323405</pub-id>
</element-citation><mixed-citation id="mc-CR75" publication-type="journal">Tapanainen JS, Koivunen R, Fauser BC, Taylor AE, Clayton RN, Rajkowa M, et al. A new contributing factor to polycystic ovary syndrome: the genetic variant of luteinizing hormone. J Clin Endocrinol Metab. 1999;84:1711&#x02013;5.<pub-id pub-id-type="pmid">10323405</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR76"><label>76.</label><citation-alternatives><element-citation id="ec-CR76" publication-type="journal"><person-group person-group-type="author"><name><surname>Branavan</surname><given-names>U</given-names></name><name><surname>Muneeswaran</surname><given-names>K</given-names></name><name><surname>Wijesundera</surname><given-names>S</given-names></name><name><surname>Jayakody</surname><given-names>S</given-names></name><name><surname>Chandrasekharan</surname><given-names>V</given-names></name><name><surname>Wijeyaratne</surname><given-names>C</given-names></name></person-group><article-title>Identification of selected genetic polymorphisms in polycystic ovary syndrome in Sri Lankan women using low-cost genotyping techniques</article-title><source>PLoS One</source><year>2018</year><volume>13</volume><fpage>e0209830</fpage><pub-id pub-id-type="doi">10.1371/journal.pone.0209830</pub-id><pub-id pub-id-type="pmid">30596735</pub-id>
</element-citation><mixed-citation id="mc-CR76" publication-type="journal">Branavan U, Muneeswaran K, Wijesundera S, Jayakody S, Chandrasekharan V, Wijeyaratne C. Identification of selected genetic polymorphisms in polycystic ovary syndrome in Sri Lankan women using low-cost genotyping techniques. PLoS One. 2018;13: e0209830.<pub-id pub-id-type="pmid">30596735</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR77"><label>77.</label><citation-alternatives><element-citation id="ec-CR77" publication-type="journal"><person-group person-group-type="author"><name><surname>Jiang</surname><given-names>M</given-names></name><name><surname>Pakarinen</surname><given-names>P</given-names></name><name><surname>Zhang</surname><given-names>FP</given-names></name><name><surname>El-Hefnawy</surname><given-names>T</given-names></name><name><surname>Koskimies</surname><given-names>P</given-names></name><name><surname>Pettersson</surname><given-names>K</given-names></name><etal/></person-group><article-title>A common polymorphic allele of the human luteinizing hormone beta-subunit gene: additional mutations and differential function of the promoter sequence</article-title><source>Hum Mol Genet</source><year>1999</year><volume>8</volume><fpage>2037</fpage><lpage>2046</lpage><pub-id pub-id-type="doi">10.1093/hmg/8.11.2037</pub-id><pub-id pub-id-type="pmid">10484773</pub-id>
</element-citation><mixed-citation id="mc-CR77" publication-type="journal">Jiang M, Pakarinen P, Zhang FP, El-Hefnawy T, Koskimies P, Pettersson K, et al. A common polymorphic allele of the human luteinizing hormone beta-subunit gene: additional mutations and differential function of the promoter sequence. Hum Mol Genet. 1999;8:2037&#x02013;46.<pub-id pub-id-type="pmid">10484773</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR78"><label>78.</label><citation-alternatives><element-citation id="ec-CR78" publication-type="journal"><person-group person-group-type="author"><name><surname>Punab</surname><given-names>AM</given-names></name><name><surname>Grigorova</surname><given-names>M</given-names></name><name><surname>Punab</surname><given-names>M</given-names></name><name><surname>Adler</surname><given-names>M</given-names></name><name><surname>Kuura</surname><given-names>T</given-names></name><name><surname>Poolamets</surname><given-names>O</given-names></name><etal/></person-group><article-title>Carriers of variant luteinizing hormone (V-LH) among 1593 baltic men have significantly higher serum LH</article-title><source>Andrology</source><year>2015</year><volume>3</volume><fpage>512</fpage><lpage>519</lpage><pub-id pub-id-type="doi">10.1111/andr.12022</pub-id><pub-id pub-id-type="pmid">25820123</pub-id>
</element-citation><mixed-citation id="mc-CR78" publication-type="journal">Punab AM, Grigorova M, Punab M, Adler M, Kuura T, Poolamets O, et al. Carriers of variant luteinizing hormone (V-LH) among 1593 baltic men have significantly higher serum LH. Andrology. 2015;3:512&#x02013;9.<pub-id pub-id-type="pmid">25820123</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR79"><label>79.</label><citation-alternatives><element-citation id="ec-CR79" publication-type="journal"><person-group person-group-type="author"><name><surname>Lamminen</surname><given-names>T</given-names></name><name><surname>Jiang</surname><given-names>M</given-names></name><name><surname>Manna</surname><given-names>PR</given-names></name><name><surname>Pakarinen</surname><given-names>P</given-names></name><name><surname>Simonsen</surname><given-names>H</given-names></name><name><surname>Herrera</surname><given-names>RJ</given-names></name><etal/></person-group><article-title>Functional study of a recombinant form of human LH beta-subunit variant carrying the gly(102)ser mutation found in Asian populations</article-title><source>Mol Hum Reprod</source><year>2002</year><volume>8</volume><fpage>887</fpage><lpage>892</lpage><pub-id pub-id-type="doi">10.1093/molehr/8.10.887</pub-id><pub-id pub-id-type="pmid">12356936</pub-id>
</element-citation><mixed-citation id="mc-CR79" publication-type="journal">Lamminen T, Jiang M, Manna PR, Pakarinen P, Simonsen H, Herrera RJ, et al. Functional study of a recombinant form of human LH beta-subunit variant carrying the gly(102)ser mutation found in Asian populations. Mol Hum Reprod. 2002;8:887&#x02013;92.<pub-id pub-id-type="pmid">12356936</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR80"><label>80.</label><citation-alternatives><element-citation id="ec-CR80" publication-type="journal"><person-group person-group-type="author"><name><surname>Zhao</surname><given-names>Y</given-names></name><name><surname>Chen</surname><given-names>T</given-names></name><name><surname>Zhou</surname><given-names>Y</given-names></name><name><surname>Li</surname><given-names>K</given-names></name><name><surname>Xiao</surname><given-names>J</given-names></name></person-group><article-title>An association study between the genetic polymorphisms within GnRHI, LH&#x003b2; and FSH&#x003b2; genes and central precocious puberty in Chinese girls</article-title><source>Neurosci Lett</source><year>2010</year><volume>486</volume><fpage>188</fpage><lpage>192</lpage><pub-id pub-id-type="doi">10.1016/j.neulet.2010.09.049</pub-id><pub-id pub-id-type="pmid">20869425</pub-id>
</element-citation><mixed-citation id="mc-CR80" publication-type="journal">Zhao Y, Chen T, Zhou Y, Li K, Xiao J. An association study between the genetic polymorphisms within GnRHI, LH&#x003b2; and FSH&#x003b2; genes and central precocious puberty in Chinese girls. Neurosci Lett. 2010;486:188&#x02013;92.<pub-id pub-id-type="pmid">20869425</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR81"><label>81.</label><citation-alternatives><element-citation id="ec-CR81" publication-type="journal"><person-group person-group-type="author"><name><surname>Dasgupta</surname><given-names>S</given-names></name><name><surname>Sirisha</surname><given-names>PVS</given-names></name><name><surname>Neelaveni</surname><given-names>K</given-names></name><name><surname>Anuradha</surname><given-names>K</given-names></name><name><surname>Sudhakar</surname><given-names>G</given-names></name><name><surname>Reddy</surname><given-names>BM</given-names></name></person-group><article-title>Role of luteinizing hormone &#x003b2;-subunit gene variants among south Indian women with polycystic ovary syndrome</article-title><source>Gene</source><year>2012</year><volume>494</volume><fpage>51</fpage><lpage>56</lpage><pub-id pub-id-type="doi">10.1016/j.gene.2011.11.054</pub-id><pub-id pub-id-type="pmid">22209983</pub-id>
</element-citation><mixed-citation id="mc-CR81" publication-type="journal">Dasgupta S, Sirisha PVS, Neelaveni K, Anuradha K, Sudhakar G, Reddy BM. Role of luteinizing hormone &#x003b2;-subunit gene variants among south Indian women with polycystic ovary syndrome. Gene. 2012;494:51&#x02013;6.<pub-id pub-id-type="pmid">22209983</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR82"><label>82.</label><citation-alternatives><element-citation id="ec-CR82" publication-type="journal"><person-group person-group-type="author"><name><surname>Cho</surname><given-names>SG</given-names></name><name><surname>Bhoumik</surname><given-names>A</given-names></name><name><surname>Broday</surname><given-names>L</given-names></name><name><surname>Ivanov</surname><given-names>V</given-names></name><name><surname>Rosenstein</surname><given-names>B</given-names></name><name><surname>Ronai</surname><given-names>Z</given-names></name></person-group><article-title>TIP49b, a regulator of activating transcription factor 2 response to stress and DNA damage</article-title><source>Mol Cell Biol</source><year>2001</year><volume>21</volume><fpage>8398</fpage><lpage>8413</lpage><pub-id pub-id-type="doi">10.1128/MCB.21.24.8398-8413.2001</pub-id><pub-id pub-id-type="pmid">11713276</pub-id>
</element-citation><mixed-citation id="mc-CR82" publication-type="journal">Cho SG, Bhoumik A, Broday L, Ivanov V, Rosenstein B, Ronai Z. TIP49b, a regulator of activating transcription factor 2 response to stress and DNA damage. Mol Cell Biol. 2001;21:8398&#x02013;413.<pub-id pub-id-type="pmid">11713276</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR83"><label>83.</label><citation-alternatives><element-citation id="ec-CR83" publication-type="journal"><person-group person-group-type="author"><name><surname>Lindgren</surname><given-names>I</given-names></name><name><surname>Nenonen</surname><given-names>H</given-names></name><name><surname>Henic</surname><given-names>E</given-names></name><name><surname>Bungum</surname><given-names>L</given-names></name><name><surname>Prahl</surname><given-names>A</given-names></name><name><surname>Bungum</surname><given-names>M</given-names></name><etal/></person-group><article-title>Gonadotropin receptor variants are linked to cumulative live birth rate after in vitro fertilization</article-title><source>J Assist Reprod Genet</source><year>2019</year><volume>36</volume><fpage>29</fpage><lpage>38</lpage><pub-id pub-id-type="doi">10.1007/s10815-018-1318-y</pub-id><pub-id pub-id-type="pmid">30232643</pub-id>
</element-citation><mixed-citation id="mc-CR83" publication-type="journal">Lindgren I, Nenonen H, Henic E, Bungum L, Prahl A, Bungum M, et al. Gonadotropin receptor variants are linked to cumulative live birth rate after in vitro fertilization. J Assist Reprod Genet. 2019;36:29&#x02013;38.<pub-id pub-id-type="pmid">30232643</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR84"><label>84.</label><citation-alternatives><element-citation id="ec-CR84" publication-type="journal"><person-group person-group-type="author"><name><surname>Lindgren</surname><given-names>I</given-names></name><name><surname>B&#x000e5;&#x000e5;th</surname><given-names>M</given-names></name><name><surname>Uvebrant</surname><given-names>K</given-names></name><name><surname>Dejmek</surname><given-names>A</given-names></name><name><surname>Kjaer</surname><given-names>L</given-names></name><name><surname>Henic</surname><given-names>E</given-names></name><etal/></person-group><article-title>Combined assessment of polymorphisms in the LHCGR and FSHR genes predict chance of pregnancy after in vitro fertilization</article-title><source>Hum Reprod</source><year>2016</year><volume>31</volume><fpage>672</fpage><lpage>683</lpage><pub-id pub-id-type="doi">10.1093/humrep/dev342</pub-id><pub-id pub-id-type="pmid">26769719</pub-id>
</element-citation><mixed-citation id="mc-CR84" publication-type="journal">Lindgren I, B&#x000e5;&#x000e5;th M, Uvebrant K, Dejmek A, Kjaer L, Henic E, et al. Combined assessment of polymorphisms in the LHCGR and FSHR genes predict chance of pregnancy after in vitro fertilization. Hum Reprod. 2016;31:672&#x02013;83.<pub-id pub-id-type="pmid">26769719</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR85"><label>85.</label><citation-alternatives><element-citation id="ec-CR85" publication-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>Z-J</given-names></name><name><surname>Zhao</surname><given-names>H</given-names></name><name><surname>He</surname><given-names>L</given-names></name><name><surname>Shi</surname><given-names>Y</given-names></name><name><surname>Qin</surname><given-names>Y</given-names></name><name><surname>Shi</surname><given-names>Y</given-names></name><etal/></person-group><article-title>Genome-wide association study identifies susceptibility loci for polycystic ovary syndrome on chromosome 2p16.3, 2p21 and 9q33.3</article-title><source>Nat Genet</source><year>2011</year><volume>43</volume><fpage>55</fpage><lpage>59</lpage><pub-id pub-id-type="doi">10.1038/ng.732</pub-id><pub-id pub-id-type="pmid">21151128</pub-id>
</element-citation><mixed-citation id="mc-CR85" publication-type="journal">Chen Z-J, Zhao H, He L, Shi Y, Qin Y, Shi Y, et al. Genome-wide association study identifies susceptibility loci for polycystic ovary syndrome on chromosome 2p16.3, 2p21 and 9q33.3. Nat Genet. 2011;43:55&#x02013;9.<pub-id pub-id-type="pmid">21151128</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR86"><label>86.</label><citation-alternatives><element-citation id="ec-CR86" publication-type="journal"><person-group person-group-type="author"><name><surname>Casarini</surname><given-names>L</given-names></name><name><surname>Brigante</surname><given-names>G</given-names></name></person-group><article-title>The polycystic ovary syndrome evolutionary paradox: a genome-wide association studies-based, in silico, evolutionary explanation</article-title><source>J Clin Endocrinol Metab</source><year>2014</year><volume>99</volume><fpage>E2412</fpage><lpage>2420</lpage><pub-id pub-id-type="doi">10.1210/jc.2014-2703</pub-id><pub-id pub-id-type="pmid">25093623</pub-id>
</element-citation><mixed-citation id="mc-CR86" publication-type="journal">Casarini L, Brigante G. The polycystic ovary syndrome evolutionary paradox: a genome-wide association studies-based, in silico, evolutionary explanation. J Clin Endocrinol Metab. 2014;99:E2412-2420.<pub-id pub-id-type="pmid">25093623</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR87"><label>87.</label><citation-alternatives><element-citation id="ec-CR87" publication-type="journal"><person-group person-group-type="author"><name><surname>Shi</surname><given-names>Y</given-names></name><name><surname>Zhao</surname><given-names>H</given-names></name><name><surname>Shi</surname><given-names>Y</given-names></name><name><surname>Cao</surname><given-names>Y</given-names></name><name><surname>Yang</surname><given-names>D</given-names></name><name><surname>Li</surname><given-names>Z</given-names></name><etal/></person-group><article-title>Genome-wide association study identifies eight new risk loci for polycystic ovary syndrome</article-title><source>Nat Genet</source><year>2012</year><volume>44</volume><fpage>1020</fpage><lpage>1025</lpage><pub-id pub-id-type="doi">10.1038/ng.2384</pub-id><pub-id pub-id-type="pmid">22885925</pub-id>
</element-citation><mixed-citation id="mc-CR87" publication-type="journal">Shi Y, Zhao H, Shi Y, Cao Y, Yang D, Li Z, et al. Genome-wide association study identifies eight new risk loci for polycystic ovary syndrome. Nat Genet. 2012;44:1020&#x02013;5.<pub-id pub-id-type="pmid">22885925</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR88"><label>88.</label><citation-alternatives><element-citation id="ec-CR88" publication-type="journal"><person-group person-group-type="author"><name><surname>Jones</surname><given-names>MR</given-names></name><name><surname>Brower</surname><given-names>MA</given-names></name><name><surname>Xu</surname><given-names>N</given-names></name><name><surname>Cui</surname><given-names>J</given-names></name><name><surname>Mengesha</surname><given-names>E</given-names></name><name><surname>Chen</surname><given-names>Y-DI</given-names></name><etal/></person-group><article-title>Systems genetics reveals the functional context of PCOS loci and identifies genetic and molecular mechanisms of disease heterogeneity</article-title><source>PLoS Genet</source><year>2015</year><volume>11</volume><fpage>e1005455</fpage><pub-id pub-id-type="doi">10.1371/journal.pgen.1005455</pub-id><pub-id pub-id-type="pmid">26305227</pub-id>
</element-citation><mixed-citation id="mc-CR88" publication-type="journal">Jones MR, Brower MA, Xu N, Cui J, Mengesha E, Chen Y-DI, et al. Systems genetics reveals the functional context of PCOS loci and identifies genetic and molecular mechanisms of disease heterogeneity. PLoS Genet. 2015;11:e1005455.<pub-id pub-id-type="pmid">26305227</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR89"><label>89.</label><citation-alternatives><element-citation id="ec-CR89" publication-type="journal"><person-group person-group-type="author"><name><surname>Deswal</surname><given-names>R</given-names></name><name><surname>Nanda</surname><given-names>S</given-names></name><name><surname>Dang</surname><given-names>AS</given-names></name></person-group><article-title>Association of luteinizing hormone and LH receptor gene polymorphism with susceptibility of polycystic ovary syndrome</article-title><source>Syst Biol Reprod Med</source><year>2019</year><volume>65</volume><fpage>400</fpage><lpage>408</lpage><pub-id pub-id-type="doi">10.1080/19396368.2019.1595217</pub-id><pub-id pub-id-type="pmid">30958034</pub-id>
</element-citation><mixed-citation id="mc-CR89" publication-type="journal">Deswal R, Nanda S, Dang AS. Association of luteinizing hormone and LH receptor gene polymorphism with susceptibility of polycystic ovary syndrome. Syst Biol Reprod Med. 2019;65:400&#x02013;8.<pub-id pub-id-type="pmid">30958034</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR90"><label>90.</label><citation-alternatives><element-citation id="ec-CR90" publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>Y-J</given-names></name><name><surname>Li</surname><given-names>L</given-names></name><name><surname>Wang</surname><given-names>Z-J</given-names></name><name><surname>Zhang</surname><given-names>X-J</given-names></name><name><surname>Zhao</surname><given-names>H</given-names></name><name><surname>Zhao</surname><given-names>Y</given-names></name><etal/></person-group><article-title>Association study between variants in LHCGR DENND1A and THADA with preeclampsia risk in Han Chinese populations</article-title><source>J Matern Fetal Neonatal Med</source><year>2019</year><volume>32</volume><fpage>3801</fpage><lpage>3805</lpage><pub-id pub-id-type="doi">10.1080/14767058.2018.1472228</pub-id><pub-id pub-id-type="pmid">29727258</pub-id>
</element-citation><mixed-citation id="mc-CR90" publication-type="journal">Zhang Y-J, Li L, Wang Z-J, Zhang X-J, Zhao H, Zhao Y, et al. Association study between variants in LHCGR DENND1A and THADA with preeclampsia risk in Han Chinese populations. J Matern Fetal Neonatal Med. 2019;32:3801&#x02013;5.<pub-id pub-id-type="pmid">29727258</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR91"><label>91.</label><citation-alternatives><element-citation id="ec-CR91" publication-type="journal"><person-group person-group-type="author"><name><surname>Singh</surname><given-names>S</given-names></name><name><surname>Kaur</surname><given-names>M</given-names></name><name><surname>Kaur</surname><given-names>R</given-names></name><name><surname>Beri</surname><given-names>A</given-names></name><name><surname>Kaur</surname><given-names>A</given-names></name></person-group><article-title>Association analysis of LHCGR variants and polycystic ovary syndrome in Punjab: a case-control approach</article-title><source>BMC Endocr Disord</source><year>2022</year><volume>22</volume><fpage>335</fpage><pub-id pub-id-type="doi">10.1186/s12902-022-01251-9</pub-id><pub-id pub-id-type="pmid">36585675</pub-id>
</element-citation><mixed-citation id="mc-CR91" publication-type="journal">Singh S, Kaur M, Kaur R, Beri A, Kaur A. Association analysis of LHCGR variants and polycystic ovary syndrome in Punjab: a case-control approach. BMC Endocr Disord. 2022;22:335.<pub-id pub-id-type="pmid">36585675</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR92"><label>92.</label><citation-alternatives><element-citation id="ec-CR92" publication-type="journal"><person-group person-group-type="author"><name><surname>Liaqat</surname><given-names>I</given-names></name><name><surname>Jahan</surname><given-names>N</given-names></name><name><surname>Krikun</surname><given-names>G</given-names></name><name><surname>Taylor</surname><given-names>HS</given-names></name></person-group><article-title>Genetic polymorphisms in Pakistani women with polycystic ovary syndrome</article-title><source>Reprod Sci</source><year>2015</year><volume>22</volume><fpage>347</fpage><lpage>357</lpage><pub-id pub-id-type="doi">10.1177/1933719114542015</pub-id><pub-id pub-id-type="pmid">25100445</pub-id>
</element-citation><mixed-citation id="mc-CR92" publication-type="journal">Liaqat I, Jahan N, Krikun G, Taylor HS. Genetic polymorphisms in Pakistani women with polycystic ovary syndrome. Reprod Sci. 2015;22:347&#x02013;57.<pub-id pub-id-type="pmid">25100445</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR93"><label>93.</label><citation-alternatives><element-citation id="ec-CR93" publication-type="journal"><person-group person-group-type="author"><name><surname>Bassiouny</surname><given-names>YA</given-names></name><name><surname>Rabie</surname><given-names>WA</given-names></name><name><surname>Hassan</surname><given-names>AA</given-names></name><name><surname>Darwish</surname><given-names>RK</given-names></name></person-group><article-title>Association of the luteinizing hormone/choriogonadotropin receptor gene polymorphism with polycystic ovary syndrome</article-title><source>Gynecol Endocrinol</source><year>2014</year><volume>30</volume><fpage>428</fpage><lpage>430</lpage><pub-id pub-id-type="doi">10.3109/09513590.2014.895982</pub-id><pub-id pub-id-type="pmid">24592983</pub-id>
</element-citation><mixed-citation id="mc-CR93" publication-type="journal">Bassiouny YA, Rabie WA, Hassan AA, Darwish RK. Association of the luteinizing hormone/choriogonadotropin receptor gene polymorphism with polycystic ovary syndrome. Gynecol Endocrinol. 2014;30:428&#x02013;30.<pub-id pub-id-type="pmid">24592983</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR94"><label>94.</label><citation-alternatives><element-citation id="ec-CR94" publication-type="journal"><person-group person-group-type="author"><name><surname>Cui</surname><given-names>L</given-names></name><name><surname>Zhao</surname><given-names>H</given-names></name><name><surname>Zhang</surname><given-names>B</given-names></name><name><surname>Qu</surname><given-names>Z</given-names></name><name><surname>Liu</surname><given-names>J</given-names></name><name><surname>Liang</surname><given-names>X</given-names></name><etal/></person-group><article-title>Genotype&#x02013;phenotype correlations of PCOS susceptibility SNPs identified by GWAS in a large cohort of Han Chinese women</article-title><source>Hum Reprod</source><year>2013</year><volume>28</volume><fpage>538</fpage><lpage>544</lpage><pub-id pub-id-type="doi">10.1093/humrep/des424</pub-id><pub-id pub-id-type="pmid">23208300</pub-id>
</element-citation><mixed-citation id="mc-CR94" publication-type="journal">Cui L, Zhao H, Zhang B, Qu Z, Liu J, Liang X, et al. Genotype&#x02013;phenotype correlations of PCOS susceptibility SNPs identified by GWAS in a large cohort of Han Chinese women. Hum Reprod. 2013;28:538&#x02013;44.<pub-id pub-id-type="pmid">23208300</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR95"><label>95.</label><citation-alternatives><element-citation id="ec-CR95" publication-type="journal"><person-group person-group-type="author"><name><surname>Liu</surname><given-names>N</given-names></name><name><surname>Ma</surname><given-names>Y</given-names></name><name><surname>Wang</surname><given-names>S</given-names></name><name><surname>Zhang</surname><given-names>X</given-names></name><name><surname>Zhang</surname><given-names>Q</given-names></name><name><surname>Zhang</surname><given-names>X</given-names></name><etal/></person-group><article-title>Association of the genetic variants of luteinizing hormone, luteinizing hormone receptor and polycystic ovary syndrome</article-title><source>Reprod Biol Endocrinol</source><year>2012</year><volume>10</volume><fpage>36</fpage><pub-id pub-id-type="doi">10.1186/1477-7827-10-36</pub-id><pub-id pub-id-type="pmid">22546001</pub-id>
</element-citation><mixed-citation id="mc-CR95" publication-type="journal">Liu N, Ma Y, Wang S, Zhang X, Zhang Q, Zhang X, et al. Association of the genetic variants of luteinizing hormone, luteinizing hormone receptor and polycystic ovary syndrome. Reprod Biol Endocrinol. 2012;10: 36.<pub-id pub-id-type="pmid">22546001</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR96"><label>96.</label><citation-alternatives><element-citation id="ec-CR96" publication-type="journal"><person-group person-group-type="author"><name><surname>Lidaka</surname><given-names>L</given-names></name><name><surname>Bekere</surname><given-names>L</given-names></name><name><surname>Rota</surname><given-names>A</given-names></name><name><surname>Isakova</surname><given-names>J</given-names></name><name><surname>Lazdane</surname><given-names>G</given-names></name><name><surname>Kivite-Urtane</surname><given-names>A</given-names></name><etal/></person-group><article-title>Role of single nucleotide variants in FSHR, GNRHR, ESR2 and LHCGR genes in adolescents with polycystic ovary syndrome</article-title><source>Diagnostics (Basel)</source><year>2021</year><volume>11</volume><fpage>2327</fpage><pub-id pub-id-type="doi">10.3390/diagnostics11122327</pub-id><pub-id pub-id-type="pmid">34943568</pub-id>
</element-citation><mixed-citation id="mc-CR96" publication-type="journal">Lidaka L, Bekere L, Rota A, Isakova J, Lazdane G, Kivite-Urtane A, et al. Role of single nucleotide variants in FSHR, GNRHR, ESR2 and LHCGR genes in adolescents with polycystic ovary syndrome. Diagnostics (Basel). 2021;11:2327.<pub-id pub-id-type="pmid">34943568</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR97"><label>97.</label><citation-alternatives><element-citation id="ec-CR97" publication-type="journal"><person-group person-group-type="author"><name><surname>Makhdoomi</surname><given-names>MJ</given-names></name><name><surname>Shah</surname><given-names>IA</given-names></name><name><surname>Rashid</surname><given-names>R</given-names></name><name><surname>Rashid</surname><given-names>A</given-names></name><name><surname>Singh</surname><given-names>S</given-names></name><name><surname>Shah</surname><given-names>ZA</given-names></name><etal/></person-group><article-title>Effect modification of LHCGR gene variant (rs2293275) on clinico-biochemical profile, and levels of luteinizing hormone in polycystic ovary syndrome patients</article-title><source>Biochem Genet</source><year>2023</year><volume>61</volume><fpage>1418</fpage><lpage>1432</lpage><pub-id pub-id-type="doi">10.1007/s10528-022-10327-z</pub-id><pub-id pub-id-type="pmid">36633772</pub-id>
</element-citation><mixed-citation id="mc-CR97" publication-type="journal">Makhdoomi MJ, Shah IA, Rashid R, Rashid A, Singh S, Shah ZA, et al. Effect modification of LHCGR gene variant (rs2293275) on clinico-biochemical profile, and levels of luteinizing hormone in polycystic ovary syndrome patients. Biochem Genet. 2023;61:1418&#x02013;32.<pub-id pub-id-type="pmid">36633772</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR98"><label>98.</label><citation-alternatives><element-citation id="ec-CR98" publication-type="journal"><person-group person-group-type="author"><name><surname>Simoni</surname><given-names>M</given-names></name><name><surname>T&#x000fc;ttelmann</surname><given-names>F</given-names></name><name><surname>Michel</surname><given-names>C</given-names></name><name><surname>B&#x000f6;ckenfeld</surname><given-names>Y</given-names></name><name><surname>Nieschlag</surname><given-names>E</given-names></name><name><surname>Gromoll</surname><given-names>J</given-names></name></person-group><article-title>Polymorphisms of the luteinizing hormone/chorionic gonadotropin receptor gene: association with maldescended testes and male infertility</article-title><source>Pharmacogenet Genomics</source><year>2008</year><volume>18</volume><fpage>193</fpage><lpage>200</lpage><pub-id pub-id-type="doi">10.1097/FPC.0b013e3282f4e98c</pub-id><pub-id pub-id-type="pmid">18300940</pub-id>
</element-citation><mixed-citation id="mc-CR98" publication-type="journal">Simoni M, T&#x000fc;ttelmann F, Michel C, B&#x000f6;ckenfeld Y, Nieschlag E, Gromoll J. Polymorphisms of the luteinizing hormone/chorionic gonadotropin receptor gene: association with maldescended testes and male infertility. Pharmacogenet Genomics. 2008;18:193&#x02013;200.<pub-id pub-id-type="pmid">18300940</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR99"><label>99.</label><citation-alternatives><element-citation id="ec-CR99" publication-type="journal"><person-group person-group-type="author"><name><surname>Singh</surname><given-names>R</given-names></name><name><surname>Kaur</surname><given-names>S</given-names></name><name><surname>Yadav</surname><given-names>S</given-names></name><name><surname>Bhatia</surname><given-names>S</given-names></name></person-group><article-title>Gonadotropins as pharmacological agents in assisted reproductive technology and polycystic ovary syndrome</article-title><source>Trends Endocrinol Metab.</source><year>2023</year><volume>S1043&#x02013;2760</volume><issue>23</issue><fpage>00031</fpage></element-citation><mixed-citation id="mc-CR99" publication-type="journal">Singh R, Kaur S, Yadav S, Bhatia S. Gonadotropins as pharmacological agents in assisted reproductive technology and polycystic ovary syndrome. Trends Endocrinol Metab. 2023;S1043&#x02013;2760(23):00031.</mixed-citation></citation-alternatives></ref><ref id="CR100"><label>100.</label><citation-alternatives><element-citation id="ec-CR100" publication-type="journal"><person-group person-group-type="author"><name><surname>Alviggi</surname><given-names>C</given-names></name><name><surname>Clarizia</surname><given-names>R</given-names></name><name><surname>Pettersson</surname><given-names>K</given-names></name><name><surname>Mollo</surname><given-names>A</given-names></name><name><surname>Humaidan</surname><given-names>P</given-names></name><name><surname>Strina</surname><given-names>I</given-names></name><etal/></person-group><article-title>Suboptimal response to GnRHa long protocol is associated with a common LH polymorphism</article-title><source>Reprod Biomed Online</source><year>2011</year><volume>22</volume><issue>Suppl 1</issue><fpage>S67</fpage><lpage>72</lpage><pub-id pub-id-type="doi">10.1016/S1472-6483(11)60011-4</pub-id><pub-id pub-id-type="pmid">21575852</pub-id>
</element-citation><mixed-citation id="mc-CR100" publication-type="journal">Alviggi C, Clarizia R, Pettersson K, Mollo A, Humaidan P, Strina I, et al. Suboptimal response to GnRHa long protocol is associated with a common LH polymorphism. Reprod Biomed Online. 2011;22(Suppl 1):S67-72.<pub-id pub-id-type="pmid">21575852</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR101"><label>101.</label><citation-alternatives><element-citation id="ec-CR101" publication-type="journal"><person-group person-group-type="author"><name><surname>Ku</surname><given-names>Y</given-names></name><name><surname>Hong</surname><given-names>MA</given-names></name><name><surname>Chae</surname><given-names>SJ</given-names></name><name><surname>Lim</surname><given-names>KS</given-names></name><name><surname>Lee</surname><given-names>W-D</given-names></name><name><surname>Lim</surname><given-names>JH</given-names></name><etal/></person-group><article-title>The effects of luteinising hormone gene polymorphism on the outcomes of in vitro fertilisation and embryo transfer</article-title><source>J Obstet Gynaecol</source><year>2021</year><volume>41</volume><fpage>1092</fpage><lpage>1096</lpage><pub-id pub-id-type="doi">10.1080/01443615.2020.1821619</pub-id><pub-id pub-id-type="pmid">33241699</pub-id>
</element-citation><mixed-citation id="mc-CR101" publication-type="journal">Ku Y, Hong MA, Chae SJ, Lim KS, Lee W-D, Lim JH, et al. The effects of luteinising hormone gene polymorphism on the outcomes of in vitro fertilisation and embryo transfer. J Obstet Gynaecol. 2021;41:1092&#x02013;6.<pub-id pub-id-type="pmid">33241699</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR102"><label>102.</label><citation-alternatives><element-citation id="ec-CR102" publication-type="journal"><person-group person-group-type="author"><name><surname>Garcia-Velasco</surname><given-names>JA</given-names></name><name><surname>Coelingh Bennink</surname><given-names>HJT</given-names></name><name><surname>Epifanio</surname><given-names>R</given-names></name><name><surname>Escudero</surname><given-names>E</given-names></name><name><surname>Pellicer</surname><given-names>A</given-names></name><name><surname>Sim&#x000f3;n</surname><given-names>C</given-names></name></person-group><article-title>High-dose recombinant LH add-back strategy using high-dose GnRH antagonist is an innovative protocol compared with standard GnRH antagonist</article-title><source>Reprod Biomed Online</source><year>2007</year><volume>15</volume><fpage>280</fpage><lpage>287</lpage><pub-id pub-id-type="doi">10.1016/S1472-6483(10)60340-9</pub-id><pub-id pub-id-type="pmid">17854525</pub-id>
</element-citation><mixed-citation id="mc-CR102" publication-type="journal">Garcia-Velasco JA, Coelingh Bennink HJT, Epifanio R, Escudero E, Pellicer A, Sim&#x000f3;n C. High-dose recombinant LH add-back strategy using high-dose GnRH antagonist is an innovative protocol compared with standard GnRH antagonist. Reprod Biomed Online. 2007;15:280&#x02013;7.<pub-id pub-id-type="pmid">17854525</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR103"><label>103.</label><citation-alternatives><element-citation id="ec-CR103" publication-type="journal"><person-group person-group-type="author"><name><surname>Kol</surname><given-names>S</given-names></name></person-group><article-title>LH supplementation in ovarian stimulation for IVF: the individual, LH deficient, patient perspective</article-title><source>Gynecol Obstet Invest</source><year>2020</year><volume>85</volume><fpage>307</fpage><lpage>311</lpage><pub-id pub-id-type="doi">10.1159/000509162</pub-id><pub-id pub-id-type="pmid">32694249</pub-id>
</element-citation><mixed-citation id="mc-CR103" publication-type="journal">Kol S. LH supplementation in ovarian stimulation for IVF: the individual, LH deficient, patient perspective. Gynecol Obstet Invest. 2020;85:307&#x02013;11.<pub-id pub-id-type="pmid">32694249</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR104"><label>104.</label><citation-alternatives><element-citation id="ec-CR104" publication-type="journal"><person-group person-group-type="author"><name><surname>Barmat</surname><given-names>LI</given-names></name><name><surname>Chantilis</surname><given-names>SJ</given-names></name><name><surname>Hurst</surname><given-names>BS</given-names></name><name><surname>Dickey</surname><given-names>RP</given-names></name></person-group><article-title>A randomized prospective trial comparing gonadotropin-releasing hormone (GnRH) antagonist/recombinant follicle-stimulating hormone (rFSH) versus GnRH-agonist/rFSH in women pretreated with oral contraceptives before in vitro fertilization</article-title><source>Fertil Steril</source><year>2005</year><volume>83</volume><fpage>321</fpage><lpage>330</lpage><pub-id pub-id-type="doi">10.1016/j.fertnstert.2004.06.076</pub-id><pub-id pub-id-type="pmid">15705369</pub-id>
</element-citation><mixed-citation id="mc-CR104" publication-type="journal">Barmat LI, Chantilis SJ, Hurst BS, Dickey RP. A randomized prospective trial comparing gonadotropin-releasing hormone (GnRH) antagonist/recombinant follicle-stimulating hormone (rFSH) versus GnRH-agonist/rFSH in women pretreated with oral contraceptives before in vitro fertilization. Fertil Steril. 2005;83:321&#x02013;30.<pub-id pub-id-type="pmid">15705369</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR105"><label>105.</label><citation-alternatives><element-citation id="ec-CR105" publication-type="journal"><person-group person-group-type="author"><name><surname>Liao</surname><given-names>WX</given-names></name><name><surname>Roy</surname><given-names>AC</given-names></name><name><surname>Chan</surname><given-names>C</given-names></name><name><surname>Arulkumaran</surname><given-names>S</given-names></name><name><surname>Ratnam</surname><given-names>SS</given-names></name></person-group><article-title>A new molecular variant of luteinizing hormone associated with female infertility</article-title><source>Fertil Steril</source><year>1998</year><volume>69</volume><fpage>102</fpage><lpage>106</lpage><pub-id pub-id-type="doi">10.1016/S0015-0282(97)00445-7</pub-id><pub-id pub-id-type="pmid">9457942</pub-id>
</element-citation><mixed-citation id="mc-CR105" publication-type="journal">Liao WX, Roy AC, Chan C, Arulkumaran S, Ratnam SS. A new molecular variant of luteinizing hormone associated with female infertility. Fertil Steril. 1998;69:102&#x02013;6.<pub-id pub-id-type="pmid">9457942</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR106"><label>106.</label><citation-alternatives><element-citation id="ec-CR106" publication-type="journal"><person-group person-group-type="author"><name><surname>Davar</surname><given-names>R</given-names></name><name><surname>Tabibnejad</surname><given-names>N</given-names></name><name><surname>Kalantar</surname><given-names>SM</given-names></name><name><surname>Sheikhha</surname><given-names>MH</given-names></name></person-group><article-title>The luteinizing hormone beta-subunit exon 3 (Gly102Ser) gene mutation and ovarian responses to controlled ovarian hyperstimulation</article-title><source>Iran J Reprod Med</source><year>2014</year><volume>12</volume><fpage>667</fpage><lpage>672</lpage><pub-id pub-id-type="pmid">25469124</pub-id>
</element-citation><mixed-citation id="mc-CR106" publication-type="journal">Davar R, Tabibnejad N, Kalantar SM, Sheikhha MH. The luteinizing hormone beta-subunit exon 3 (Gly102Ser) gene mutation and ovarian responses to controlled ovarian hyperstimulation. Iran J Reprod Med. 2014;12:667&#x02013;72.<pub-id pub-id-type="pmid">25469124</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR107"><label>107.</label><citation-alternatives><element-citation id="ec-CR107" publication-type="journal"><person-group person-group-type="author"><name><surname>Gardner</surname><given-names>DK</given-names></name><name><surname>Lane</surname><given-names>M</given-names></name><name><surname>Schoolcraft</surname><given-names>WB</given-names></name></person-group><article-title>Physiology and culture of the human blastocyst</article-title><source>J Reprod Immunol</source><year>2002</year><volume>55</volume><fpage>85</fpage><lpage>100</lpage><pub-id pub-id-type="doi">10.1016/S0165-0378(01)00136-X</pub-id><pub-id pub-id-type="pmid">12062824</pub-id>
</element-citation><mixed-citation id="mc-CR107" publication-type="journal">Gardner DK, Lane M, Schoolcraft WB. Physiology and culture of the human blastocyst. J Reprod Immunol. 2002;55:85&#x02013;100.<pub-id pub-id-type="pmid">12062824</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR108"><label>108.</label><citation-alternatives><element-citation id="ec-CR108" publication-type="journal"><person-group person-group-type="author"><name><surname>Gardner</surname><given-names>DK</given-names></name><name><surname>Lane</surname><given-names>M</given-names></name><name><surname>Stevens</surname><given-names>J</given-names></name><name><surname>Schlenker</surname><given-names>T</given-names></name><name><surname>Schoolcraft</surname><given-names>WB</given-names></name></person-group><article-title>Blastocyst score affects implantation and pregnancy outcome: towards a single blastocyst transfer</article-title><source>Fertil Steril</source><year>2000</year><volume>73</volume><fpage>1155</fpage><lpage>1158</lpage><pub-id pub-id-type="doi">10.1016/S0015-0282(00)00518-5</pub-id><pub-id pub-id-type="pmid">10856474</pub-id>
</element-citation><mixed-citation id="mc-CR108" publication-type="journal">Gardner DK, Lane M, Stevens J, Schlenker T, Schoolcraft WB. Blastocyst score affects implantation and pregnancy outcome: towards a single blastocyst transfer. Fertil Steril. 2000;73:1155&#x02013;8.<pub-id pub-id-type="pmid">10856474</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR109"><label>109.</label><citation-alternatives><element-citation id="ec-CR109" publication-type="journal"><person-group person-group-type="author"><name><surname>Guo</surname><given-names>C</given-names></name><name><surname>Yu</surname><given-names>H</given-names></name><name><surname>Feng</surname><given-names>G</given-names></name><name><surname>Lv</surname><given-names>Q</given-names></name><name><surname>Liu</surname><given-names>X</given-names></name><name><surname>Liu</surname><given-names>X</given-names></name></person-group><article-title>Associations of FSHR and LHCGR gene variants with ovarian reserve and clinical pregnancy rates</article-title><source>Reprod Biomed Online</source><year>2021</year><volume>43</volume><fpage>561</fpage><lpage>569</lpage><pub-id pub-id-type="doi">10.1016/j.rbmo.2021.06.016</pub-id><pub-id pub-id-type="pmid">34391684</pub-id>
</element-citation><mixed-citation id="mc-CR109" publication-type="journal">Guo C, Yu H, Feng G, Lv Q, Liu X, Liu X. Associations of FSHR and LHCGR gene variants with ovarian reserve and clinical pregnancy rates. Reprod Biomed Online. 2021;43:561&#x02013;9.<pub-id pub-id-type="pmid">34391684</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR110"><label>110.</label><citation-alternatives><element-citation id="ec-CR110" publication-type="journal"><person-group person-group-type="author"><name><surname>Alviggi</surname><given-names>C</given-names></name><name><surname>Longobardi</surname><given-names>S</given-names></name><name><surname>Papaleo</surname><given-names>E</given-names></name><name><surname>Santi</surname><given-names>D</given-names></name><name><surname>Alfano</surname><given-names>S</given-names></name><name><surname>Vanni</surname><given-names>VS</given-names></name><etal/></person-group><article-title>Genetic variants of gonadotropins and their receptors could influence controlled ovarian stimulation: IVF data from a prospective multicenter study</article-title><source>Genes (Basel)</source><year>2023</year><volume>14</volume><fpage>1269</fpage><pub-id pub-id-type="doi">10.3390/genes14061269</pub-id><pub-id pub-id-type="pmid">37372449</pub-id>
</element-citation><mixed-citation id="mc-CR110" publication-type="journal">Alviggi C, Longobardi S, Papaleo E, Santi D, Alfano S, Vanni VS, et al. Genetic variants of gonadotropins and their receptors could influence controlled ovarian stimulation: IVF data from a prospective multicenter study. Genes (Basel). 2023;14:1269.<pub-id pub-id-type="pmid">37372449</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR111"><label>111.</label><citation-alternatives><element-citation id="ec-CR111" publication-type="journal"><person-group person-group-type="author"><name><surname>Pirtea</surname><given-names>P</given-names></name><name><surname>de Ziegler</surname><given-names>D</given-names></name><name><surname>Marin</surname><given-names>D</given-names></name><name><surname>Sun</surname><given-names>L</given-names></name><name><surname>Tao</surname><given-names>X</given-names></name><name><surname>Ayoubi</surname><given-names>JM</given-names></name><etal/></person-group><article-title>Gonadotropin receptor polymorphisms (FSHR N680S and LHCGR N312S) are not predictive of clinical outcome and live birth in assisted reproductive technology</article-title><source>Fertil Steril</source><year>2022</year><volume>118</volume><fpage>494</fpage><lpage>503</lpage><pub-id pub-id-type="doi">10.1016/j.fertnstert.2022.06.011</pub-id><pub-id pub-id-type="pmid">35842313</pub-id>
</element-citation><mixed-citation id="mc-CR111" publication-type="journal">Pirtea P, de Ziegler D, Marin D, Sun L, Tao X, Ayoubi JM, et al. Gonadotropin receptor polymorphisms (FSHR N680S and LHCGR N312S) are not predictive of clinical outcome and live birth in assisted reproductive technology. Fertil Steril. 2022;118:494&#x02013;503.<pub-id pub-id-type="pmid">35842313</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR112"><label>112.</label><citation-alternatives><element-citation id="ec-CR112" publication-type="journal"><person-group person-group-type="author"><name><surname>Piersma</surname><given-names>D</given-names></name><name><surname>Verhoef-Post</surname><given-names>M</given-names></name><name><surname>Look</surname><given-names>MP</given-names></name><name><surname>Uitterlinden</surname><given-names>AG</given-names></name><name><surname>Pols</surname><given-names>HAP</given-names></name><name><surname>Berns</surname><given-names>EMJJ</given-names></name><etal/></person-group><article-title>Polymorphic variations in exon 10 of the luteinizing hormone receptor: functional consequences and associations with breast cancer</article-title><source>Mol Cell Endocrinol</source><year>2007</year><volume>276</volume><fpage>63</fpage><lpage>70</lpage><pub-id pub-id-type="doi">10.1016/j.mce.2007.06.007</pub-id><pub-id pub-id-type="pmid">17709176</pub-id>
</element-citation><mixed-citation id="mc-CR112" publication-type="journal">Piersma D, Verhoef-Post M, Look MP, Uitterlinden AG, Pols HAP, Berns EMJJ, et al. Polymorphic variations in exon 10 of the luteinizing hormone receptor: functional consequences and associations with breast cancer. Mol Cell Endocrinol. 2007;276:63&#x02013;70.<pub-id pub-id-type="pmid">17709176</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR113"><label>113.</label><citation-alternatives><element-citation id="ec-CR113" publication-type="journal"><person-group person-group-type="author"><name><surname>Capalbo</surname><given-names>A</given-names></name><name><surname>Sagnella</surname><given-names>F</given-names></name><name><surname>Apa</surname><given-names>R</given-names></name><name><surname>Fulghesu</surname><given-names>AM</given-names></name><name><surname>Lanzone</surname><given-names>A</given-names></name><name><surname>Morciano</surname><given-names>A</given-names></name><etal/></person-group><article-title>The 312&#x000a0;N variant of the luteinizing hormone/choriogonadotropin receptor gene (LHCGR) confers up to 2&#x000b7;7-fold increased risk of polycystic ovary syndrome in a sardinian population</article-title><source>Clin Endocrinol (Oxf)</source><year>2012</year><volume>77</volume><fpage>113</fpage><lpage>119</lpage><pub-id pub-id-type="doi">10.1111/j.1365-2265.2012.04372.x</pub-id><pub-id pub-id-type="pmid">22356187</pub-id>
</element-citation><mixed-citation id="mc-CR113" publication-type="journal">Capalbo A, Sagnella F, Apa R, Fulghesu AM, Lanzone A, Morciano A, et al. The 312&#x000a0;N variant of the luteinizing hormone/choriogonadotropin receptor gene (LHCGR) confers up to 2&#x000b7;7-fold increased risk of polycystic ovary syndrome in a sardinian population. Clin Endocrinol (Oxf). 2012;77:113&#x02013;9.<pub-id pub-id-type="pmid">22356187</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR114"><label>114.</label><citation-alternatives><element-citation id="ec-CR114" publication-type="journal"><person-group person-group-type="author"><name><surname>Valkenburg</surname><given-names>O</given-names></name><name><surname>Uitterlinden</surname><given-names>AG</given-names></name><name><surname>Piersma</surname><given-names>D</given-names></name><name><surname>Hofman</surname><given-names>A</given-names></name><name><surname>Themmen</surname><given-names>APN</given-names></name><name><surname>de Jong</surname><given-names>FH</given-names></name><etal/></person-group><article-title>Genetic polymorphisms of GnRH and gonadotrophic hormone receptors affect the phenotype of polycystic ovary syndrome</article-title><source>Hum Reprod</source><year>2009</year><volume>24</volume><fpage>2014</fpage><lpage>2022</lpage><pub-id pub-id-type="doi">10.1093/humrep/dep113</pub-id><pub-id pub-id-type="pmid">19403562</pub-id>
</element-citation><mixed-citation id="mc-CR114" publication-type="journal">Valkenburg O, Uitterlinden AG, Piersma D, Hofman A, Themmen APN, de Jong FH, et al. Genetic polymorphisms of GnRH and gonadotrophic hormone receptors affect the phenotype of polycystic ovary syndrome. Hum Reprod. 2009;24:2014&#x02013;22.<pub-id pub-id-type="pmid">19403562</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR115"><label>115.</label><citation-alternatives><element-citation id="ec-CR115" publication-type="journal"><person-group person-group-type="author"><name><surname>Aschim</surname><given-names>EL</given-names></name><name><surname>Oldenburg</surname><given-names>J</given-names></name><name><surname>Kristiansen</surname><given-names>W</given-names></name><name><surname>Giwercman</surname><given-names>A</given-names></name><name><surname>Witczak</surname><given-names>O</given-names></name><name><surname>Foss&#x000e5;</surname><given-names>SD</given-names></name><etal/></person-group><article-title>Genetic variations associated with the effect of testicular cancer treatment on gonadal hormones</article-title><source>Hum Reprod</source><year>2014</year><volume>29</volume><fpage>2844</fpage><lpage>2851</lpage><pub-id pub-id-type="doi">10.1093/humrep/deu274</pub-id><pub-id pub-id-type="pmid">25336703</pub-id>
</element-citation><mixed-citation id="mc-CR115" publication-type="journal">Aschim EL, Oldenburg J, Kristiansen W, Giwercman A, Witczak O, Foss&#x000e5; SD, et al. Genetic variations associated with the effect of testicular cancer treatment on gonadal hormones. Hum Reprod. 2014;29:2844&#x02013;51.<pub-id pub-id-type="pmid">25336703</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR116"><label>116.</label><citation-alternatives><element-citation id="ec-CR116" publication-type="journal"><person-group person-group-type="author"><name><surname>Alviggi</surname><given-names>C</given-names></name><name><surname>Conforti</surname><given-names>A</given-names></name><name><surname>Cariati</surname><given-names>F</given-names></name><name><surname>Alfano</surname><given-names>S</given-names></name><name><surname>Strina</surname><given-names>I</given-names></name><name><surname>Huhtaniemi</surname><given-names>I</given-names></name><etal/></person-group><article-title>Impact of polymorphisms of gonadotropins and their receptors on controlled ovarian stimulation: a prospective observational study</article-title><source>Hum Reprod</source><year>2016</year><volume>31</volume><fpage>443</fpage><lpage>443</lpage></element-citation><mixed-citation id="mc-CR116" publication-type="journal">Alviggi C, Conforti A, Cariati F, Alfano S, Strina I, Huhtaniemi I, et al. Impact of polymorphisms of gonadotropins and their receptors on controlled ovarian stimulation: a prospective observational study. Hum Reprod. 2016;31:443&#x02013;443.</mixed-citation></citation-alternatives></ref><ref id="CR117"><label>117.</label><citation-alternatives><element-citation id="ec-CR117" publication-type="journal"><person-group person-group-type="author"><name><surname>Wan</surname><given-names>P</given-names></name><name><surname>Meng</surname><given-names>L</given-names></name><name><surname>Huang</surname><given-names>C</given-names></name><name><surname>Dai</surname><given-names>B</given-names></name><name><surname>Jin</surname><given-names>Y</given-names></name><name><surname>Chai</surname><given-names>L</given-names></name><etal/></person-group><article-title>Replication study and meta-analysis of selected genetic variants and polycystic ovary syndrome susceptibility in Asian population</article-title><source>J Assist Reprod Genet</source><year>2021</year><volume>38</volume><fpage>2781</fpage><lpage>2789</lpage><pub-id pub-id-type="doi">10.1007/s10815-021-02291-1</pub-id><pub-id pub-id-type="pmid">34403018</pub-id>
</element-citation><mixed-citation id="mc-CR117" publication-type="journal">Wan P, Meng L, Huang C, Dai B, Jin Y, Chai L, et al. Replication study and meta-analysis of selected genetic variants and polycystic ovary syndrome susceptibility in Asian population. J Assist Reprod Genet. 2021;38:2781&#x02013;9.<pub-id pub-id-type="pmid">34403018</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR118"><label>118.</label><citation-alternatives><element-citation id="ec-CR118" publication-type="journal"><person-group person-group-type="author"><name><surname>Cao</surname><given-names>CH</given-names></name><name><surname>Wei</surname><given-names>Y</given-names></name><name><surname>Liu</surname><given-names>R</given-names></name><name><surname>Lin</surname><given-names>XR</given-names></name><name><surname>Luo</surname><given-names>JQ</given-names></name><name><surname>Zhang</surname><given-names>QJ</given-names></name><etal/></person-group><article-title>Three-dimensional genome interactions identify potential adipocyte metabolism-associated gene STON1 and immune-correlated gene FSHR at the rs13405728 locus in polycystic ovary syndrome</article-title><source>Front Endocrinol (Lausanne)</source><year>2021</year><volume>12</volume><fpage>686054</fpage><pub-id pub-id-type="doi">10.3389/fendo.2021.686054</pub-id><pub-id pub-id-type="pmid">34248847</pub-id>
</element-citation><mixed-citation id="mc-CR118" publication-type="journal">Cao CH, Wei Y, Liu R, Lin XR, Luo JQ, Zhang QJ, et al. Three-dimensional genome interactions identify potential adipocyte metabolism-associated gene STON1 and immune-correlated gene FSHR at the rs13405728 locus in polycystic ovary syndrome. Front Endocrinol (Lausanne). 2021;12:686054.<pub-id pub-id-type="pmid">34248847</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR119"><label>119.</label><citation-alternatives><element-citation id="ec-CR119" publication-type="journal"><person-group person-group-type="author"><name><surname>Zou</surname><given-names>J</given-names></name><name><surname>Wu</surname><given-names>D</given-names></name><name><surname>Liu</surname><given-names>Y</given-names></name><name><surname>Tan</surname><given-names>S</given-names></name></person-group><article-title>Association of luteinizing hormone/choriogonadotropin receptor gene polymorphisms with polycystic ovary syndrome risk: a meta-analysis</article-title><source>Gynecol Endocrinol</source><year>2019</year><volume>35</volume><fpage>81</fpage><lpage>85</lpage><pub-id pub-id-type="doi">10.1080/09513590.2018.1498834</pub-id><pub-id pub-id-type="pmid">30182769</pub-id>
</element-citation><mixed-citation id="mc-CR119" publication-type="journal">Zou J, Wu D, Liu Y, Tan S. Association of luteinizing hormone/choriogonadotropin receptor gene polymorphisms with polycystic ovary syndrome risk: a meta-analysis. Gynecol Endocrinol. 2019;35:81&#x02013;5.<pub-id pub-id-type="pmid">30182769</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR120"><label>120.</label><citation-alternatives><element-citation id="ec-CR120" publication-type="journal"><person-group person-group-type="author"><name><surname>Thathapudi</surname><given-names>S</given-names></name><name><surname>Kodati</surname><given-names>V</given-names></name><name><surname>Erukkambattu</surname><given-names>J</given-names></name><name><surname>Addepally</surname><given-names>U</given-names></name><name><surname>Qurratulain</surname><given-names>H</given-names></name></person-group><article-title>Association of luteinizing hormone chorionic gonadotropin receptor gene polymorphism (rs2293275) with polycystic ovarian syndrome</article-title><source>Genet Test Mol Biomarkers</source><year>2015</year><volume>19</volume><fpage>128</fpage><lpage>132</lpage><pub-id pub-id-type="doi">10.1089/gtmb.2014.0249</pub-id><pub-id pub-id-type="pmid">25565299</pub-id>
</element-citation><mixed-citation id="mc-CR120" publication-type="journal">Thathapudi S, Kodati V, Erukkambattu J, Addepally U, Qurratulain H. Association of luteinizing hormone chorionic gonadotropin receptor gene polymorphism (rs2293275) with polycystic ovarian syndrome. Genet Test Mol Biomarkers. 2015;19:128&#x02013;32.<pub-id pub-id-type="pmid">25565299</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR121"><label>121.</label><citation-alternatives><element-citation id="ec-CR121" publication-type="journal"><person-group person-group-type="author"><name><surname>Sychev</surname><given-names>DA</given-names></name><name><surname>Malova</surname><given-names>EU</given-names></name></person-group><article-title>Evidence-based pharmacogenetics: is it possible?</article-title><source>Int J Risk Saf Med</source><year>2015</year><volume>27</volume><issue>Suppl 1</issue><fpage>S97</fpage><lpage>98</lpage><pub-id pub-id-type="doi">10.3233/JRS-150706</pub-id><pub-id pub-id-type="pmid">26639733</pub-id>
</element-citation><mixed-citation id="mc-CR121" publication-type="journal">Sychev DA, Malova EU. Evidence-based pharmacogenetics: is it possible? Int J Risk Saf Med. 2015;27(Suppl 1):S97-98.<pub-id pub-id-type="pmid">26639733</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR122"><label>122.</label><citation-alternatives><element-citation id="ec-CR122" publication-type="journal"><person-group person-group-type="author"><name><surname>Iorio</surname><given-names>GG</given-names></name><name><surname>Rovetto</surname><given-names>MY</given-names></name><name><surname>Conforti</surname><given-names>A</given-names></name><name><surname>Carbone</surname><given-names>L</given-names></name><name><surname>Vallone</surname><given-names>R</given-names></name><name><surname>Cariati</surname><given-names>F</given-names></name><etal/></person-group><article-title>Severe ovarian hyperstimulation syndrome in a woman with breast cancer under letrozole triggered with GnRH agonist: a case report and review of the literature</article-title><source>Front Reprod Health</source><year>2021</year><volume>3</volume><fpage>704153</fpage><pub-id pub-id-type="doi">10.3389/frph.2021.704153</pub-id><pub-id pub-id-type="pmid">36303992</pub-id>
</element-citation><mixed-citation id="mc-CR122" publication-type="journal">Iorio GG, Rovetto MY, Conforti A, Carbone L, Vallone R, Cariati F, et al. Severe ovarian hyperstimulation syndrome in a woman with breast cancer under letrozole triggered with GnRH agonist: a case report and review of the literature. Front Reprod Health. 2021;3: 704153.<pub-id pub-id-type="pmid">36303992</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR123"><label>123.</label><citation-alternatives><element-citation id="ec-CR123" publication-type="journal"><person-group person-group-type="author"><name><surname>Feferkorn</surname><given-names>I</given-names></name><name><surname>Ata</surname><given-names>B</given-names></name><name><surname>Esteves</surname><given-names>SC</given-names></name><name><surname>La Marca</surname><given-names>A</given-names></name><name><surname>Paulson</surname><given-names>R</given-names></name><name><surname>Blockeel</surname><given-names>C</given-names></name><etal/></person-group><article-title>The HERA (Hyper-response risk Assessment) Delphi consensus definition of hyper-responders for in-vitro fertilization</article-title><source>J Assist Reprod Genet</source><year>2023</year><volume>40</volume><fpage>1071</fpage><lpage>1081</lpage><pub-id pub-id-type="doi">10.1007/s10815-023-02757-4</pub-id><pub-id pub-id-type="pmid">36933094</pub-id>
</element-citation><mixed-citation id="mc-CR123" publication-type="journal">Feferkorn I, Ata B, Esteves SC, La Marca A, Paulson R, Blockeel C, et al. The HERA (Hyper-response risk Assessment) Delphi consensus definition of hyper-responders for in-vitro fertilization. J Assist Reprod Genet. 2023;40:1071&#x02013;81.<pub-id pub-id-type="pmid">36933094</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR124"><label>124.</label><citation-alternatives><element-citation id="ec-CR124" publication-type="journal"><person-group person-group-type="author"><name><surname>Verberg</surname><given-names>MFG</given-names></name><name><surname>Eijkemans</surname><given-names>MJC</given-names></name><name><surname>Heijnen</surname><given-names>EMEW</given-names></name><name><surname>Broekmans</surname><given-names>FJ</given-names></name><name><surname>de Klerk</surname><given-names>C</given-names></name><name><surname>Fauser</surname><given-names>BCJM</given-names></name><etal/></person-group><article-title>Why do couples drop-out from IVF treatment? A prospective cohort study</article-title><source>Hum Reprod</source><year>2008</year><volume>23</volume><fpage>2050</fpage><lpage>2055</lpage><pub-id pub-id-type="doi">10.1093/humrep/den219</pub-id><pub-id pub-id-type="pmid">18544578</pub-id>
</element-citation><mixed-citation id="mc-CR124" publication-type="journal">Verberg MFG, Eijkemans MJC, Heijnen EMEW, Broekmans FJ, de Klerk C, Fauser BCJM, et al. Why do couples drop-out from IVF treatment? A prospective cohort study. Hum Reprod. 2008;23:2050&#x02013;5.<pub-id pub-id-type="pmid">18544578</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR125"><label>125.</label><citation-alternatives><element-citation id="ec-CR125" publication-type="journal"><person-group person-group-type="author"><name><surname>Wong</surname><given-names>PC</given-names></name><name><surname>Qiao</surname><given-names>J</given-names></name><name><surname>Ho</surname><given-names>C</given-names></name><name><surname>Ramaraju</surname><given-names>GA</given-names></name><name><surname>Wiweko</surname><given-names>B</given-names></name><name><surname>Takehara</surname><given-names>Y</given-names></name><etal/></person-group><article-title>Current opinion on use of luteinizing hormone supplementation in assisted reproduction therapy: an Asian perspective</article-title><source>Reprod Biomed Online</source><year>2011</year><volume>23</volume><fpage>81</fpage><lpage>90</lpage><pub-id pub-id-type="doi">10.1016/j.rbmo.2011.03.023</pub-id><pub-id pub-id-type="pmid">21550853</pub-id>
</element-citation><mixed-citation id="mc-CR125" publication-type="journal">Wong PC, Qiao J, Ho C, Ramaraju GA, Wiweko B, Takehara Y, et al. Current opinion on use of luteinizing hormone supplementation in assisted reproduction therapy: an Asian perspective. Reprod Biomed Online. 2011;23:81&#x02013;90.<pub-id pub-id-type="pmid">21550853</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR126"><label>126.</label><citation-alternatives><element-citation id="ec-CR126" publication-type="journal"><person-group person-group-type="author"><name><surname>De Placido</surname><given-names>G</given-names></name><name><surname>Alviggi</surname><given-names>C</given-names></name><name><surname>Perino</surname><given-names>A</given-names></name><name><surname>Strina</surname><given-names>I</given-names></name><name><surname>Lisi</surname><given-names>F</given-names></name><name><surname>Fasolino</surname><given-names>A</given-names></name><etal/></person-group><article-title>Recombinant human LH supplementation versus recombinant human FSH (rFSH) step-up protocol during controlled ovarian stimulation in normogonadotrophic women with initial inadequate ovarian response to rFSH. A multicentre, prospective, randomized controlled trial</article-title><source>Hum Reprod</source><year>2005</year><volume>20</volume><fpage>390</fpage><lpage>396</lpage><pub-id pub-id-type="doi">10.1093/humrep/deh625</pub-id><pub-id pub-id-type="pmid">15576390</pub-id>
</element-citation><mixed-citation id="mc-CR126" publication-type="journal">De Placido G, Alviggi C, Perino A, Strina I, Lisi F, Fasolino A, et al. Recombinant human LH supplementation versus recombinant human FSH (rFSH) step-up protocol during controlled ovarian stimulation in normogonadotrophic women with initial inadequate ovarian response to rFSH. A multicentre, prospective, randomized controlled trial. Hum Reprod. 2005;20:390&#x02013;6.<pub-id pub-id-type="pmid">15576390</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR127"><label>127.</label><citation-alternatives><element-citation id="ec-CR127" publication-type="journal"><person-group person-group-type="author"><name><surname>Ferraretti</surname><given-names>AP</given-names></name><name><surname>Gianaroli</surname><given-names>L</given-names></name><name><surname>Magli</surname><given-names>MC</given-names></name><name><surname>D&#x02019;angelo</surname><given-names>A</given-names></name><name><surname>Farfalli</surname><given-names>V</given-names></name><name><surname>Montanaro</surname><given-names>N</given-names></name></person-group><article-title>Exogenous luteinizing hormone in controlled ovarian hyperstimulation for assisted reproduction techniques</article-title><source>Fertil Steril</source><year>2004</year><volume>82</volume><fpage>1521</fpage><lpage>6</lpage><pub-id pub-id-type="doi">10.1016/j.fertnstert.2004.06.041</pub-id><pub-id pub-id-type="pmid">15589853</pub-id>
</element-citation><mixed-citation id="mc-CR127" publication-type="journal">Ferraretti AP, Gianaroli L, Magli MC, D&#x02019;angelo A, Farfalli V, Montanaro N. Exogenous luteinizing hormone in controlled ovarian hyperstimulation for assisted reproduction techniques. Fertil Steril. 2004;82:1521&#x02013;6.<pub-id pub-id-type="pmid">15589853</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR128"><label>128.</label><citation-alternatives><element-citation id="ec-CR128" publication-type="journal"><person-group person-group-type="author"><name><surname>Lisi</surname><given-names>F</given-names></name><name><surname>Rinaldi</surname><given-names>L</given-names></name><name><surname>Fishel</surname><given-names>S</given-names></name><name><surname>Caserta</surname><given-names>D</given-names></name><name><surname>Lisi</surname><given-names>R</given-names></name><name><surname>Campbell</surname><given-names>A</given-names></name></person-group><article-title>Evaluation of two doses of recombinant luteinizing hormone supplementation in an unselected group of women undergoing follicular stimulation for in vitro fertilization</article-title><source>Fertil Steril</source><year>2005</year><volume>83</volume><fpage>309</fpage><lpage>315</lpage><pub-id pub-id-type="doi">10.1016/j.fertnstert.2004.07.969</pub-id><pub-id pub-id-type="pmid">15705367</pub-id>
</element-citation><mixed-citation id="mc-CR128" publication-type="journal">Lisi F, Rinaldi L, Fishel S, Caserta D, Lisi R, Campbell A. Evaluation of two doses of recombinant luteinizing hormone supplementation in an unselected group of women undergoing follicular stimulation for in vitro fertilization. Fertil Steril. 2005;83:309&#x02013;15.<pub-id pub-id-type="pmid">15705367</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR129"><label>129.</label><citation-alternatives><element-citation id="ec-CR129" publication-type="journal"><person-group person-group-type="author"><name><surname>Ruvolo</surname><given-names>G</given-names></name><name><surname>Bosco</surname><given-names>L</given-names></name><name><surname>Pane</surname><given-names>A</given-names></name><name><surname>Morici</surname><given-names>G</given-names></name><name><surname>Cittadini</surname><given-names>E</given-names></name><name><surname>Roccheri</surname><given-names>MC</given-names></name></person-group><article-title>Lower apoptosis rate in human cumulus cells after administration of recombinant luteinizing hormone to women undergoing ovarian stimulation for in vitro fertilization procedures</article-title><source>Fertil Steril</source><year>2007</year><volume>87</volume><fpage>542</fpage><lpage>546</lpage><pub-id pub-id-type="doi">10.1016/j.fertnstert.2006.06.059</pub-id><pub-id pub-id-type="pmid">17126339</pub-id>
</element-citation><mixed-citation id="mc-CR129" publication-type="journal">Ruvolo G, Bosco L, Pane A, Morici G, Cittadini E, Roccheri MC. Lower apoptosis rate in human cumulus cells after administration of recombinant luteinizing hormone to women undergoing ovarian stimulation for in vitro fertilization procedures. Fertil Steril. 2007;87:542&#x02013;6.<pub-id pub-id-type="pmid">17126339</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR130"><label>130.</label><citation-alternatives><element-citation id="ec-CR130" publication-type="journal"><person-group person-group-type="author"><name><surname>Conforti</surname><given-names>A</given-names></name><name><surname>Esteves</surname><given-names>SC</given-names></name><name><surname>Humaidan</surname><given-names>P</given-names></name><name><surname>Longobardi</surname><given-names>S</given-names></name><name><surname>D&#x02019;Hooghe</surname><given-names>T</given-names></name><name><surname>Orvieto</surname><given-names>R</given-names></name><etal/></person-group><article-title>Recombinant human luteinizing hormone co-treatment in ovarian stimulation for assisted reproductive technology in women of advanced reproductive age: a systematic review and meta-analysis of randomized controlled trials</article-title><source>Reprod Biol Endocrinol</source><year>2021</year><volume>19</volume><fpage>91</fpage><pub-id pub-id-type="doi">10.1186/s12958-021-00759-4</pub-id><pub-id pub-id-type="pmid">34154604</pub-id>
</element-citation><mixed-citation id="mc-CR130" publication-type="journal">Conforti A, Esteves SC, Humaidan P, Longobardi S, D&#x02019;Hooghe T, Orvieto R, et al. Recombinant human luteinizing hormone co-treatment in ovarian stimulation for assisted reproductive technology in women of advanced reproductive age: a systematic review and meta-analysis of randomized controlled trials. Reprod Biol Endocrinol. 2021;19:91.<pub-id pub-id-type="pmid">34154604</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR131"><label>131.</label><citation-alternatives><element-citation id="ec-CR131" publication-type="journal"><person-group person-group-type="author"><name><surname>Clarke</surname><given-names>JF</given-names></name><name><surname>van Rumste</surname><given-names>MME</given-names></name><name><surname>Farquhar</surname><given-names>CM</given-names></name><name><surname>Johnson</surname><given-names>NP</given-names></name><name><surname>Mol</surname><given-names>BWJ</given-names></name><name><surname>Herbison</surname><given-names>P</given-names></name></person-group><article-title>Measuring outcomes in fertility trials: can we rely on clinical pregnancy rates?</article-title><source>Fertil Steril</source><year>2010</year><volume>94</volume><fpage>1647</fpage><lpage>1651</lpage><pub-id pub-id-type="doi">10.1016/j.fertnstert.2009.11.018</pub-id><pub-id pub-id-type="pmid">20056216</pub-id>
</element-citation><mixed-citation id="mc-CR131" publication-type="journal">Clarke JF, van Rumste MME, Farquhar CM, Johnson NP, Mol BWJ, Herbison P. Measuring outcomes in fertility trials: can we rely on clinical pregnancy rates? Fertil Steril. 2010;94:1647&#x02013;51.<pub-id pub-id-type="pmid">20056216</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR132"><label>132.</label><citation-alternatives><element-citation id="ec-CR132" publication-type="journal"><person-group person-group-type="author"><name><surname>Desai</surname><given-names>SS</given-names></name><name><surname>Achrekar</surname><given-names>SK</given-names></name><name><surname>Paranjape</surname><given-names>SR</given-names></name><name><surname>Desai</surname><given-names>SK</given-names></name><name><surname>Mangoli</surname><given-names>VS</given-names></name><name><surname>Mahale</surname><given-names>SD</given-names></name></person-group><article-title>Association of allelic combinations of FSHR gene polymorphisms with ovarian response</article-title><source>Reprod Biomed Online</source><year>2013</year><volume>27</volume><fpage>400</fpage><lpage>406</lpage><pub-id pub-id-type="doi">10.1016/j.rbmo.2013.07.007</pub-id><pub-id pub-id-type="pmid">23953588</pub-id>
</element-citation><mixed-citation id="mc-CR132" publication-type="journal">Desai SS, Achrekar SK, Paranjape SR, Desai SK, Mangoli VS, Mahale SD. Association of allelic combinations of FSHR gene polymorphisms with ovarian response. Reprod Biomed Online. 2013;27:400&#x02013;6.<pub-id pub-id-type="pmid">23953588</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR133"><label>133.</label><citation-alternatives><element-citation id="ec-CR133" publication-type="journal"><person-group person-group-type="author"><name><surname>Allegra</surname><given-names>A</given-names></name><name><surname>Marino</surname><given-names>A</given-names></name><name><surname>Raimondo</surname><given-names>S</given-names></name><name><surname>Maiorana</surname><given-names>A</given-names></name><name><surname>Gullo</surname><given-names>S</given-names></name><name><surname>Scaglione</surname><given-names>P</given-names></name><etal/></person-group><article-title>The carriers of the A/G-G/G allelic combination of the c.2039 a &#x0003e; G and c.-29 G &#x0003e; A FSH receptor polymorphisms retrieve the highest number of oocytes in IVF/ICSI cycles</article-title><source>J Assist Reprod Genet</source><year>2017</year><volume>34</volume><fpage>263</fpage><lpage>273</lpage><pub-id pub-id-type="doi">10.1007/s10815-016-0835-9</pub-id><pub-id pub-id-type="pmid">27817039</pub-id>
</element-citation><mixed-citation id="mc-CR133" publication-type="journal">Allegra A, Marino A, Raimondo S, Maiorana A, Gullo S, Scaglione P, et al. The carriers of the A/G-G/G allelic combination of the c.2039 a &#x0003e; G and c.-29 G &#x0003e; A FSH receptor polymorphisms retrieve the highest number of oocytes in IVF/ICSI cycles. J Assist Reprod Genet. 2017;34:263&#x02013;73.<pub-id pub-id-type="pmid">27817039</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR134"><label>134.</label><citation-alternatives><element-citation id="ec-CR134" publication-type="journal"><person-group person-group-type="author"><name><surname>Alviggi</surname><given-names>C</given-names></name><name><surname>Conforti</surname><given-names>A</given-names></name><name><surname>Esteves</surname><given-names>SC</given-names></name><name><surname>Vallone</surname><given-names>R</given-names></name><name><surname>Venturella</surname><given-names>R</given-names></name><name><surname>Staiano</surname><given-names>S</given-names></name><etal/></person-group><article-title>Understanding ovarian hypo-response to exogenous gonadotropin in ovarian stimulation and its new proposed marker-the Follicle-To-Oocyte (FOI) index</article-title><source>Front Endocrinol (Lausanne)</source><year>2018</year><volume>9</volume><fpage>589</fpage><pub-id pub-id-type="doi">10.3389/fendo.2018.00589</pub-id><pub-id pub-id-type="pmid">30386293</pub-id>
</element-citation><mixed-citation id="mc-CR134" publication-type="journal">Alviggi C, Conforti A, Esteves SC, Vallone R, Venturella R, Staiano S, et al. Understanding ovarian hypo-response to exogenous gonadotropin in ovarian stimulation and its new proposed marker-the Follicle-To-Oocyte (FOI) index. Front Endocrinol (Lausanne). 2018;9:589.<pub-id pub-id-type="pmid">30386293</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR135"><label>135.</label><citation-alternatives><element-citation id="ec-CR135" publication-type="journal"><person-group person-group-type="author"><name><surname>Bosch</surname><given-names>E</given-names></name><name><surname>Alviggi</surname><given-names>C</given-names></name><name><surname>Lispi</surname><given-names>M</given-names></name><name><surname>Conforti</surname><given-names>A</given-names></name><name><surname>Hanyaloglu</surname><given-names>AC</given-names></name><name><surname>Chuderland</surname><given-names>D</given-names></name><etal/></person-group><article-title>Reduced FSH and LH action: implications for medically assisted reproduction</article-title><source>Hum Reprod</source><year>2021</year><volume>36</volume><fpage>1469</fpage><lpage>1480</lpage><pub-id pub-id-type="doi">10.1093/humrep/deab065</pub-id><pub-id pub-id-type="pmid">33792685</pub-id>
</element-citation><mixed-citation id="mc-CR135" publication-type="journal">Bosch E, Alviggi C, Lispi M, Conforti A, Hanyaloglu AC, Chuderland D, et al. Reduced FSH and LH action: implications for medically assisted reproduction. Hum Reprod. 2021;36:1469&#x02013;80.<pub-id pub-id-type="pmid">33792685</pub-id>
</mixed-citation></citation-alternatives></ref></ref-list></back></article>